E. De Clercq

发表

HIV Genome-Wide Protein Associations: a Review of 30 Years of Research

Guangdi Li, E. De Clercq, 2016, Microbiology and Molecular Reviews.

Synthesis and Preliminary Antiviral Activities of Piperidine‐substituted Purines against HIV and Influenza A/H1N1 Infections

E. De Clercq, Dongwei Kang, Zengjun Fang, 2015, Chemical biology & drug design.

Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.

R. Esnouf, E. De Clercq, B. Degrève, 2001, Molecular pharmacology.

Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.

R. Esnouf, E. De Clercq, B. Degrève, 2000, Molecular pharmacology.

Characterization of multiple nuclear localization signals in herpes simplex virus type 1 thymidine kinase.

R. Esnouf, E. De Clercq, B. Degrève, 1999, Biochemical and biophysical research communications.

Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein.

E. De Clercq, P. Cherepanov, Z. Debyser, 1999, Virology.

HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells*

Zeger Debyser, Yves Engelborghs, Bart Devreese, 2003, The Journal of Biological Chemistry.

Ether phospholipid-AZT conjugates possessing anti-HIV and antitumor cell activity. Synthesis, conformational analysis, and study of their thermal effects on membrane bilayers.

E. De Clercq, J. Balzarini, T. Mavromoustakos, 2001, Journal of medicinal chemistry.

Selective inhibitors of picornavirus replication

E. De Clercq, J. Neyts, A. D. De Palma, 2008, Medicinal research reviews.

Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

E. De Clercq, A. Vandamme, K. Van Laethem, 1999, Drugs.

Approved Antiviral Drugs over the Past 50 Years

Guangdi Li, E. De Clercq, 2016, Clinical Microbiology Reviews.

Design, Synthesis, and Molecular Docking Studies of a Conjugated Thiadiazole-Thiourea Scaffold as Antituberculosis Agents.

P. Yogeeswari, D. Sriram, E. De Clercq, 2016, Biological & pharmaceutical bulletin.

Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin mannich bases.

D. Sriram, E. De Clercq, S. Pandeya, 2000, European journal of medicinal chemistry.

A novel approach for the virtual screening and rational design of anticancer compounds.

Ernesto Estrada, L. Santana, E. Uriarte, 2000, Journal of medicinal chemistry.

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Guangdi Li, E. De Clercq, 2020, Nature Reviews Drug Discovery.

A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export

J. Kjems, E. De Clercq, A. Vandamme, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The HIV‐1 Reverse Transcription (RT) Process as Target for RT Inhibitors

E. De Clercq, J. Anné, H. Jonckheere, 2000, Medicinal research reviews.

A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase.

E. De Clercq, P. Herdewijn, M. Froeyen, 2009, Antiviral research.

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

E. De Clercq, A. Silverman, J. Balzarini, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

E. De Clercq, 2009, International journal of antimicrobial agents.

Thiosugars. Part 9: synthesis and biological evaluation of some 4'-thio-L-arabino nucleoside analogues.

E. De Clercq, J. Balzarini, J. Wirsching, 2001, Bioorganic & medicinal chemistry letters.

Use of Cotton Rats to Evaluate the Efficacy of Antivirals in Treatment of Measles Virus Infections

E. De Clercq, N. Minakawa, A. Matsuda, 2000, Antimicrobial Agents and Chemotherapy.

Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Journal of medicinal chemistry.

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Bioorganic & medicinal chemistry.

Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring.

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2021, Journal of medicinal chemistry.

Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021 .

Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, European journal of medicinal chemistry.

Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Journal of medicinal chemistry.

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

E. De Clercq, C. Pannecouque, H. Piao, 2021, European journal of medicinal chemistry.

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.

E. De Clercq, C. Pannecouque, P. Zhan, 2021, Bioorganic & medicinal chemistry.

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity.

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2021, Bioorganic chemistry.

Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Bioorganic & Medicinal Chemistry.

In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, European journal of medicinal chemistry.

Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties.

E. De Clercq, Dongwei Kang, Boshi Huang, 2020, European journal of medicinal chemistry.

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2020, Molecules.

Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, ACS infectious diseases.

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2019, Acta pharmaceutica Sinica. B.

Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2019, Acta pharmaceutica Sinica. B.

Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2020 .

Discovery and Characterization of Fluorine-Substituted Diarylpyrimidines Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.

Peng Zhan, Dongwei Kang, Yanying Sun, 2020, Journal of medicinal chemistry.

Structure-Based Bioisosterism Yields HIV 1 NNRTIs with Improved Drug Resistance Profiles and Favorable Pharmacokinetic Properties.

E. De Clercq, Dongwei Kang, Zengjun Fang, 2020, Journal of medicinal chemistry.

Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2020, European journal of medicinal chemistry.

Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, European journal of medicinal chemistry.

Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, European journal of medicinal chemistry.

Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors

E. De Clercq, Dongwei Kang, Boshi Huang, 2019, Communications Chemistry.

Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2019, Bioorganic chemistry.

Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, Chun-lin Zhuang, 2019, European journal of medicinal chemistry.

Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2017, ACS medicinal chemistry letters.

Design strategies of novel NNRTIs to overcome drug resistance.

Peng Zhan, Christophe Pannecouque, E. De Clercq, 2009, Current medicinal chemistry.

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

Youcef Mehellou, E. De Clercq, Y. Mehellou, 2010, Journal of medicinal chemistry.

Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.

Peng Zhan, E. De Clercq, P. Zhan, 2012, Journal of medicinal chemistry.

Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, ACS medicinal chemistry letters.

The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase

E. De Clercq, J. Neyts, J. Balzarini, 2005, Journal of Virology.

Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

E. De Clercq, M. Van Ranst, J. Balzarini, 2005, The Journal of antimicrobial chemotherapy.

Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

E. De Clercq, R. Pauwels, M. Baba, 1990, Antimicrobial Agents and Chemotherapy.

Antiviral agents active against influenza A viruses

E. De Clercq, Erik De Clercq, 2006, Nature reviews. Drug discovery.

Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists

J. Barretina, E. De Clercq, B. Clotet, 2003, Antiviral therapy.

Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue.

E. De Clercq, J. Grivel, L. Margolis, 2001, Virology.

Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.

B Clotet, E. De Clercq, B. Clotet, 1999, Molecular pharmacology.

Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

E. De Clercq, J. Grivel, L. Margolis, 1999, The Journal of clinical investigation.

Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4

E. De Clercq, B. Clotet, J. Blanco, 1999, Journal of Virology.

Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity

E. De Clercq, Steven Wolinsky, K. Kunstman, 2001, Journal of Virology.

Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives.

Angela Rao, Maria Zappalà, Pietro Monforte, 2002, Farmaco.

Prospects for antiviral therapy.

E. De Clercq, J. Neyts, E. Clercq, 2003, Advances in virus research.

Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivatives.

E. De Clercq, C. Pannecouque, J. Balzarini, 2006, Chemical & pharmaceutical bulletin.

Antiviral drugs in current clinical use.

E. De Clercq, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Overview of Recent Strategic Advances in Medicinal Chemistry.

Peng Zhan, Yuning Song, Dongwei Kang, 2019, Journal of medicinal chemistry.

Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist

Dominique Schols, E. De Clercq, T. Schwartz, 2004, Journal of Virology.

Potential antivirals and antiviral strategies against SARS coronavirus infections

E. De Clercq, Erik De Clercq, 2006, Expert review of anti-infective therapy.

Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.

E. De Clercq, J. Neyts, G. Fytas, 2001, Bioorganic & medicinal chemistry letters.

Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm.

E. De Clercq, P. Zhan, Xinyong Liu, 2010, Current medicinal chemistry.

Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, Xiaodong Ma, 2012, European journal of medicinal chemistry.

4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: Synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation

B. Narasimhan, E. De Clercq, C. Pannecouque, 2010, European Journal of Medicinal Chemistry.

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.

W. Freeman, E. De Clercq, F. Rahhal, 1997, American journal of ophthalmology.

Expression of HIV‐1 integrase in CEM cells inhibits HIV‐1 replication

E. De Clercq, P. Cherepanov, J. van Griensven, 2004, The journal of gene medicine.

In Search of Authentic Inhibitors of HIV-1 Integration

E. De Clercq, P. Cherepanov, Z. Debyser, 2002, Antiviral chemistry & chemotherapy.

Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues.

E. De Clercq, J. Neyts, J. Balzarini, 2007, Bioorganic chemistry.

Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses

E. De Clercq, 2007, Advances in Antiviral Drug Design.

The emerging role of fusion inhibitors in HIV infection.

E. De Clercq, 1999, Drugs in R&D.

Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor

E. De Clercq, T. Schwartz, D. Schols, 2007, Journal of Virology.

New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs

E. De Clercq, R. Pauwels, Z. Debyser, 1994, Antimicrobial Agents and Chemotherapy.

HIV resistance to reverse transcriptase inhibitors.

E. De Clercq, 1994, Biochemical pharmacology.

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-did

E. De Clercq, J. Balzarini, M. Roesner, 1998, Biochemical pharmacology.

Analysis of inhibition of retroviral reverse transcriptase.

E. De Clercq, J. Balzarini, 1996, Methods in enzymology.

Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication.

E. De Clercq, J. Neyts, J. Balzarini, 1993, Antiviral Research.

Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo.

E. De Clercq, L. Naesens, J. Balzarini, 1991, Antiviral research.

Non-nucleoside HIV-1 reverse transcriptase inhibitors, Part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues.

E. De Clercq, C. Pannecouque, J. Balzarini, 2006, Chemical & pharmaceutical bulletin.

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.

E. De Clercq, J. Balzarini, M. Roesner, 1997, The Journal of infectious diseases.

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.

E. De Clercq, A. Vandamme, J. Balzarini, 1996, The Journal of infectious diseases.

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

E. De Clercq, D. Schols, S. Hatse, 2004, AIDS.

Highlights in antiviral drug research: antivirals at the horizon.

E. De Clercq, 2013, Medicinal research reviews.

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.

E. De Clercq, R. Pauwels, J. Le Pecq, 1996, Journal of medicinal chemistry.

N′-[4-[(Substituted imino)methyl]benzylidene]-substituted benzohydrazides: synthesis, antimicrobial, antiviral, and anticancer evaluation, and QSAR studies

B. Narasimhan, E. De Clercq, K. Ramasamy, 2012, Monatshefte für Chemie - Chemical Monthly.

Benzylidene/2-chlorobenzylidene hydrazides: Synthesis, antimicrobial activity, QSAR studies and antiviral evaluation

B. Narasimhan, E. De Clercq, J. Balzarini, 2010, European Journal of Medicinal Chemistry.

HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling.

E. De Clercq, B. Freedman, Qing‐Hua Liu, 2001, Blood.

Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.

E. De Clercq, C. Pannecouque, E. Arnold, 2009, Journal of medicinal chemistry.

Apoptosis of Bystander T Cells Induced by Human Immunodeficiency Virus Type 1 with Increased Envelope/Receptor Affinity and Coreceptor Binding Site Exposure

E. De Clercq, P. Gorry, K. Peden, 2004, Journal of Virology.

Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins

E. De Clercq, A. Vandamme, K. Van Laethem, 2004, Journal of Virology.

Hematopoietic stem cell-based gene therapy against HIV infection: promises and caveats.

E. De Clercq, J. van Griensven, Z. Debyser, 2005, AIDS reviews.

Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.

E. De Clercq, K. Pavelić, M. Grdiša, 1999, Journal of medicinal chemistry.

Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.

E. De Clercq, J. Rozenski, J. Neyts, 2006, Journal of medicinal chemistry.

The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis

P. Carmeliet, E. De Clercq, J. Aerts, 2004, Antimicrobial Agents and Chemotherapy.

Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice

E. De Clercq, J. Aerts, J. Neyts, 2003, BMC Microbiology.

Fluorosubstitution and 7-alkylation as prospective modifications of biologically active 6-aryl derivatives of tricyclic acyclovir and ganciclovir analogues.

E. De Clercq, J. Balzarini, B. Golankiewicz, 2005, Bioorganic & medicinal chemistry.

Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace

E. De Clercq, 2015, Reviews in medical virology.

3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Journal of medicinal chemistry.

QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices.

Maykel Cruz-Monteagudo, Lourdes Santana, Humberto González-Díaz, 2005, Bioorganic & medicinal chemistry letters.

Purine Derivatives of 1,2-Disubstituted Cyclohexane Analogues of Nucleosides

L. Santana, E. Uriarte, E. De Clercq, 2003, Nucleosides, nucleotides & nucleic acids.

The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells

E. Vanstreels, E. De Clercq, S. Liekens, 2007, Molecular Pharmacology.

Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections

E. De Clercq, 2001, Clinical Microbiology Reviews.

Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid.

E. De Clercq, T. L. Gilchrist, M. M. Marques, 2004, Bioorganic & medicinal chemistry.

Synthesis and antiviral activity of monofluorinated cyclopropanoid nucleosides.

E. De Clercq, J. Balzarini, G. Haufe, 2004, Organic & biomolecular chemistry.

Perspectives for the treatment of infections with Flaviviridae.

E. De Clercq, J. Neyts, P. Leyssen, 2000, Clinical microbiology reviews.

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

E. De Clercq, R. Pauwels, M. Baba, 1987, Antiviral research.

Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.

E. De Clercq, P. Herdewijn, G. Janssen, 1993, Journal of medicinal chemistry.

Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100

E. De Clercq, N. Heveker, D. Schols, 1998, Journal of Virology.

A time-of–drug addition approach to target identification of antiviral compounds

E. De Clercq, R. Pauwels, C. Pannecouque, 2011, Nature Protocols.

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.

E. De Clercq, C. Biot, D. Dive, 2006, Journal of medicinal chemistry.

Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives.

E. De Clercq, D. Khalili, J. Brunel, 2007, Molecules.

Synthesis, Structural Studies, and Biological Evaluation of Some Purine Substituted 1-Aminocyclopropane-1-carboxylic Acids and 1-Amino-1-hydroxymethylcyclopropanes

E. De Clercq, K. Pavelić, N. Slade, 2003, Nucleosides, nucleotides & nucleic acids.

Sulphated and Sulphonated Polymers Inhibit the Initial Interaction of Hepatitis B Virus with Hepatocytes

E. De Clercq, M. Van Ranst, J. Neyts, 2002, Antiviral chemistry & chemotherapy.

Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.

W. Freeman, E. De Clercq, F. Rahhal, 1997, Ophthalmology.

Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.

W. Freeman, E. De Clercq, B. Kuppermann, 1996, The Journal of infectious diseases.

Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.

E. De Clercq, D. Munguia, K. Assil, 1995, Archives of ophthalmology.

Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

W. Freeman, E. De Clercq, C. Wiley, 1994, The Journal of infectious diseases.

Strategies for the treatment and prevention of cytomegalovirus infections.

E. De Clercq, J. Neyts, 1993, International journal of antimicrobial agents.

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

E. De Clercq, P. Herdewijn, S. Broder, 1987, Molecular pharmacology.

env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

E. De Clercq, C. Pannecouque, A. Vandamme, 2002, Antimicrobial Agents and Chemotherapy.

Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection

E. De Clercq, 2000, Medicinal research reviews.

Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production

E. De Clercq, D. Schols, 1996, Journal of virology.

Arylazolyl(azinyl)thioacetanilides: Part 19 : Discovery of Novel Substituted Imidazo[4,5‐b]pyridin‐2‐ylthioacetanilides as Potent HIV NNRTIs Via a Structure‐based Bioisosterism Approach

E. De Clercq, Boshi Huang, C. Pannecouque, 2016, Chemical biology & drug design.

Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, European journal of medicinal chemistry.

Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.

E. De Clercq, C. Pannecouque, Fener Chen, 2018, European journal of medicinal chemistry.

Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.

E. De Clercq, Dongwei Kang, Boshi Huang, 2018, European journal of medicinal chemistry.

The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, Bioorganic & medicinal chemistry.

Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.

E. De Clercq, Boshi Huang, Huiqing Liu, 2017, European journal of medicinal chemistry.

Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.

E. De Clercq, Dongwei Kang, Boshi Huang, 2016, Bioorganic & medicinal chemistry.

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.

E. De Clercq, Boshi Huang, Huiqing Liu, 2015, European journal of medicinal chemistry.

Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

E. De Clercq, C. Pannecouque, D. Daelemans, 2015, Bioorganic & medicinal chemistry.

Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.

E. De Clercq, Dongwei Kang, Boshi Huang, 2016, European journal of medicinal chemistry.

The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling.

E. De Clercq, B. Clotet, J. Blanco, 1999, AIDS.

Substituted imidazopyridines as potent inhibitors of HCV replication☆

William A. Lee, I. Shih, E. De Clercq, 2009, Journal of Hepatology.

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Antimicrobial Agents and Chemotherapy.

Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus.

E. De Clercq, J. Neyts, C. Ying, 2000, Antiviral research.

The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro

E. De Clercq, R. Bartenschlager, B. Rosenwirth, 2006, Hepatology.

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine

E. De Clercq, R. Bartenschlager, J. Neyts, 2006, Antimicrobial Agents and Chemotherapy.

Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.

E. De Clercq, C. Pannecouque, D. Daelemans, 2015, European journal of medicinal chemistry.

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

R. Esnouf, E. De Clercq, J. Balzarini, 2000, Molecular pharmacology.

Meningoradiculoneuritis due to acyclovir‐resistant varicella zoster virus in an acquired immune deficiency syndrome patient

E. De Clercq, J. Piette, J. Balzarini, 1994, Journal of medical virology.

Synthesis and Antiviral Activities of 3-Aralkyl-Thiomethylimidazo[1,2-b]Pyridazine Derivatives

E. De Clercq, C. Pannecouque, J. Balzarini, 2003, Antiviral chemistry & chemotherapy.

Increased susceptibility of cells treated with interferon to the toxicity of polyriboinosinic-polyribocytidylic acid.

E. De Clercq, W. Stewart, A. Billiau, 1972, Proceedings of the National Academy of Sciences of the United States of America.

Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?

E. De Clercq, 2012, Medicinal research reviews.

Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase

E. De Clercq, V. Marquez, J. Murase, 1991, Biochemical Pharmacology.

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.

E. De Clercq, J. Neyts, P. McKenna, 1996, Antiviral research.

Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one.

D. Sriram, E. De Clercq, E. Clercq, 1999, Pharmaceutica acta Helvetiae.

Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein—Barr Virus Replication

E. De Clercq, J. Neyts, P. Wutzler, 1998, Antiviral chemistry & chemotherapy.

Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains.

E. De Clercq, M. Baba, K. Konno, 1986, The Tohoku journal of experimental medicine.

Effect of (E)-5-(2-Bromovinyl)-2′-deoxyuridine on the Growth and Viral Capsid Antigen Expression of Epstein-Barr Virus-Associated Tumor (B-95-8) Cells Transplanted to Nude Mice

E. De Clercq, Zhen Xu, Wen Dong, 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on several parameters of Epstein-Barr virus infection.

E. De Clercq, Z. Zhang, H. Allaudeen, 1984, The Journal of general virology.

Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta.

R. Derynck, E. De Clercq, K. Itakura, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders.

E. De Clercq, J. Balzarini, P. Baraldi, 2004, Journal of medicinal chemistry.

Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses.

E. De Clercq, D. Růžek, L. Eyer, 2017, Antiviral research.

2‐(2,6‐Dihalo‐phenyl)‐3‐heteroaryl‐2‐ylmethyl‐1, 3‐thiazolidin‐4‐ones: Anti‐HIV agents

Ravindra K Rawal, Christophe Pannecouque, E. De Clercq, 2008, Chemical biology & drug design.

Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents.

E. De Clercq, C. Pannecouque, J. Balzarini, 2001, Bioorganic & medicinal chemistry letters.

Targets and strategies for the antiviral chemotherapy of AIDS.

E. De Clercq, 1990, Trends in pharmacological sciences.

Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents.

E. De Clercq, C. Pannecouque, J. Balzarini, 2002, Journal of Medicinal Chemistry.

Anti-HIV activity of N-1-adamantyl-4-aminophthalimide.

E. De Clercq, J. Poupaert, J. Balzarini, 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Integrity of cell-bound poly(I).poly(C).

E. De Clercq, W. Stewart, 1974, The Journal of general virology.

Nucleoside Inhibitors of Tick-Borne Encephalitis Virus

E. De Clercq, J. Černý, J. Valdés, 2015, Antimicrobial Agents and Chemotherapy.

Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423.

M. Otto, E. De Clercq, L. Naesens, 2004, Biochemical pharmacology.

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.

E. De Clercq, R. Pauwels, M. Baba, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-substituted-hydrazinecarbothioamides

E. De Clercq, J. Balzarini, Sujeet Kumar, 2012, Medicinal Chemistry Research.

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus

E. De Clercq, R. Pauwels, M. Baba, 1988, Antimicrobial Agents and Chemotherapy.

Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1.

E. De Clercq, R. Pauwels, E. Clercq, 1990, Virology.

Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins

E. De Clercq, M. Hosoya, J. Balzarini, 1991, Antimicrobial Agents and Chemotherapy.

Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect.

E. De Clercq, R. Pauwels, M. Baba, 1993, Journal of medicinal chemistry.

Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.

E. De Clercq, E. Godehardt, E. Clercq, 2001, Archives of ophthalmology.

Activity of recombinant HIV-1 integrase on mini-HIV DNA.

E. De Clercq, J. Griffith, P. Cherepanov, 1999, Nucleic Acids Research.

Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.

E. De Clercq, P. Cherepanov, G. Reekmans, 1997, Molecular pharmacology.

1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.

E. De Clercq, C. Perno, J. Balzarini, 1994, Journal of medicinal chemistry.

Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine.

E. De Clercq, L. Naesens, J. Balzarini, 1992, Drug metabolism and disposition: the biological fate of chemicals.

Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound.

E. De Clercq, P. Herdewijn, J. Balzarini, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

E. De Clercq, 2003, Clinical Microbiology Reviews.

5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives.

E. De Clercq, J. Balzarini, 1991, The Journal of biological chemistry.

Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018

Y. Hao, Guangdi Li, E. De Clercq, 2022, Frontiers in Public Health.

Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.

E. De Clercq, 2018, Biochemical pharmacology.

Cidofovir in the treatment of poxvirus infections

E. De Clercq, 2002, Antiviral research.

Novel 6-Azapyrimidine-2′-Deoxy-4′-Thionucleosides: Synthesis, Biological Evaluation and Conformational Analysis

E. De Clercq, J. Balzarini, C. Simons, 1999, Antiviral chemistry & chemotherapy.

Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies

E. De Clercq, D. Schols, S. Liekens, 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin.

E. De Clercq, J. Neyts, I. Vliegen, 2006, Biochemical and biophysical research communications.

Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

E. De Clercq, J. Neyts, S. Kaptein, 2008, Reviews in medical virology.

Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.

E. De Clercq, S. Ikeda, J. Balzarini, 1995, Journal of medicinal chemistry.

The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations.

E. De Clercq, K. Pavelić, M. Kralj, 2009, European journal of medicinal chemistry.

Cytostatic and Antiviral Activity Evaluations of Hydroxamic Derivatives of Some Non‐steroidal Anti‐inflammatory Drugs

E. De Clercq, L. Naesens, K. Pavelić, 2009, Chemical Biology and Drug Design.

Current treatment of hepatitis B virus infections

E. De Clercq, 2015, Reviews in medical virology.

Escape of Tick-Borne Flavivirus from 2′-C-Methylated Nucleoside Antivirals Is Mediated by a Single Conservative Mutation in NS5 That Has a Dramatic Effect on Viral Fitness

E. De Clercq, R. Kizek, J. Černý, 2017, Journal of Virology.

The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice.

E. De Clercq, N. Raab-Traub, J. Neyts, 1998, Cancer research.

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

E. De Clercq, J. Balzarini, C. Mcguigan, 1996, Biochemical and biophysical research communications.

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, Fen‐er Chen, 2019, European journal of medicinal chemistry.

Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2008, Bioorganic & medicinal chemistry.

Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.

E. De Clercq, C. Pannecouque, J. Balzarini, 2004, Bioorganic chemistry.

5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.

E. De Clercq, C. Pannecouque, J. Balzarini, 2004, Bioorganic & medicinal chemistry letters.

(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.

E. De Clercq, R. Snoeck, S. Schneller, 1992, Journal of medicinal chemistry.

Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor.

E. De Clercq, A. Mantovani, P. Proost, 1998, Journal of immunology.

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

E. De Clercq, 2009, Biochemical pharmacology.

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Journal of medicinal chemistry.

(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

R. T. Walker, E. De Clercq, P. Barr, 1979, Proceedings of the National Academy of Sciences of the United States of America.

The synthesis and properties of some 5-substituted uracil derivatives.

R. T. Walker, E. De Clercq, J. Kozarich, 1980, Nucleic acids symposium series.

Drug targeting: anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosphonylmethoxyethyl)adenine.

E. De Clercq, M. Monsigny, J. Balzarini, 1990, Biochemical and biophysical research communications.

2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.

M. Otto, E. De Clercq, L. Naesens, 2002, Antiviral research.

Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.

E. De Clercq, E. Clercq, G. Andrei, 1990, Antiviral research.

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition): DNA Viruses

E. De Clercq, H. Field, 2008, Antiviral chemistry & chemotherapy.

Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro.

E. De Clercq, M. Hosoya, S. Shigeta, 1989, Antiviral research.

2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action.

E. De Clercq, D. Schols, S. Raghavan, 2014, European journal of medicinal chemistry.

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

E. De Clercq, J. Neyts, C. Drosten, 2003, Antimicrobial Agents and Chemotherapy.

Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro.

E. De Clercq, M. Baba, A. Sato, 1989, Biochemical and biophysical research communications.

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.

E. De Clercq, P. Proost, J. Van Damme, 1999, The Journal of clinical investigation.

CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.

E. De Clercq, M. Parmentier, G. Opdenakker, 1999, Journal of immunology.

Processing by CD26/dipeptidyl‐peptidase IV reduces the chemotactic and anti‐HIV‐1 activity of stromal‐cell‐derived factor‐1α

E. De Clercq, C. Durinx, P. Proost, 1998, FEBS letters.

9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase.

E. De Clercq, J. Balzarini, D. Schols, 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Synthesis of 4-substituted-1,2,3-triazole carbanucleoside analogues of ribavirin via click chemistry.

E. De Clercq, Marcos D. García, F. Fernández, 2007, Organic & biomolecular chemistry.

Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120.

H. Schuitemaker, E. De Clercq, R. Pauwels, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Human herpesvirus 6 infection arrests cord blood mononuclear cells in G2 phase of the cell cycle

E. De Clercq, L. Naesens, E. Verbeken, 2004 .

Fifty Years in Search of Selective Antiviral Drugs.

E. De Clercq, 2019, Journal of medicinal chemistry.

Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus.

E. De Clercq, T. V. van Berkel, J. Neyts, 2001, Molecular pharmacology.

Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety and oral pharmacokinetic profiles.

E. De Clercq, C. Pannecouque, Fener Chen, 2019, Journal of medicinal chemistry.

Structure-Based Discovery of Novel NH2-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH2-Naphthyl-Diarylpyrimidine to NH2-Biphenyl-Diarylpyrimidine.

F. Chen, E. De Clercq, C. Pannecouque, 2022, Journal of medicinal chemistry.

Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS).

W. Freeman, E. De Clercq, C. Wiley, 1997, Ophthalmology.

Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

W. Freeman, E. De Clercq, R. García, 1995, American journal of ophthalmology.

Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV‐2 in mice: Impact on the search for vaginal microbicides

E. De Clercq, J. Neyts, E. Clercq, 2000, Journal of medical virology.

Cytostatic activity of novel 4'-aminochalcone-based imides.

E. De Clercq, A. Jha, J. Balzarini, 2007, Bioorganic & medicinal chemistry letters.

Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase.

R. Esnouf, E. De Clercq, A. Esteban-Gamboa, 2000, Journal of medicinal chemistry.

Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease

M. L. Penn, E. De Clercq, M. Goldsmith, 2000, Journal of Virology.

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

E. De Clercq, R. Pauwels, B. Rosenwirth, 1994, Antimicrobial Agents and Chemotherapy.

Impact of 9‐(2‐phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells

E. De Clercq, J. Balzarini, S. Hatse, 1999, FEBS letters.

Antiviral and Anticellular Activities of Human and Murine Type I and Type II Interferons in Human Cells Monosomic, Disomic, and Trisomic for Chromosome 21

E. De Clercq, H. Heremans, Z. Zhang, 1982, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid

E. De Clercq, J. Balzarini, A. Bhargava, 2009, European Journal of Medicinal Chemistry.

Carrier Mechanisms Involved in the Transepithelial Transport of bis(POM)-PMEA and Its Metabolites Across Caco-2 Monolayers

E. De Clercq, L. Naesens, P. Annaert, 1998, Pharmaceutical Research.

Emerging anti-HIV drugs

E. De Clercq, 2005, Expert opinion on emerging drugs.

Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.

E. De Clercq, R. Pauwels, D. Meijer, 1996, Biochimica et biophysica acta.

Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay.

E. De Clercq, J. Neyts, P. Wutzler, 2004, Antiviral research.

Synthesis and anti-HCMV activity of 1-acyl-beta-lactams and 1-acylazetidines derived from phenylalanine.

E. De Clercq, M. García-López, R. González-Muñiz, 2004, Bioorganic & medicinal chemistry letters.

Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy

E. De Clercq, H. Field, 2006, British journal of pharmacology.

Antiviral drug susceptibility of human herpesvirus 8

E. De Clercq, J. Neyts, E. Clercq, 1997, Antimicrobial agents and chemotherapy.

From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.

E. De Clercq, M. García-López, R. González-Muñiz, 2005, Journal of medicinal chemistry.

The Antiherpesvirus Activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil

E. De Clercq, J. Neyts, G. Andrei, 1998, Antimicrobial Agents and Chemotherapy.

Antiviral agents active against human herpesviruses HHV‐6, HHV‐7 and HHV‐8

E. De Clercq, L. Naesens, J. Neyts, 2001, Reviews in Medical Virology.

Synthesis and biological evaluation of 3,3-difluoropyridine-2,4(1H,3H)-dione and 3-deaza-3-fluorouracil base and nucleoside derivatives.

E. De Clercq, J. Balzarini, M. Robins, 2009, Journal of medicinal chemistry.

Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.

R. T. Walker, E. De Clercq, J. Balzarini, 1994, Molecular pharmacology.

Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus.

R. T. Walker, E. De Clercq, E. Clercq, 1980, The Journal of infectious diseases.

Dual infection with polyomavirus BK and acyclovir‐resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient

E. De Clercq, G. Opdenakker, R. Snoeck, 2007, Transplant infectious disease : an official journal of the Transplantation Society.

Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient.

E. De Clercq, M. Van Ranst, P. Martiat, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus.

E. De Clercq, J. Piette, M. Winkler, 2008, Journal of virological methods.

Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.

E. De Clercq, J. Balzarini, P. Jansa, 2011, Bioorganic & medicinal chemistry.

Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis.

E. De Clercq, R. Pauwels, D. Schols, 1992, Virology.

New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

E. De Clercq, 2019, Chemistry, an Asian journal.

Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

E. De Clercq, D. Schols, G. Bridger, 2011, Bioorganic & medicinal chemistry letters.

Broad-Spectrum Antiviral Activity of 3′-Deoxy-3′-Fluoroadenosine against Emerging Flaviviruses

E. De Clercq, Z. Hubálek, D. Růžek, 2020, Antimicrobial Agents and Chemotherapy.

Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor.

E. De Clercq, R. Pauwels, M. Baba, 1989, Proceedings of the National Academy of Sciences of the United States of America.

The Holý Trinity: the acyclic nucleoside phosphonates.

E. De Clercq, 2013, Advances in pharmacology.

Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period

Guangdi Li, E. De Clercq, Ting Cai, 2022, Frontiers in Public Health.

Antiviral activity of S-adenosylhomocysteine hydrolase inhibitors against plant viruses.

E. De Clercq, G. De Fazio, A. Alba, 1990, Antiviral research.

Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro

E. De Clercq, C. Verslype, J. Neyts, 1999, Journal of viral hepatitis.

Antiviral Portrait Series: 4. Polysuifates as Inhibitors of HIV and Other Enveloped Viruses

E. De Clercq, M. Witvrouw, J. Desmyter, 1994 .

Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.

E. De Clercq, G. Andrei, R. Snoeck, 2002, Gynecologic oncology.

Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella‐zoster virus infections in severely immunosuppressed patients: A preliminary clinical trial

E. De Clercq, G. Tricot, R. Verwilghen, 1986, Journal of medical virology.

CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.

E. De Clercq, P. Proost, I. De Meester, 1998, Antiviral research.

RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE)

E. De Clercq, P. Proost, J. Van Damme, 1997, Journal of virology.

AIDS dementia: Synthesis and properties of a derivative of 3′‐azido‐3′‐deoxythymidine (AZT) that may become ‘locked’ in the central nervous system

E. De Clercq, J. Balzarini, P. Torrence, 1988, FEBS letters.

Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models.

E. De Clercq, A. Foli, C. Perno, 1991, Antiviral research.

Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, G. Maga, 2008, Bioorganic & medicinal chemistry.

The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.

E. De Clercq, D. Schols, G. Bridger, 2003, AIDS research and human retroviruses.

Evaluation of SDF‐1/CXCR4‐induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry

E. De Clercq, D. Schols, S. Hatse, 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

E. De Clercq, H. Degreef, E. Clercq, 1980, British medical journal.

Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally Infected with simian immunodeficiency virus (SIVsm).

E. De Clercq, E. Fenyö, D. Schols, 2001, Virology.

The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.

E. De Clercq, D. Schols, 1998, The Journal of general virology.

Successful treatment of a squamous papilloma of the hypopharynx‐esophagus by local injections of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine

P. Rutgeerts, E. De Clercq, M. Van Ranst, 1995, Journal of medical virology.

Mouse Adenovirus Type 1 Infection in SCID Mice: an Experimental Model for Antiviral Therapy of Systemic Adenovirus Infections

E. De Clercq, L. Naesens, E. Verbeken, 2005, Antimicrobial Agents and Chemotherapy.

Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro.

E. De Clercq, M. Baba, A. Sato, 1990, Biochemical and biophysical research communications.

Antiviral, antimetabolic, and cytotoxic activities of 5-substituted 2'-deoxycytidines.

R. T. Walker, E. De Clercq, J. Balzarini, 1982, Molecular Pharmacology.

Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth.

R. T. Walker, E. De Clercq, P. Barr, 1981, Molecular pharmacology.

HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections

E. De Clercq, L. Naesens, J. Neyts, 1997 .

Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.

E. De Clercq, R. Pauwels, D. Meijer, 1996, AIDS research and human retroviruses.

Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.

E. De Clercq, R. Pauwels, D. Meijer, 1995, The Journal of infectious diseases.

Comparative efficacy of antiherpes drugs in different cell lines

E. De Clercq, 1982, Antimicrobial Agents and Chemotherapy.

Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kappaB binding.

E. De Clercq, C. Pannecouque, J. Balzarini, 2006, Biochemical pharmacology.

Activities of various compounds against murine and primate polyomaviruses

E. De Clercq, E. Clercq, G. Andrei, 1997, Antimicrobial agents and chemotherapy.

Towards Efficient and Accurate SARS-CoV-2 Genome Sequence Typing Based on Supervised Learning Approaches

Guangdi Li, E. De Clercq, Miao Miao, 2022, Microorganisms.

Selective Anti-Herpesvirus Agents

E. De Clercq, 2013, Antiviral chemistry & chemotherapy.

In vitro cotranslational processing of human pre-interferon beta 1 enhances its biological activity.

R. Derynck, E. De Clercq, W. Fiers, 1982, Virology.

Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures

E. De Clercq, J. J. van den Oord, G. Andrei, 2002, Antimicrobial Agents and Chemotherapy.

Cidofovir in the therapy and short-term prophylaxis of poxvirus infections

E. De Clercq, 2002, Trends in pharmacological sciences.

Anti-human immunodeficiency virus effects of cationic metalloporphyrin-ellipticine complexes.

E. De Clercq, J. Balzarini, D. Schols, 1992, Biochemical pharmacology.

The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis.

E. De Clercq, J. Neyts, B. Degrève, 1997, Oncology research.

Historical Perspectives in the Development of Antiviral Agents Against Poxviruses

E. De Clercq, 2010, Viruses.

Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice

E. De Clercq, J. Neyts, 2001, Antimicrobial Agents and Chemotherapy.

Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

E. De Clercq, J. Neyts, J. Balzarini, 1991, Antimicrobial Agents and Chemotherapy.

Inhibitory Effects of Polycations on the Replication of Enveloped Viruses (HIV, HSV, CMV, RSV, Influenza A Virus and Togaviruses) in vitro

E. De Clercq, R. Pauwels, M. Hosoya, 1991 .

Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight.

E. De Clercq, E. Clercq, D. Schols, 1991, Journal of medicinal chemistry.

Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds.

E. De Clercq, D. Schols, M. Cushman, 1991, Journal of medicinal chemistry.

Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication.

E. De Clercq, D. Schols, P. Wutzler, 1991, Journal of acquired immune deficiency syndromes.

Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

E. De Clercq, R. Pauwels, L. Naesens, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells.

E. De Clercq, R. Pauwels, M. Baba, 1989, Journal of acquired immune deficiency syndromes.

Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain.

E. De Clercq, A. Vandamme, K. Van Laethem, 1998, AIDS research and human retroviruses.

How a Modification (8‐Aza‐3‐deaza‐2′‐deoxyguanosine) Influences the Quadruplex Structure of Hotoda's 6‐Mer TGGGAG with 5′‐ and 3′‐End Modifications

E. De Clercq, C. Pannecouque, J. Balzarini, 2004, Nucleosides, Nucleotides & Nucleic Acids.

Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).

E. De Clercq, C. Pannecouque, B. Clotet, 1998, Molecular pharmacology.

Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation.

E. De Clercq, L. Naesens, J. Balzarini, 1997, Antiviral research.

Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT.

E. De Clercq, J. Balzarini, C. Mcguigan, 1993, Journal of medicinal chemistry.

Studies on the antiviral activity and cell interaction of synthetic double-stranded polyribo- and polydeoxyribonucleotides.

T. Merigan, E. De Clercq, R. Wells, 1972, Virology.

Synthesis and Biological Activity of N-(arylsulfonyl) Valine Hydrazones and Assistance of NMR Spectroscopy for Definitive 3D Structure

E. De Clercq, C. Pannecouque, M. Paci, 2019, Letters in Drug Design & Discovery.

Potent inhibition of hemangiosarcoma development in mice by cidofovir

E. De Clercq, J. Neyts, E. Verbeken, 2001, International journal of cancer.

Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene.

R. Esnouf, E. De Clercq, G. Opdenakker, 2000, The Journal of general virology.

The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo

E. De Clercq, J. Neyts, G. Andrei, 1998, Antimicrobial Agents and Chemotherapy.

Simple quantitative radioiodination of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by exchange labelling.

C. Julien, E. De Clercq, A. Verbruggen, 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

Mutations in Both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology

E. De Clercq, A. Vandamme, Z. Debyser, 2005, Antiviral chemistry & chemotherapy.

Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon

E. De Clercq, F. Rapp, B. Wigdahl, 1986, Antimicrobial Agents and Chemotherapy.

Analysis of the herpes simplex virus genome during in vitro latency in human diploid fibroblasts and rat sensory neurons

E. De Clercq, F. Rapp, B. Wigdahl, 1984, Journal of virology.

Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study

Guangdi Li, E. De Clercq, Yongfang Jiang, 2020, Hepatology International.

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

E. De Clercq, J. Neyts, S. Kaptein, 2010, Viruses.

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.

E. De Clercq, D. Schols, G. Andrei, 2002, Virology.

Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.

E. De Clercq, B. Clotet, D. Meijer, 1999, AIDS research and human retroviruses.

Human cytomegalovirus increases constitutive production of interleukin-6 and leukemia inhibitory factor by bone marrow stromal cells.

E. De Clercq, E. Bosmans, J. Moreau, 1996, Blood.

Synthesis, 18F‐Radiolabelling and Biological Evaluations of C‐6 Alkylated Pyrimidine Nucleoside Analogues

E. De Clercq, S. Ametamey, G. Folkers, 2004, Nucleosides, nucleotides & nucleic acids.

Nucleoside Inhibitors of Zika Virus.

E. Gould, E. De Clercq, D. Růžek, 2016, The Journal of infectious diseases.

An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice

E. Gould, X. de Lamballerie, E. De Clercq, 2019, Journal of Virology.

Human Brain Tumour Cell Lines as Cell Substrate to Demonstrate Sensitivity/Resistance of Herpes Simplex Virus Types 1 and 2 to Nucleoside Analogues

E. De Clercq, R. Snoeck, G. Andrei, 1994 .

Broad-spectrum antiviral activity of adenosine analogues.

E. De Clercq, J. Montgomery, E. Clercq, 1984, Antiviral research.

Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry.

E. De Clercq, J. Neyts, D. Schols, 1989, Journal of virological methods.

An Approach towards the Synthesis of Potential Metal-Chelating TSAO-T Derivatives as Bidentate Inhibitors of Human Immunodeficiency virus Type 1 Reverse Transcriptase

E. De Clercq, J. Balzarini, M. Camarasa, 1998, Antiviral chemistry & chemotherapy.

Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, Organic & biomolecular chemistry.

Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.

E. De Clercq, P. Zhan, Xinyong Liu, 2015, European journal of medicinal chemistry.

The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A

E. De Clercq, F. Ceccherini‐Silberstein, F. Gago, 2005, Molecular Pharmacology.

Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, M. Witvrouw, 1999, Bioorganic & medicinal chemistry.

New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase.

E. De Clercq, R. Pauwels, G. Antonelli, 1996, Antiviral research.

Synthesis and Antiviral Activities of 1,2,3-triazole Functionalized Thymidines: 1,3-dipolar Cycloaddition for Efficient Regioselective Diversity Generation

E. De Clercq, J. Balzarini, Michael R. Korn, 2005, Antiviral chemistry & chemotherapy.

Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity--preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties.

E. De Clercq, J. Poupaert, J. Balzarini, 1998, Life sciences.

Effect of human and mouse interferon and of polyriboinosinic acid.polyribocytidylic acid on the growth of human fibrosarcoma and melanoma tumors in nude mice.

E. De Clercq, H. Sobis, V. Edy, 1978, European journal of cancer.

Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases.

E. De Clercq, K. Nishikata, E. Clercq, 1990, European journal of cancer.

Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.

E. De Clercq, J. Balzarini, L. Wiebe, 1995, Gene Therapy.

Quantitative analysis of human herpesvirus 6 cell tropism

Wiley Interscience, E. De Clercq, L. Naesens, 2005, Journal of medical virology.

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile 2008 (2nd Edition): RNA Viruses

E. De Clercq, H. Field, 2008, Antiviral chemistry & chemotherapy.

Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles.

E. De Clercq, J. Neyts, A. D. De Palma, 2007, Biochemical and biophysical research communications.

Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides.

E. De Clercq, W. Prusoff, M. Hitchcock, 2010, Antiviral research.

Modified Cyclodextrin Sulphates(mCDS11) have Potent Inhibitory Activity against HIV and High Oral Bioavailability

E. De Clercq, L. Naesens, D. Schols, 1994 .

[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1

E. De Clercq, J. Balzarini, M. Camarasa, 1992, Antimicrobial Agents and Chemotherapy.

Screening of Compounds for Activity against HIV: A Collaborative Study

D. Jeffries, E. De Clercq, R. Pauwels, 1991 .

Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro

R. T. Walker, E. De Clercq, M. Baba, 1991, Antimicrobial Agents and Chemotherapy.

Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon.

R. T. Walker, E. De Clercq, M. Baba, 1991, Antiviral research.

Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives

E. De Clercq, M. Baba, H. Nakashima, 1990, Antimicrobial Agents and Chemotherapy.

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

E. De Clercq, M. Baba, H. Nakashima, 1991, Proceedings of the National Academy of Sciences of the United States of America.

An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.

E. De Clercq, R. Pauwels, Z. Debyser, 1991, Proceedings of the National Academy of Sciences of the United States of America.

The LD78β Isoform of MIP-1α Is the Most Potent CC-Chemokine in Inhibiting CCR5-Dependent Human Immunodeficiency Virus Type 1 Replication in Human Macrophages

E. De Clercq, P. Proost, J. Van Damme, 2001, Journal of Virology.

Interferon induction by polynucleotides, modified polynucleotides, and polycarboxylates.

E. De Clercq, 1981, Methods in enzymology.

Nitroimidazoles Part 6. Synthesis, Structure and in Vitro anti-HIV Activity of New 5-substituted Piperazinyl-4-nitroimidazole Derivatives

E. De Clercq, C. Pannecouque, N. Al-Masoudi, 2007, Antiviral chemistry & chemotherapy.

Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts.

E. De Clercq, L. Naesens, H. Agut, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Activities of Acyclic Nucleoside Phosphonates against Orf Virus in Human and Ovine Cell Monolayers and Organotypic Ovine Raft Cultures

E. De Clercq, J. J. van den Oord, G. Andrei, 2005, Antimicrobial Agents and Chemotherapy.

SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME ACYCLIC α-(1H-PYRAZOLO[3,4-d]PYRIMIDIN-4-YL)THIOALKYLAMIDE NUCLEOSIDES

E. De Clercq, J. Vasseur, H. Lazrek, 2002, Nucleosides, nucleotides & nucleic acids.

SYNTHESIS AND BIOLOGICAL ACTIVITY OF 4-SUBSTITUTED 1-[1-(2-HYDROXYETHOXY)- METHYL-1,2,3-TRIAZOL-(4 & 5)-YLMETHYL]-1H-PYRAZOLO[3,4-d]PYRIMIDINES

E. De Clercq, C. Pannecouque, M. Witvrouw, 2001, Nucleosides, nucleotides & nucleic acids.

SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME 4-SUBSTITUTED 1-[1-(4-HYDROXYBUTYL)-1,2,3-TRIAZOL-(4 & 5)-YLMETHYL]-1H-PYRAZOLO-[3,4-d]PYRIMIDINES

E. De Clercq, C. Pannecouque, M. Witvrouw, 2001, Nucleosides, nucleotides & nucleic acids.

SYNTHESIS AND ANTI-HIV ACTIVITY OF NEW MODIFIED 1,2,3-TRIAZOLE ACYCLONUCLEOSIDES

E. De Clercq, C. Pannecouque, J. Imbach, 2001, Nucleosides, nucleotides & nucleic acids.

Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication

E. De Clercq, D. Schols, G. Bridger, 2010 .

Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists

E. De Clercq, D. Schols, S. Hatse, 2004, Retrovirology.

Synthesis and Structure−Activity Relationships of Phenylenebis(methylene)- Linked Bis-tetraazamacrocycles That Inhibit Human Immunodeficiency Virus Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams

E. De Clercq, R. Pauwels, M. Witvrouw, 1996 .

Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.

E. De Clercq, R. Pauwels, G. Bridger, 1995, Journal of medicinal chemistry.

Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design.

E. De Clercq, C. Pannecouque, R. Moreira, 2009, European journal of medicinal chemistry.

Efficacy of oral 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice

E. De Clercq, L. Naesens, J. Neyts, 1993, Journal of medical virology.

Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.

A. Bergamini, E. De Clercq, R. Pauwels, 1992, Antiviral research.

Synthesis and Antiviral Activity of 6-Benzoyl-Benzoxazolin-2-One and 6-Benzoyl-Benzothiazolin-2-One Derivatives

E. De Clercq, J. Poupaert, J. Balzarini, 1999, Antiviral chemistry & chemotherapy.

Mechanism of the Antiviral Activity of New Aurintricarboxylic Acid Analogues

E. De Clercq, J. Neyts, D. Schols, 1996 .

Syncytium formation and destruction of bystander CD4+ cells cocultured with T cells persistently infected with human immunodeficiency virus as demonstrated by flow cytometry.

E. De Clercq, R. Pauwels, M. Baba, 1989, The Journal of general virology.

Combined antiviral effects of acyclovir or bromovinyldeoxyuridine and human immunoglobulin in herpes simplex virus-infected mice.

E. De Clercq, R. Köhler, F. Seiler, 1987, Antiviral research.

Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6.

E. De Clercq, L. Naesens, J. Balzarini, 1995, Antiviral research.

Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin

E. De Clercq, G. Opdenakker, J. Balzarini, 2005, Journal of Virology.

Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides

M. Otto, E. De Clercq, W. Prusoff, 1984, Antimicrobial Agents and Chemotherapy.

Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate.

A. Van Schepdael, E. De Clercq, J. Esko, 1992, Virology.

Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, P. Fanwick, 2005, Journal of medicinal chemistry.

A newly developed immunofluorescent assay for determining the Pichinde virus-inhibitory effects of selected nucleoside analogues.

E. De Clercq, M. Dawson, M. Kende, 1988, Antiviral Research.

Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.

E. De Clercq, 2007, Biochemical pharmacology.

Antiviral drug development--success and failure: a personal perspective with a Japanese connection.

E. De Clercq, 2013, Antiviral chemistry & chemotherapy.

Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors

A. Engelman, E. De Clercq, D. Daelemans, 2007, Journal of Virology.

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV.

E. De Clercq, R. Pauwels, Erik De Clercq, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Selective Inhibition of Myxovirus Replication by a Novel Series of Cholesterol-Naphthalenesulfonic Acid Hybrid Molecules

E. De Clercq, S. Ikeda, P. Mohan, 1994 .

In vitro Activity of a Novel Series of Polyoxosilicotungstates against Human Myxo-, Herpes- and Retroviruses

E. De Clercq, S. Ikeda, J. Neyts, 1993 .

Molecular approaches for the treatment of hemorrhagic fever virus infections.

E. De Clercq, G. Andrei, G. Andrei, 1993, Antiviral research.

New Polyacetal Polysulphate Active against Human Immunodeficiency Virus and other Enveloped Viruses

A. Van Schepdael, E. De Clercq, R. Pauwels, 1992 .

Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells.

E. De Clercq, R. Pauwels, J. Balzarini, 1990, Journal of virological methods.

Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity.

E. De Clercq, R. Pauwels, M. Baba, 1990, The Journal of infectious diseases.

Anti‐angiogenic activity of a novel multi‐substrate analogue inhibitor of thymidine phosphorylase

E. De Clercq, J. Balzarini, S. Liekens, 2002, FEBS letters.

Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells.

E. De Clercq, J. Balzarini, 1984, Biochimica et biophysica acta.

Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, C. Trépo, O. Hantz, 1984, Antiviral research.

Inhibitory effect of E-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on herpes simplex virus replication and DNA synthesis

E. De Clercq, J. Descamps, H. Allaudeen, 1982, Journal of Virology.

C-Nucleosides To Be Revisited.

E. De Clercq, 2016, Journal of medicinal chemistry.

Assays for the evaluation of HIV-1 integrase inhibitors.

E. De Clercq, Z. Debyser, W. Pluymers, 2001, Methods in molecular biology.

Interferon induction by a 2'-modified double-helical RNA, poly(2'-azido-2'-deoxyinosinic acid) . polycytidylic acid.

E. De Clercq, M. Ikehara, B. Stollar, 1978, European journal of biochemistry.

Recent highlights in the development of new antiviral drugs

E. De Clercq, 2005, Current Opinion in Microbiology.

Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.

E. De Clercq, R. Borchardt, J. Balzarini, 1997, Journal of medicinal chemistry.

E. De Clercq, R. Borchardt, J. Balzarini, 1994, Journal of medicinal chemistry.

Selective Activity of Various Nucleoside and Nucleotide Analogues against Human Herpesvirus 6 and 7

E. De Clercq, K. Yamanishi, Y. Iwata, 1997 .

Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections

E. De Clercq, J. Neyts, G. Painter, 2007, Antimicrobial Agents and Chemotherapy.

Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections

E. De Clercq, J. Neyts, G. Painter, 2007, Antimicrobial Agents and Chemotherapy.

Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.

E. De Clercq, J. Neyts, R. Colonno, 2007, Antiviral research.

Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities

E. De Clercq, J. Neyts, A. Holý, 2005, Antimicrobial Agents and Chemotherapy.

Selective inhibition of hepatitis B virus replication by RNA interference.

E. De Clercq, J. Neyts, C. Ying, 2003, Biochemical and biophysical research communications.

Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl] x guanine (A-5021) in vitro and in vivo.

E. De Clercq, L. Naesens, J. Neyts, 2001, Antiviral research.

Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation.

E. De Clercq, J. Neyts, S. Yap, 1999, Journal of Virological Methods.

cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.

E. De Clercq, J. Balzarini, V. Marquez, 1999, Journal of medicinal chemistry.

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.

E. De Clercq, J. Balzarini, M. Lorey, 1998, Journal of medicinal chemistry.

Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro

E. De Clercq, M. Hosoya, S. Shigeta, 1987, Antimicrobial Agents and Chemotherapy.

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor.

E. De Clercq, D. Schols, K. Vermeire, 2003, Molecular pharmacology.

Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine

E. De Clercq, C. Bruggeman, F. Stals, 1993, Antimicrobial Agents and Chemotherapy.

In vitro Sensitivity of Kaposi's Sarcoma Cells to Various Chemotherapeutic Agents Including Acyclic Nucleoside Phosphonates

E. De Clercq, G. Andrei, R. Snoeck, 1999, Antiviral chemistry & chemotherapy.

Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives

E. De Clercq, R. Borchardt, J. Balzarini, 1989, Antimicrobial Agents and Chemotherapy.

Budding yeast as a screening tool for discovery of nucleoside analogs for use in HSV-1 TK suicide-gene therapy.

J. Thevelein, E. De Clercq, J. Neyts, 1999, BioTechniques.

Exploring the role of the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives.

E. De Clercq, F. Gago, J. Balzarini, 2001, Antiviral research.

The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A

E. De Clercq, P. Zhan, Xinyong Liu, 2015, Current medicinal chemistry.

Coumarin-purine ribofuranoside conjugates as new agents against hepatitis C virus.

E. De Clercq, J. Neyts, P. Leyssen, 2011, Journal of medicinal chemistry.

Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7.

E. De Clercq, Dongwei Kang, Boshi Huang, 2020, Bioorganic & Medicinal Chemistry Letters.

Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof.

E. De Clercq, Yan Wang, Xin-yong Liu, 2009, Mini reviews in medicinal chemistry.

Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro

E. De Clercq, T. Yokota, K. Konno, 1988, Antimicrobial Agents and Chemotherapy.

Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.

E. De Clercq, J. Neyts, J. Balzarini, 1996, Journal of medicinal chemistry.

Selective activity of various antiviral compounds against HHV-7 infection.

E. De Clercq, D. Schols, Y. Zhang, 1999, Antiviral research.

Poly(Hydroxy)Carboxylates as Selective Inhibitors of Cytomegalovirus and Herpes Simplex Virus Replication

E. De Clercq, J. Neyts, P. Wutzler, 1992 .

Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir 1

E. De Clercq, D. Ribatti, J. Neyts, 2001 .

Infections with flaviviridae.

E. De Clercq, J. Neyts, P. Leyssen, 1999, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

Chemotherapy of varicella zoster virus infections.

E. De Clercq, G. Andrei, R. Snoeck, 1994, International journal of antimicrobial agents.

Cellular uptake of phosphonylmethoxyalkylpurine derivatives.

E. De Clercq, G. Palù, J. Balzarini, 1991, Antiviral research.

Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability

E. De Clercq, C. Pannecouque, H. Piao, 2022, Acta pharmaceutica Sinica. B.

Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.

E. De Clercq, D. Schols, G. Bridger, 2011, Bioorganic & medicinal chemistry letters.

Interferon inducers: general survey and classification.

E. De Clercq, P. Torrence, 1981, Methods in enzymology.

Inhibition of terminal N- and O-glycosylation specific for herpesvirus-infected cells: mechanism of an inhibitor of sugar nucleotide transport across Golgi membranes.

E. De Clercq, S. Olofsson, C. Hirschberg, 1988, Virology.

Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes.

E. De Clercq, C. Pannecouque, J. Greenman, 2009, Journal of the American Chemical Society.

Syntheses and anti-HIV activities of (+/-)-norcarbovir and (+/-)-norabacavir.

E. De Clercq, J. Balzarini, Weiqiang Huang, 2007, Organic & biomolecular chemistry.

Synthesis and anti-HIV activity of novel cyclopentenyl nucleoside analogues of 8-azapurine.

E. Uriarte, E. De Clercq, C. Pannecouque, 2006, Chemical & pharmaceutical bulletin.

Carbocyclic analogues of nucleosides from bis-(Hydroxymethyl)-cyclopentane: synthesis, antiviral and cytostatic activities of adenosine, inosine and uridine analogues.

E. De Clercq, O. Caamaño, J. Balzarini, 2003, Chemical & pharmaceutical bulletin.

SYNTHESIS, ANTIVIRAL AND CYTOSTATIC ACTIVITIES, OF CARBOCYCLIC NUCLEOSIDES INCORPORATING A MODIFIED CYCLOPENTANE RING. IV. ADENOSINE AND URIDINE ANALOGUES

E. De Clercq, J. Balzarini, F. Fernández, 2002, Nucleosides, nucleotides & nucleic acids.

Synthesis and antiviral activity of carbocyclic nucleosides incorporating a modified cyclopentane ring. Part 3: Adenosine and uridine analogues.

E. De Clercq, X. García‐Mera, J. Balzarini, 1999, Nucleosides & nucleotides.

SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques.

E. De Clercq, K. Überla, K. Uberla, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones

E. De Clercq, S. Ganguly, R. Veerasamy, 2010, European Journal of Medicinal Chemistry.

Thiazolo[4,5-d]Pyrimidines. Part II. Synthesis and Anti-Human Cytomegalovirus Activity in Vitro of Certain Acyclonucleosides and Acyclonucleotides Derived from the Guanine Analogue 5-Aminothiazolo[4,5-d]Pyrimidine-2,7(3H,6H)-Dione

E. De Clercq, J. Ojwang, J. Sommadossi, 1998, Antiviral chemistry & chemotherapy.

Herpesvirus infections in immunocompromised patients.

E. De Clercq, R. Snoeck, 1995, Cancer treatment and research.

Renaturation of inactivated interferons by "defensive reversible denaturation".

E. De Clercq, W. Stewart, P. De Somer, 1974, Preparative biochemistry.

Inhibitory effect of interferon on the growth of spontaneous mammary tumors in mice.

E. De Clercq, Z. Zhang, K. Huygen, 1982, Journal of the National Cancer Institute.

Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on replication of Epstein-Barr virus in human lymphoblastoid cell lines.

E. De Clercq, A. Verbruggen, J. Pagano, 1985, Antiviral Research.

Efficacy of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine and 9‐(1,3‐dihydroxy‐2‐propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice

E. De Clercq, L. Naesens, J. Neyts, 1992, Journal of medical virology.

The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil.

E. De Clercq, J. Neyts, 2001, Antiviral research.

Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs

E. De Clercq, J. Neyts, 1999, Antimicrobial Agents and Chemotherapy.

The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses.

E. De Clercq, J. Neyts, 1999, Transplantation.

The Thiocarboxanilides UC-10 and UC-781 Have an Additive Inhibitory Effect against Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Replication in Cell Culture When Combined with other Antiretroviral Drugs

E. De Clercq, J. Balzarini, 1997 .

Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds

E. De Clercq, N. Minakawa, A. Matsuda, 1991, Antimicrobial Agents and Chemotherapy.

Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro

E. De Clercq, M. Baba, M. Ito, 1984, Antimicrobial Agents and Chemotherapy.

Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine.

E. De Clercq, J. Montgomery, E. D. Clercq, 1983, Antiviral research.

Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.

E. De Clercq, C. Pannecouque, M. Cushman, 2007, Journal of medicinal chemistry.

Antiviral and Cytostatic Evaluation of the Novel 6-acyclic Chain Substituted Thymine Derivatives

E. De Clercq, K. Pavelić, J. Plavec, 2005, Antiviral Chemistry & Chemotherapy.

Synthesis and Antiviral Evaluation of Some 3′‐Fluoro Bicyclic Nucleoside Analogues

E. De Clercq, J. Balzarini, C. Mcguigan, 2004, Nucleosides, nucleotides & nucleic acids.

Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain.

E. De Clercq, A. Brancale, J. Balzarini, 2000, Bioorganic & medicinal chemistry letters.

Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine.

E. De Clercq, L. Missotten, E. Clercq, 1982, Archives of ophthalmology.

Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds.

E. De Clercq, J. Dimmock, Rajendra K. Sharma, 2006, European journal of medicinal chemistry.

Desferrioxamine enhances aids‐associated Kaposi's sarcoma tumor development in a xenograft model

E. De Clercq, J. J. van den Oord, G. Andrei, 2002, International journal of cancer.

Mechanism of Antiviral Drug Resistance of Vaccinia Virus: Identification of Residues in the Viral DNA Polymerase Conferring Differential Resistance to Antipoxvirus Drugs

E. De Clercq, G. Opdenakker, D. Gammon, 2008, Journal of Virology.

Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections

E. De Clercq, 2021, Viruses.

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition): Retroviruses and Hepadnaviruses

E. De Clercq, H. Field, 2008, Antiviral chemistry & chemotherapy.

Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, E. Clercq, 2000, AIDS research and human retroviruses.

Synthesis and anti-HIV Evaluation of Alkyl and Alkoxyethyl Phosphodiester AZT Derivatives

E. De Clercq, A. Tsotinis, J. Balzarini, 1995 .

The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.

E. De Clercq, J. Balzarini, P. Meeus, 1989, Advances in experimental medicine and biology.

9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats.

E. De Clercq, L. Naesens, J. Balzarini, 1999, Oncology research.

Synthesis, structure–activity relationship and antiviral activity of 3′-N,N-dimethylamino-2′,3′-dideoxythymidine and its prodrugs

E. De Clercq, C. Pannecouque, E. Clercq, 2010, European Journal of Medicinal Chemistry.

Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure

E. De Clercq, L. Naesens, Mariola Koszytkowska-Stawińska, 2008, Bioorganic & Medicinal Chemistry.

Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.

E. De Clercq, C. Perno, J. Balzarini, 1991, Biochemical and biophysical research communications.

Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine

E. De Clercq, L. Naesens, J. Balzarini, 1996, Antimicrobial agents and chemotherapy.

Antiviral activity of C-5 substituted tubercidin analogues.

E. De Clercq, J. Balzarini, D. Bergstrom, 1984, Journal of medicinal chemistry.

Synthesis and Anti-HIV Activity of some Novel Chain-Extended Phosphoramidate Derivatives of d4T (Stavudine): Esterase Hydrolysis as a Rapid Predictive Test for Antiviral Potency

E. De Clercq, J. Balzarini, C. Mcguigan, 1998, Antiviral chemistry & chemotherapy.

Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.

E. De Clercq, C. Pannecouque, Y. Sang, 2018, Bioorganic & medicinal chemistry letters.

Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues

E. De Clercq, 2012, Nucleosides, nucleotides & nucleic acids.

Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents.

E. De Clercq, C. Pannecouque, P. Herdewijn, 2005, Journal of the American Chemical Society.

5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.

E. De Clercq, J. Balzarini, G. Andrei, 2003, Journal of medicinal chemistry.

Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase.

E. De Clercq, J. Balzarini, M. Camarasa, 1995, Journal of medicinal chemistry.

Synthesis, Anti-Human Immunodeficiency Virus Activity and Esterase Lability of Some Novel Carboxylic Ester-Modified Phosphoramidate Derivatives of Stavudine (d4T)

E. De Clercq, M. Gumbleton, J. Balzarini, 1998, Antiviral chemistry & chemotherapy.

Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.

E. De Clercq, L. Naesens, P. Augustijns, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

E. De Clercq, J. Balzarini, S. Schalm, 1994, Antimicrobial Agents and Chemotherapy.

New 3'-azido-3'-deoxythymidin-5'-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: synthesis and anti-HIV evaluation.

E. De Clercq, C. Pannecouque, J. Kraus, 2001, Journal of medicinal chemistry.

Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.

E. De Clercq, J. Balzarini, E. Clercq, 2001, Bioorganic & medicinal chemistry letters.

New 3'-azido-3'-deoxythymidin-5'-yl O-(omega-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation.

E. De Clercq, C. Pannecouque, F. Bihel, 2001, Journal of medicinal chemistry.

Phosphoramidate Derivatives of Stavudine as Inhibitors of HIV: Unnatural Amino Acids May Substitute for Alanine

E. De Clercq, J. Balzarini, C. Mcguigan, 2000, Antiviral chemistry & chemotherapy.

Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.

E. De Clercq, J. Neyts, G. Andrei, 2000, Antiviral research.

cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.

E. De Clercq, J. Balzarini, C. Meier, 1999, Journal of medicinal chemistry.

Conversion of 2′,3′‐dideoxyadenosine (ddA) and 2′,3′‐didehydro‐2′,3′‐dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus

E. De Clercq, C. Pannecouque, L. Naesens, 1997, FEBS letters.

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.

E. De Clercq, L. Naesens, C. Perno, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.

E. De Clercq, J. Balzarini, E. Clercq, 1996, Journal of medicinal chemistry.

Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.

E. De Clercq, T. Burnette, J. Balzarini, 2005, Journal of medicinal chemistry.

Cytotoxic and anticancer properties of some 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinols and related compounds.

E. De Clercq, J. Dimmock, T. Allen, 2001, Die Pharmazie.

Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine.

E. De Clercq, L. Naesens, J. Neyts, 2008, Biochemical pharmacology.

Inhibition of the in vitro growth of Plasmodium falciparum by acyclic nucleoside phosphonates.

E. De Clercq, L. Naesens, J. Balzarini, 1999, International journal of antimicrobial agents.

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.

E. De Clercq, R. Pauwels, M. Baba, 1987, Antiviral research.

The Acyclic Nucleoside Phosphonates (ANPs): Antonín Holý's Legacy

E. De Clercq, 2013, Medicinal research reviews.

Enhanced 9-(2-phosphonylmethoxyethyl)adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line.

E. De Clercq, J. Balzarini, S. Hatse, 1998, Molecular pharmacology.

Selection and characterisation of murine leukaemia L1210 cells with high-level resistance to the cytostatic activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) adenine (PMEA).

E. De Clercq, L. Naesens, J. Balzarini, 1998, Biochimica et biophysica acta.

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

E. De Clercq, L. Naesens, J. Balzarini, 1993, Antimicrobial Agents and Chemotherapy.

9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo.

E. De Clercq, P. Herdewijn, J. Balzarini, 1991, Proceedings of the National Academy of Sciences of the United States of America.

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.

E. De Clercq, 2007, Antiviral research.

Recent developments in herpesvirus therapy.

E. De Clercq, L. Naesens, E. Declercq, 2001, Herpes : the journal of the IHMF.

Tricyclic etheno analogs of PMEG and PMEDAP: synthesis and biological activity.

E. De Clercq, R. Pohl, G. Andrei, 2006, Bioorganic & medicinal chemistry.

6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.

E. De Clercq, L. Naesens, J. Balzarini, 2002, Journal of medicinal chemistry.

Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.

E. De Clercq, J. Balzarini, R. Snoeck, 1999, Journal of medicinal chemistry.

Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance.

C. Manichanh, E. De Clercq, L. Naesens, 2004, Antiviral research.

Antiretroviral drugs.

E. De Clercq, 2010, Current opinion in pharmacology.

ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES

E. De Clercq, C. Pannecouque, L. Naesens, 2005, Nucleosides, nucleotides & nucleic acids.

Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds.

E. De Clercq, J. Balzarini, G. Andrei, 2004, Bioorganic & medicinal chemistry.

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.

E. De Clercq, C. Perno, J. Balzarini, 1996, Biochemical and biophysical research communications.

Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.

E. De Clercq, J. Balzarini, L. Párkányi, 1986, Journal of medicinal chemistry.

A 40-year journey in search of selective antiviral chemotherapy.

E. De Clercq, 2011, Annual review of pharmacology and toxicology.

N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties.

E. De Clercq, L. Naesens, J. Balzarini, 1999, Biochemical pharmacology.

Inhibitory Effects of Acyclic Nucleoside Phosphonate Analogues on Hepatitis B Virus DNA Synthesis in HB611 Cells

E. De Clercq, J. Balzarini, T. Yokota, 1994 .

Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice

E. De Clercq, L. Naesens, P. Annaert, 1998, Antimicrobial Agents and Chemotherapy.

Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.

M. Wulfsohn, E. De Clercq, M. Van Ranst, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.

P. Delvenne, E. De Clercq, J. Piette, 1998, Oncology research.

Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine.

E. De Clercq, A. Tsotinis, J. Balzarini, 1996, Journal of medicinal chemistry.

Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.

E. De Clercq, J. Balzarini, L. Otvös, 1986, Journal of medicinal chemistry.

Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.

E. De Clercq, J. Balzarini, L. Otvös, 1986, Journal of medicinal chemistry.

Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability.

F. Chen, E. De Clercq, C. Pannecouque, 2022, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, Bioorganic & medicinal chemistry.

Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf

Guangdi Li, E. De Clercq, Yike Jiang, 2022, Travel medicine and infectious disease.

Activity of the Anti-Orthopoxvirus Compound ST-246 against Vaccinia, Cowpox and Camelpox Viruses in Cell Monolayers and Organotypic Raft Cultures

E. De Clercq, J. J. van den Oord, R. Jordan, 2007, Antiviral therapy.

Synthesis and antiviral evaluation of some β-l-2′,3′-dideoxy-5-chloropyrimidine nucleosides and pronucleotides☆

E. De Clercq, P. Herdewijn, A. Aerschot, 2000 .

SYNTHESIS OF 1-(2-DEOXY-β-D-RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENES*: “THYMINE REPLACEMENT” ANALOGS OF THYMIDINE FOR EVALUATION AS ANTICANCER AND ANTIVIRAL AGENTS

E. De Clercq, J. Balzarini, L. Wiebe, 2001, Nucleosides, nucleotides & nucleic acids.

Studies on the Mechanism of the Priming Effect of Interferon on Interferon Production by Cell Cultures Exposed to Poly(rI) · Poly(rC)

E. De Clercq, W. Stewart, P. De Somer, 1973, Infection and immunity.

Polynucleotide displacement reactions: detection by interferon induction.

E. De Clercq, B. Witkop, P. Torrence, 1976, Biochemistry.

Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity.

E. De Clercq, J. Neyts, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Comparative efficacy of broad-spectrum antiviral agents as inhibitors of rotavirus replication in vitro.

E. De Clercq, T. Konno, S. Kitaoka, 1986, Antiviral research.

Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo.

E. De Clercq, H. Doerr, R. Blaheta, 2002, Antiviral research.

Clinical features and treatment of adenovirus infections

E. De Clercq, L. Naesens, L. Lenaerts, 2008, Reviews in medical virology.

Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case

E. De Clercq, R. Snoeck, T. Simonart, 1998, Journal of medical virology.

Highlights in the discovery of antiviral drugs: a personal retrospective.

E. De Clercq, 2010, Journal of medicinal chemistry.

Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

E. De Clercq, J. Neyts, F. V. van Kuppeveld, 2009, Antimicrobial Agents and Chemotherapy.

Side-Chain Derivatives of Biologically Active Nucleosides. Part 2: Synthesis and anti-HIV Activity of 5′-C-Methyl Derivatives of 3′-Fluoro-3′-Deoxythymidine

E. De Clercq, J. Balzarini, E. Zbiral, 1996 .

Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication

E. De Clercq, J. Pagano, J. Lin, 1991, Antimicrobial Agents and Chemotherapy.

Design, Synthesis, and Mechanism Study of Benzenesulfonamide-containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, Journal of medicinal chemistry.

Intrathecal administration of interferon in neonatal herpes.

E. De Clercq, J. Desmyter, R. Eeckels, 1975, The Journal of pediatrics.

Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives

E. De Clercq, C. Pannecouque, N. Neamati, 2002, Antimicrobial Agents and Chemotherapy.

CXC-Chemokine Receptor 4 Is Not a Coreceptor for Human Herpesvirus 7 Entry into CD4+ T Cells

E. De Clercq, D. Schols, S. Hatse, 2000, Journal of Virology.

Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.

E. De Clercq, L. Naesens, R. Pohl, 2010, Journal of medicinal chemistry.

Linker optimization of HEPT derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors: from S=O to CHOR

E. De Clercq, C. Pannecouque, Fener Chen, 2022, Chinese Chemical Letters.

A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.

E. De Clercq, C. Pannecouque, J. Balzarini, 2015, Bioorganic & medicinal chemistry.

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.

E. De Clercq, C. Pannecouque, G. Maga, 2007, Bioorganic & medicinal chemistry letters.

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.

E. De Clercq, L. Naesens, G. Georgsson, 1995, Proceedings of the National Academy of Sciences of the United States of America.

9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections

E. De Clercq, R. Cozens, H. Hochkeppel, 1989, Antimicrobial Agents and Chemotherapy.

Interferon and Its Inducers—A Never-Ending Story: “Old” and “New” Data in a New Perspective

E. De Clercq, 2006, The Journal of infectious diseases.

Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.

B. Narasimhan, E. De Clercq, J. Balzarini, 2009, European journal of medicinal chemistry.

2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.

E. De Clercq, J. Molnár, J. Dimmock, 2009, Bioorganic & medicinal chemistry.

Synthesis, antimicrobial and antiviral activity of substituted benzimidazoles

B. Narasimhan, E. De Clercq, J. Balzarini, 2009, Journal of enzyme inhibition and medicinal chemistry.

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Journal of medicinal chemistry.

Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors

E. De Clercq, C. Pannecouque, J. Balzarini, 2014, Medicinal Chemistry Research.

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

E. De Clercq, C. Pannecouque, Xiaodong Ma, 2011, Bioorganic & medicinal chemistry.

Synthesis and antiretrovirus properties of 5'-isocyano-5'-deoxythymidine, 5'-isocyano-2',5'-dideoxyuridine, 3'-azido-5'-isocyano-3',5'-dideoxythymidine, and 3'-azido-5'-isocyano-2',3',5'-trideoxyuridine.

E. De Clercq, J. Balzarini, E. Zbiral, 1991, Journal of medicinal chemistry.

Synthesis, antiretrovirus effects, and phosphorylation kinetics of 3'-isocyano-3'-deoxythymidine and 3'-isocyano-2',3'-dideoxyuridine.

E. De Clercq, J. Balzarini, E. Zbiral, 1990, Journal of medicinal chemistry.

E-5-(2-Chlorovinyl)-2′-Deoxycytidine: Synthesis and Antiherpetic Activity

R. T. Walker, E. De Clercq, A. Kumar, 1990 .

Comparative metabolism of E-5-(2-bromovinyl)-2'-deoxyuridine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells.

E. De Clercq, S. Sacks, R. J. Wanklin, 1987, Molecular pharmacology.

Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs.

R. T. Walker, E. De Clercq, E. Clercq, 1984, Pharmacology & therapeutics.

Synthesis of Novel AZA-Analogues of Tiazofurin with 2-[5,5-bis(Hydroxymethyl)Pyrrolidin-2-yl] Framework as Sugar Mimic

E. De Clercq, L. Naesens, Mariola Koszytkowska-Stawińska, 2012, Nucleosides, nucleotides & nucleic acids.

Novel imidazo[1,2-c]pyrimidine base-modified nucleosides: synthesis and antiviral evaluation.

E. De Clercq, N. Kifli, J. Balzarini, 2004, Bioorganic & medicinal chemistry.

Structure modifications of 6-aminoquinolones with potent anti-HIV activity.

E. De Clercq, C. Pannecouque, M. Palumbo, 2004, Journal of medicinal chemistry.

Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?

E. De Clercq, J. Balzarini, 1995, Farmaco.

Synthesis and Biological Evaluation of Novel 1′‐Branched and Spironucleoside Analogues

E. De Clercq, J. Balzarini, C. Chatgilialoglu, 2004, Nucleosides, Nucleotides & Nucleic Acids.

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

J Desmyter, E. De Clercq, R. Pauwels, 1988, Journal of virological methods.

Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.

Peng Zhan, Jan Balzarini, Christophe Pannecouque, 2014, Bioorganic & medicinal chemistry.

Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.

E. De Clercq, C. Pannecouque, Esra Tatar, 2016, European journal of medicinal chemistry.

Synthesis and Anti‐HIV Activity of 4‐(Naphthalen‐1‐yl)‐1,2,5‐thiadiazol‐3‐hydroxyl Derivatives

E. De Clercq, C. Pannecouque, P. Zhan, 2014, Chemical biology & drug design.

Synthesis and antileishmanial activity of (1,3-benzothiazol-2-yl) amino-9-(10H)-acridinone derivatives.

E. De Clercq, J. Galy, C. Di Giorgio, 2004, European journal of medicinal chemistry.

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

J Desmyter, E. De Clercq, R. Pauwels, 1987, Biochemical and biophysical research communications.

Synthesis and Anti‐HIV Activity Evaluation of Novel 2,4‐Disubstituted 7‐Methyl‐1,1,3‐trioxo‐2,4‐dihydro‐pyrazolo‐[4,5‐e][1,2]thiadiazines

E. De Clercq, C. Pannecouque, P. Zhan, 2008, Archiv der Pharmazie.

Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Chemical Society reviews.

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

Guangdi Li, E. De Clercq, Miao Miao, 2020, Drug design, development and therapy.

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

Peng Zhan, Christophe Pannecouque, E. De Clercq, 2016, Journal of medicinal chemistry.

Antivirals for the treatment of herpesvirus infections.

E. De Clercq, 1993, The Journal of antimicrobial chemotherapy.

Ajoene [(e,z)-4,5,9-trithiadodeca-1,6,11-triene 9 oxide] does not exhibit antiviral activity at subtoxic concentrations.

E. De Clercq, J. Esté, 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Antiviral therapy for human immunodeficiency virus infections

E. De Clercq, E. Clercq, E De Clercq, 1995, Clinical microbiology reviews.

Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.

E. De Clercq, A. Rescifina, M. Chiacchio, 2006, Journal of medicinal chemistry.

Synthesis and evaluation of in vitro antiviral activity of 2-[3-(substituted phenyl)-4,5-dihydro-1H-5-pyrazolyl]benzofuran-3-yl chloride derivatives

E. De Clercq, E. Clercq, A. Husain, 2009, Journal of enzyme inhibition and medicinal chemistry.

Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid.

E. De Clercq, T. L. Gilchrist, M. M. Marques, 2004, Bioorganic & medicinal chemistry.

Benzylidene-bis-(4-Hydroxycoumarin) and Benzopyrano-Coumarin Derivatives: Synthesis, 1H/13C-NMR Conformational and X-ray Crystal Structure Studies and In Vitro Antiviral Activity Evaluations

E. De Clercq, J. Plavec, J. Balzarini, 2011, Molecules.

Design and synthesis of bioactive adamantane spiro heterocycles.

Lieve Naesens, Grigoris Zoidis, George Fytas, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2002, Farmaco.

Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses

E. De Clercq, D. Růžek, L. Eyer, 2018, Antiviral chemistry & chemotherapy.

Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide.

E. De Clercq, F. Şahin, M. Güllüce, 2006, European journal of medicinal chemistry.

Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents.

E. De Clercq, Jianji Wang, G. Andrei, 2010, Bioorganic & medicinal chemistry letters.

Viral Infection and Host Defense

E. De Clercq, W. Carter, 1974, Science.

Cytotoxic activities of Mannich bases of chalcones and related compounds.

T. Myers, E. De Clercq, J. Quail, 1998, Journal of medicinal chemistry.

Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents.

E. De Clercq, J. Neyts, Asish R. Das, 2008, Antiviral research.

Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, D. Daelemans, 2015, Bioorganic & medicinal chemistry.

Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.

Peng Zhan, Xuwang Chen, Christophe Pannecouque, 2012, Bioorganic & medicinal chemistry.

Solvent-Free Synthesis of Pyrimidine Nucleoside-Aminophosphonate Hybrids and Their Biological Activity Evaluation

E. De Clercq, G. Andrei, R. Snoeck, 2010, Nucleosides, nucleotides & nucleic acids.

Antiviral and antimetabolic activities of formycin and its N1-, N2-, 2'-O- and 3'-O-methylated derivatives.

E. De Clercq, M. Luczak, D. Shugar, 1975, Biochemical pharmacology.

Specific phosphorylation of 5-ethyl-2'-deoxyuridine by herpes simplex virus-infected cells and incorporation into viral DNA.

E. De Clercq, R. Bernaerts, 1987, The Journal of biological chemistry.

Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline–triazine derivatives

E. De Clercq, C. Pannecouque, K. Chikhalia, 2014, Journal of enzyme inhibition and medicinal chemistry.

Synthesis and Evaluation of Novel 4‐Substituted Styryl Quinazolines as Potential Antimicrobial Agents

Amit C. Patel, E. De Clercq, C. Pannecouque, 2012, Archiv der Pharmazie.

Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4 & 5)-ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines.

Myriam Witvrouw, Jean-Jacques Vasseur, Christophe Pannecouque, 2002, Farmaco.

Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.

E. De Clercq, Esra Tatar, Ş. Küçükgüzel, 2008, European journal of medicinal chemistry.

Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.

Ilkay Küçükgüzel, E. De Clercq, L. Kabasakal, 2007, European journal of medicinal chemistry.

Synthesis and Studies of New 2‐(Coumarin‐4‐yloxy)‐4,6‐(substituted)‐s‐Triazine Derivatives as Potential Anti‐HIV Agents

Christophe Pannecouque, E. De Clercq, C. Pannecouque, 2009, Archiv der Pharmazie.

Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.

Jan Balzarini, Christophe Pannecouque, E. De Clercq, 2008, European journal of medicinal chemistry.

Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles.

E. De Clercq, C. Pannecouque, A. Chimirri, 2002, Farmaco.

Chiral synthesis of 4-[1-(2-deoxy-beta-L-ribofuranosyl)] derivatives of 2-substituted 5-fluoroaniline: "cytosine replacement" analogues of deoxy-beta-L-cytidine.

E. De Clercq, J. Balzarini, L. Wiebe, 2000, The Journal of organic chemistry.

Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.

E. De Clercq, J. Lown,, J. Balzarini, 1986, Journal of medicinal chemistry.

Synthesis, Antibacterial, Antifungal and Anti-HIV Evaluation of Schiff and Mannich Bases of Isatin and its Derivatives with Triazole

D. Sriram, E. De Clercq, E. Clercq, 2000, Arzneimittelforschung.

New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2002, Bioorganic & medicinal chemistry letters.

Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir.

E. De Clercq, N. Margiotta, G. Natile, 2004, Journal of inorganic biochemistry.

Anti-HIV Activities of Anionic Metalloporphyrins and Related Compounds

E. De Clercq, J. Balzarini, D. Schols, 1997 .

Geiparvarin analogues. 4. Synthesis and cytostatic activity of geiparvarin analogues bearing a carbamate moiety or a furocoumarin fragment on the alkenyl side chain.

E. De Clercq, J. Balzarini, S. Manfredini, 1994, Journal of Medicinal Chemistry.

Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action.

E. De Clercq, C. Pannecouque, J. Balzarini, 2005, The Journal of antimicrobial chemotherapy.

Zinc(II) complexes of constrained antiviral macrocycles.

P. Sadler, E. De Clercq, C. Pannecouque, 2012, Dalton transactions.

Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.

Antonios Kolocouris, Johan Neyts, George Fytas, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and Biological Activity of Novel 1H,3H-Thiazolo[3,4-a]Benzimidazoles: Non-nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors

E. De Clercq, C. Pannecouque, J. Balzarini, 1999, Antiviral chemistry & chemotherapy.

A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.

E. De Clercq, J. Quail, J. Dimmock, 2001, Journal of medicinal chemistry.

Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones.

E. De Clercq, J. Balzarini, E. Clercq, 2001, Bioorganic & medicinal chemistry.

Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones.

Jan Balzarini, James P Stables, Theresa M Allen, 2003, European journal of medicinal chemistry.

Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates.

E. De Clercq, J. Neyts, Asish R. Das, 2009, Journal of medicinal chemistry.

Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.

E. De Clercq, C. Pannecouque, Zhigang Zhou, 2006, Bioorganic & medicinal chemistry.

Regiospecific Synthesis and Anti-Human Immunodeficiency Virus Activity of Novel 5-Substituted N-Alkylcarbamoyl and N,N-Dialkyl Carbamoyl 1,2,3-Triazole-TSAO Analogues

E. De Clercq, F. Gago, J. Balzarini, 1998, Antiviral chemistry & chemotherapy.

Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.

E. De Clercq, J. Neyts, Christos Fytas, 2007, Bioorganic & medicinal chemistry letters.

One-Pot Synthesis of Novel 3-(2-Oxo-2H-chromen-3-yl)-[1,3,4] Thiadiazino [2,3-b] Quinazolin-6 (2H)-ones Under Microwave Irradiation

E. De Clercq, B. Rajitha, V. Kumar, 2007 .

Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies

B. Narasimhan, P. Yogeeswari, D. Sriram, 2012, Medicinal Chemistry Research.

Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.

E. De Clercq, G. Andrei, R. Snoeck, 2007, Bioorganic & medicinal chemistry.

Palladium-catalyzed synthesis of [E]-6-(2-acylvinyl)uracils and [E]-6-(2-acylvinyl)-1-[(2-hydroxyethoxy)methyl]uracils--their antiviral and cytotoxic activities.

E. De Clercq, J. Balzarini, E. Clercq, 1997, Bioorganic & medicinal chemistry.

Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.

Ravindra K Rawal, Christophe Pannecouque, E. De Clercq, 2007, Bioorganic & medicinal chemistry.

Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

Jan Balzarini, Angela Rao, Maria Zappalà, 2004, Farmaco.

A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.

R T Walker, R. T. Walker, E. De Clercq, 1989, Journal of medicinal chemistry.

Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.

E. De Clercq, J. Balzarini, K. Harrap, 1992, Journal of medicinal chemistry.

Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1

E. De Clercq, C. Pannecouque, Neerja Kaushik-Basu, 2013, Archiv der Pharmazie.

Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions

E. De Clercq, 2010, Medicinal research reviews.

Palladium(II) complexes of dialkyl alpha-Anilinobenzylphosphonates. Synthesis, characterization, and cytostatic activity.

E. De Clercq, D. Vikić-Topić, J. Balzarini, 1996, Journal of inorganic biochemistry.

Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine.

D. Sriram, E. De Clercq, E. Clercq, 1999, Farmaco.

Design, Synthesis and Structure—Activity Relationships of Phenylalanine-Containing Peptidomimetics as Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Molecules.

Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, European journal of medicinal chemistry.

Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.

Stephen G. Dimmock, E. De Clercq, J. Dimmock, 2014, European journal of medicinal chemistry.

SYNTHESIS AND BIOLOGICAL ACTIVITIES OF (Z) AND (E) α-ETHENYL ACYCLONUCLEOSIDES

E. De Clercq, J. Balzarini, M. Witvrouw, 2001 .

Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.

R. T. Walker, E. De Clercq, J. Sayers, 1988, Journal of medicinal chemistry.

Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.

E. De Clercq, C. Pannecouque, M. Cushman, 2006, Journal of medicinal chemistry.

5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.

E. De Clercq, J. Balzarini, G. Andrei, 2007, Journal of medicinal chemistry.

Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.

E. De Clercq, P. Herdewijn, R. Snoeck, 1993, Journal of medicinal chemistry.

5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.

E. De Clercq, C. Pannecouque, P. Herdewijn, 1991, Journal of medicinal chemistry.

Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.

E. De Clercq, D. Bergstrom, J. Ruth, 1984, Journal of medicinal chemistry.

Functional roles of azoles motif in anti-HIV agents.

E. De Clercq, P. Zhan, Xinyong Liu, 2011, Current medicinal chemistry.

Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, M. Cushman, 2004, Journal of medicinal chemistry.

Design and synthesis of bioactive 1,2-annulated adamantane derivatives.

E. De Clercq, L. Naesens, A. Tsotinis, 2008, Organic & biomolecular chemistry.

Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.

R T Walker, R. T. Walker, E. De Clercq, 1989, Biochemical and biophysical research communications.

Antiviral drug discovery and development: where chemistry meets with biomedicine.

E. De Clercq, 2005, Antiviral research.

Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.

E. De Clercq, C. Pannecouque, F. Şahin, 2009, European journal of medicinal chemistry.

Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidones and related compounds.

E. De Clercq, J. Quail, J. Dimmock, 2002, European journal of medicinal chemistry.

Heterocyclic rimantadine analogues with antiviral activity.

E. De Clercq, C. Pannecouque, J. Neyts, 2003, Bioorganic & medicinal chemistry.

2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.

E. De Clercq, B. Rosenwirth, H. Griengl, 1987, Journal of medicinal chemistry.

Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.

E. De Clercq, M. Roberti, L. Garuti, 2002, Bioorganic & medicinal chemistry letters.

Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, Zengjun Fang, C. Pannecouque, 2009, European journal of medicinal chemistry.

1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, P. Zhan, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.

E. De Clercq, K. Pavelić, M. Kralj, 2007, Journal of medicinal chemistry.

Geiparvarin analogues. 3. Synthesis and cytostatic activity of 3(2H)-furanone and 4,5-dihydro-3(2H)-furanone congeners of geiparvarin, containing a geraniol-like fragment in the side chain.

E. De Clercq, J. Balzarini, S. Manfredini, 1992, Journal of medicinal chemistry.

Synthesis and antiviral evaluation of cis-substituted cyclohexenyl and cyclohexanyl nucleosides.

E. De Clercq, J. Courcambeck, J. Neyts, 2005, Journal of medicinal chemistry.

Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.

E. De Clercq, J. Balzarini, A. Nagl, 2000, Journal of medicinal chemistry.

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Journal of virology.

2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

E. De Clercq, A. Vandamme, C. Perno, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.

E. De Clercq, J. Balzarini, J. Cannon, 2007, Journal of medicinal chemistry.

A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.

E. De Clercq, J. Balzarini, V. Nair, 2002, Journal of medicinal chemistry.

Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, J. Balzarini, H. Griengl, 1989, Journal of medicinal chemistry.

Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.

E. De Clercq, P. Herdewijn, J. Balzarini, 1985, Journal of medicinal chemistry.

Synthesis and Preliminary Biologic Evaluation of 5‐Substituted‐2‐(4‐substituted phenyl)‐1,3‐Benzoxazoles as A Novel Class of Influenza Virus A Inhibitors

E. De Clercq, L. Naesens, P. Zhan, 2012, Chemical biology & drug design.

Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12

E. De Clercq, C. Pannecouque, A. Vandamme, 1998, Antiviral chemistry & chemotherapy.

Synthesis and Biological Evaluation of Novel 1′‐Branched and Spironucleoside Analogues

E. De Clercq, J. Balzarini, C. Chatgilialoglu, 2004, Nucleosides, nucleotides & nucleic acids.

Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections

E. De Clercq, J. Neyts, 2004, Reviews in medical virology.

Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.

E. De Clercq, M. Hosoya, J. Balzarini, 1992, Journal of medicinal chemistry.

Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Journal of medicinal chemistry.

5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.

J. Champness, E. De Clercq, P. Herdewijn, 1998, Journal of medicinal chemistry.

Synthesis, antiviral, antibacterial and antitumor cell activities of 2'-deoxy-2'-fluoropuromycin.

E. De Clercq, T. Maruyama, Y. Sato, 1995, Chemical & pharmaceutical bulletin.

In vivo effect of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-carboxamide) on experimental infected rainbow trout (Oncorhynchus mykiss) and coho salmon (Oncorhynchus kisutch) fry with infectious pancreatic necrosis virus.

E. De Clercq, A. Sandino, M. Jashés, 2000, Antiviral research.

Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication.

E. De Clercq, A. Sandino, M. Jashés, 2000, Antiviral research.

TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl 3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) purine and purine-modified nucleosides.

E. De Clercq, J. Balzarini, M. Camarasa, 1993, Journal of medicinal chemistry.

(S)-9-(2,3-Dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity

E. De Clercq, J. Descamps, P. De Somer, 1978, Science.

Antiviral activity of aliphatic nucleoside analogues: structure-function relationship.

E. De Clercq, A. Holý, 1979, Journal of medicinal chemistry.

John Montgomery's Legacy: Carbocyclic Adenosine Analogues as Sah Hydrolase Inhibitors with Broad-Spectrum Antiviral Activity

E. De Clercq, 2005, Nucleosides, nucleotides & nucleic acids.

Antirhinovirus activity of purine nucleoside analogs

E. De Clercq, J. Montgomery, D. Bergstrom, 1986, Antimicrobial Agents and Chemotherapy.

Antiviral and antimetabolic activities of neplanocins

E. De Clercq, E. D. Clercq, Rega, 1985, Antimicrobial Agents and Chemotherapy.

Nucleoside-catabolizing enzyme activities in primary rabbit kidney cells and human skin fibroblasts.

E. De Clercq, D. Shugar, E. Krajewska, 1978, Biochemical pharmacology.

Antiviral activity of O'-methylated derivatives of adenine arabinoside.

E. De Clercq, J. Descamps, D. Shugar, 1977, Biochemical pharmacology.

Antiviral activity of 5-ethyl pyrimidine deoxynucleosides.

E. De Clercq, D. Shugar, 1975, Biochemical pharmacology.

Antiviral activity of O'-alkylated derivatives of cytosine arabinoside.

E. De Clercq, E. Darżynkiewicz, D. Shugar, 1975, Biochemical pharmacology.

Synthesis and Antiviral Activity of Novel Fluorinated 2′,3′‐Dideoxynucleosides

E. De Clercq, J. Balzarini, Piyush Kumar, 2004, Nucleosides, nucleotides & nucleic acids.

Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds

E. De Clercq, J. Balzarini, Satyavati Dhulipala, 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors.

Yenamandra S Prabhakar, Y. S. Prabhakar, Ravindra K Rawal, 2005, Bioorganic & medicinal chemistry.

Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

Ravindra K Rawal, Christophe Pannecouque, E. De Clercq, 2008, European journal of medicinal chemistry.

Antiviral activity of Hawaiian medicinal plants against human immunodeficiency Virus Type-1 (HIV-1).

E. De Clercq, R. Pauwels, M. Witvrouw, 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.

E. De Clercq, J. Balzarini, G. Andrei, 2006, Journal of medicinal chemistry.

Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.

E. De Clercq, J. Balzarini, G. Andrei, 2005, Journal of medicinal chemistry.

6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.

E. De Clercq, J. Balzarini, C. Simons, 2004, Journal of medicinal chemistry.

Polysulfonates Derived from Metal Thiolate Complexes as Inhibitors of HIV-1 and Various other Enveloped Viruses In Vitro

E. De Clercq, S. Ikeda, D. Bergstrom, 2002, Antiviral chemistry & chemotherapy.

3,5-Bis(Phenylmethylene)-1-(N-arylmaleamoyl)-4-piperidones: A Novel Group of Cytotoxic Agents

E. De Clercq, R. Sharma, J. Dimmock, 2003, Journal of enzyme inhibition and medicinal chemistry.

(E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity.

E. De Clercq, C. Desgranges, R. Bernaerts, 1989, Biochemical pharmacology.

Synthesis and Conformational Study of 3-Hydroxy-4-(Hydroxymethyl)-1-Cyclohexanyl Purines and Pyrimidines.

E. De Clercq, P. Herdewijn, R. Busson, 1997, The Journal of organic chemistry.

Inhibitory Effect of Pyridobenzoazoles on Orthomyxo-and Paramyxovirus Replication in vitro

E. De Clercq, M. Hosoya, M. Baba, 1992 .

Synthesis and Biological Evaluation of Some Acyclic 4,6-Disubstituted 1H-Pyrazolo[3,4-d]pyrimidine Nucleosides

E. De Clercq, J. Vasseur, H. Lazrek, 2003, Nucleosides, nucleotides & nucleic acids.

Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents.

Ravindra K Rawal, Christophe Pannecouque, E. De Clercq, 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

Ravindra K Rawal, Christophe Pannecouque, E. De Clercq, 2007, Bioorganic & medicinal chemistry.

2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2004, Antiviral research.

Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones.

Angela Rao, Maria Zappalà, Pietro Monforte, 2003, Farmaco.

Cytotoxic and anticonvulsant aryloxyaryl Mannich bases and related compounds.

E. De Clercq, J. Dimmock, J. Balzarini, 2004, European journal of medicinal chemistry.

The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.

Jan Balzarini, Marko Marjanović, E. De Clercq, 2007, Bioorganic & medicinal chemistry.

Synthesis and Screening for Anti-HIV Activity of Some N-Mannich Bases of Isatin Derivatives

P. Yogeeswari, D. Sriram, E. De Clercq, 1999, Chemotherapy.

Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.

E. De Clercq, C. Pannecouque, J. Balzarini, 2010, Bioorganic & medicinal chemistry.

Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of new s-triazine-based heterocycles.

E. De Clercq, C. Pannecouque, P. Kumari, 2012, Future Medicinal Chemistry.

Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus.

E. De Clercq, J. Neyts, F. Shieh, 2013, European journal of medicinal chemistry.

Geiparvarin analogues. 2. Synthesis and cytostatic activity of 5-(4-arylbutadienyl)-3(2H)-furanones and of N-substituted 3-(4-oxo-2-furanyl)-2-buten-2-yl carbamates.

E. De Clercq, J. Balzarini, S. Manfredini, 1991, Journal of medicinal chemistry.

Synthesis and cytostatic activity of geiparvarin analogues.

E. De Clercq, J. Balzarini, S. Manfredini, 1989, Journal of medicinal chemistry.

Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives.

Peng Zhan, E. De Clercq, P. Zhan, 2008, Current medicinal chemistry.

Synthesis and biological evaluation of 1,2-disubstituted carbonucleosides of 2-amino-6-substituted purine and 8-azapurine.

L. Santana, E. Uriarte, E. De Clercq, 1998, Bioorganic & medicinal chemistry letters.

Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs.

Peng Zhan, E. De Clercq, P. Zhan, 2009, Mini reviews in medicinal chemistry.

Design, synthesis, and biological evaluation of piperidinyl‐substituted [1,2,4]triazolo[1,5‐a]pyrimidine derivatives as potential anti‐HIV‐1 agents with reduced cytotoxicity

E. De Clercq, Dongwei Kang, Boshi Huang, 2020, Chemical biology & drug design.

Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.

Peng Zhan, Ye Tian, Xuwang Chen, 2012, Bioorganic & medicinal chemistry letters.

Synthesis, anticancer and cytostatic activity of some 6H-indolo[2,3-b]quinoxalines

E. De Clercq, J. Balzarini, Sujeet Kumar, 2009, Acta pharmaceutica.

N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.

E. De Clercq, C. Pannecouque, P. Herdewijn, 2003, Journal of medicinal chemistry.

Anti-HIV agents: design and discovery of new potent RT inhibitors.

E. De Clercq, L. De Luca, M. Barreca, 2003, Farmaco.

Sydnone Sulfonamide Derivatives as Antibacterial, Antifungal, Antiproliferative and Anti-HIV Agents

E. De Clercq, C. Pannecouque, K. Patel, 2014, Pharmaceutical Chemistry Journal.

Spirobipyridopyrans, spirobinaphthopyrans, indolinospiropyridopyrans, indolinospironaphthopyrans and indolinospironaphtho-1,4-oxazines: synthesis, study of X-ray crystal structure, antitumoral and antiviral evaluation.

E. De Clercq, K. Pavelić, Linda Tomašković, 2004, Bioorganic & medicinal chemistry.

Synthesis and Anti-Human Immunodeficiency virus Type 1 Activity of Novel 3′-Spiro Nucleoside Analogues of TSAO-T

E. De Clercq, M. Camarasa, M. Jimeno, 1997 .

Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.

R T Walker, R. T. Walker, S Shigeta, 1992, Journal of medicinal chemistry.

E. De Clercq, J. Balzarini, F. Hansske, 1987, Journal of medicinal chemistry.

Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.

R T Walker, R. T. Walker, S Shigeta, 2010, Journal of medicinal chemistry.

Non-Nucleoside Structures Retain Full Anti-HCMV Potency of the Dideoxy Furanopyrimidine Family

E. De Clercq, O. Bidet, J. Balzarini, 2004, Antiviral chemistry & chemotherapy.

Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.

R. Esnouf, E. De Clercq, A. V. van Kuilenburg, 2002, Molecular pharmacology.

Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.

E. De Clercq, L. Naesens, A. Brancale, 2002, Molecular pharmacology.

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.

J. T. Erichsen, J. Erichsen, E. De Clercq, 2000, Journal of medicinal chemistry.

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.

E. De Clercq, A. Brancale, J. Balzarini, 1999, Journal of medicinal chemistry.

Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice.

E. De Clercq, R. Pauwels, H. Keizer, 1988, Cancer letters.

Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice.

E. De Clercq, E. Clercq, M. Iigo, 1987, European journal of cancer & clinical oncology.

Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.

E. De Clercq, P. Herdewijn, J. Balzarini, 1986, Cancer research.

The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, 1984, The Journal of antimicrobial chemotherapy.

Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets.

E. De Clercq, J. Balzarini, C. Desgranges, 1983, Biochemical pharmacology.

Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.

E. De Clercq, J. Balzarini, M. Witvrouw, 1996, Journal of medicinal chemistry.

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N, E138K Mutants, and Pharmacokinetic Profiles.

E. De Clercq, C. Pannecouque, Fener Chen, 2020, ACS infectious diseases.

Furano Pyrimidines as Novel Potent and Selective Anti-VZV Agents

E. De Clercq, A. Brancale, O. Bidet, 2001, Antiviral chemistry & chemotherapy.

Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles

E. De Clercq, C. Pannecouque, N. Patel, 2013, Medicinal Chemistry Research.

Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs.

E. De Clercq, C. Pannecouque, Xinyong Liu, 2007, Molecules.

Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives.

E. De Clercq, J. Neyts, J. Balzarini, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and Antiviral Properties of Arabino and Ribonucleosides of 1,3‐Dideazaadenine, 4‐Nitro‐1, 3‐dideazaadenine and Diketopiperazine

E. De Clercq, R. Srivastava, Ramendra K. Singh, 2004, Nucleosides, nucleotides & nucleic acids.

Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus.

E. De Clercq, D. Růžek, L. Eyer, 2016, Antiviral research.

1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation.

E. De Clercq, Zengjun Fang, C. Pannecouque, 2009, Bioorganic & medicinal chemistry.

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Guangdi Li, E. De Clercq, 2017, Antiviral Research.

Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.

E. De Clercq, M. Preobrazhenskaya, J. Balzarini, 2005, Journal of medicinal chemistry.

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

E. De Clercq, M. Van Ranst, M. Preobrazhenskaya, 2006, Antiviral Research.

Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines.

E. De Clercq, C. Pannecouque, J. Balzarini, 2009, Yao xue xue bao = Acta pharmaceutica Sinica.

Heterocyclic rimantadine analogues with antiviral activity.

E. De Clercq, L. Naesens, J. Neyts, 2003, Bioorganic & medicinal chemistry.

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

Dominique Schols, E. De Clercq, D. Schols, 2010, Journal of medicinal chemistry.

Synthesis of acyclic 6,7-dihaloquinolone nucleoside analogues as potential antibacterial and antiviral agents.

E. De Clercq, E. Clercq, Yaseen A. Al-Soud, 2000, Bioorganic & medicinal chemistry.

Synthesis of novel biologically active methylene derivatives of sydnones

E. De Clercq, C. Pannecouque, C. Supuran, 2013, Medicinal Chemistry Research.

Niacin esters of chalcones with tumor-selective properties

E. De Clercq, J. Dimmock, J. Balzarini, 2016, Journal of enzyme inhibition and medicinal chemistry.

Imidazothiadiazine dioxides: synthesis and antiviral activity.

E. De Clercq, J. Balzarini, R. Snoeck, 1999, Bioorganic & medicinal chemistry.

The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures

E. De Clercq, 2010, Medicinal research reviews.

Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.

Peng Zhan, Ye Tian, Christophe Pannecouque, 2014, Bioorganic & medicinal chemistry.

Probing key coordination interactions: configurationally restricted metal activated CXCR4 antagonists.

E. De Clercq, C. Pannecouque, S. Archibald, 2007, Dalton transactions.

Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Peng Zhan, Jing Zhang, Christophe Pannecouque, 2011, Bioorganic & medicinal chemistry.

Stereospecific synthesis and biological evaluations of beta-L-pentofuranonucleoside derivatives of 5-fluorouracil and 5-fluorocytosine.

E. De Clercq, J. Balzarini, J. Sommadossi, 2001, European journal of medicinal chemistry.

Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.

Peng Zhan, Jan Balzarini, Christophe Pannecouque, 2014, Bioorganic & medicinal chemistry.

Basic approaches to anti-retroviral treatment.

E. De Clercq, 1991, Journal of acquired immune deficiency syndromes.

Synthesis, Structure and in Vitro Anti-Human Immunodeficiency virus Activity of Novel 3-Methyl-1H,3H-Thiazolo[3,4-a]Benzimidazoles

E. De Clercq, C. Pannecouque, M. Witvrouw, 1998, Antiviral chemistry & chemotherapy.

Structural Features and Anti-Human Immunodeficiency Virus (HIV) Activity of the Isomers of 1-(2′,6′-Difluorophenyl)-1H,3H-Thiazolo[3,4-a]Benzimidazole, a Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor

E. De Clercq, J. Balzarini, M. Witvrouw, 1997 .

Antiviral Activity of low-MW Dextran Sulphate (Derived from dextran MW 1000) Compared to Dextran Sulphate Samples of Higher MW

E. De Clercq, R. Pauwels, M. Hosoya, 1991 .

New neplanocin analogues. 6. Synthesis and potent antiviral activity of 6'-homoneplanocin A1.

E. De Clercq, S. Shuto, R. Snoeck, 1996, Journal of medicinal chemistry.

5-Substituted 2'-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase.

E. De Clercq, J. Balzarini, D. Shugar, 1982, Biochemical pharmacology.

Synthesis and biological evaluation of a carbocyclic azanoraristeromycin siderophore conjugate.

E. De Clercq, M. Miller, J. Balzarini, 1999, Nucleosides & nucleotides.

The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides.

E. De Clercq, P. Herdewijn, 2001, Bioorganic & medicinal chemistry letters.

Novel Human Immunodeficiency Virus (HIV) Inhibitors That Have a Dual Mode of Anti-HIV Action

E. De Clercq, C. Pannecouque, J. Balzarini, 2003, Antimicrobial Agents and Chemotherapy.

Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives

E. De Clercq, C. Pannecouque, J. Balzarini, 2003, Antimicrobial Agents and Chemotherapy.

Antiproliferative and Antiviral Activity of Three Libraries of Adamantane Derivatives

E. De Clercq, J. Balzarini, N. Basarić, 2014, Archiv der Pharmazie.

Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides

B. Narasimhan, P. Yogeeswari, D. Sriram, 2011, Medicinal Chemistry Research.

Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, G. Maga, 2010, Bioorganic & medicinal chemistry.

Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT.

Jan Balzarini, Angela Rao, Maria Zappalà, 2005, Journal of medicinal chemistry.

Anti‐HIV Activity of Thiosemicarbazone and Semicarbazone Derivatives of (±)‐3‐Menthone

E. De Clercq, C. Pannecouque, M. Witvrouw, 2002, Archiv der Pharmazie.

Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: from anti-pestivirus to anti-hepatitis C virus activity.

E. De Clercq, J. Neyts, J. Paeshuyse, 2007, Bioorganic & medicinal chemistry letters.

Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action.

I. Morize, E. De Clercq, R. Pauwels, 1996, Journal of medicinal chemistry.

Comparative Study of Bis(Benzyl)Phosphate Triesters of 2′,3′-Dideoxy-2′,3′-Didehydrothymidine (d4T) and CycloSal-d4TMP — Hydrolysis, Mechanistic Insights and Anti-HIV Activity

E. De Clercq, L. Naesens, J. Balzarini, 2002, Antiviral chemistry & chemotherapy.

Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments.

E. De Clercq, C. Pannecouque, E. Clercq, 2001, Bioorganic & medicinal chemistry.

Molecular strategies to inhibit the replication of RNA viruses

E. De Clercq, J. Neyts, P. Leyssen, 2008, Antiviral Research.

Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.

E. De Clercq, B. Golankiewicz, J. Boryski, 1991, Journal of medicinal chemistry.

Resolution of aristeromycin enantiomers.

E. De Clercq, P. Herdewijn, J. Balzarini, 1985, Journal of medicinal chemistry.

Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles.

E. De Clercq, J. Balzarini, P. Baraldi, 2005, Bioorganic & medicinal chemistry letters.

Angiogenesis: regulators and clinical applications.

E. De Clercq, J. Neyts, E. Clercq, 2001, Biochemical pharmacology.

Synthesis of Unusual Bicyclic Nucleosides Bearing an Unsaturated Side-Chain, as Potential Inhibitors of Varicella-Zoster Virus (VZV)

E. De Clercq, O. Bidet, J. Balzarini, 2003, Nucleosides, nucleotides & nucleic acids.

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, Organic & biomolecular chemistry.

Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.

E. De Clercq, J. Balzarini, Aihua Zhou, 2003, Journal of medicinal chemistry.

Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity.

E. De Clercq, J. Balzarini, G. Andrei, 1996, Journal of medicinal chemistry.

An epimer of 5'-noraristeromycin and its antiviral properties.

E. De Clercq, S. Ikeda, J. Balzarini, 1994, Journal of medicinal chemistry.

Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.

E. De Clercq, J. Balzarini, N. Poopeiko, 1991, Journal of medicinal chemistry.

Investigations on the anti-HIV activity of 2',3'-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Potent and selective anti-HIV activity of 2,6-diaminopurine 2',3'-dideoxyriboside.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

Antiviral, antimetabolic and antineoplastic activities of 2'- or 3'-amino or -azido-substituted deoxyribonucleosides.

E. De Clercq, J. Balzarini, J. Descamps, 1980, Biochemical pharmacology.

E-5-(2-bromovinyl)-2'-deoxyuridine vs. interferon in the systemic treatment of infection with herpes simplex virus of athymic nude mice.

E. De Clercq, J. Descamps, K. Huygen, 1981, The Journal of infectious diseases.

SYNTHESIS AND IN VITRO ANTIVIRAL ACTIVITY EVALUATION OF 9-(2-AZIDO-2,3-DIDEOXY-β-D-THREO-PENTOFURANOSYL)ADENINE DERIVATIVES

E. De Clercq, S. Takamatsu, E De Clercq, 2001, Nucleosides, nucleotides & nucleic acids.

Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Journal of medicinal chemistry.

Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Journal of virological methods.

The 2',3'-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication in vitro.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Biochemical and biophysical research communications.

Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).

E. De Clercq, R. Borchardt, J. Balzarini, 1998, Journal of medicinal chemistry.

Evaluation of Antiviral and Cytotoxic Activities of Methanolic Extract of Thespesia Populnea (Malvaceae) Flowers

E. De Clercq, J. Vanitha, Saravanakumar Arthanari, 2011 .

On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, J. Bertino, J. Kozarich, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Monoglycosyl, diglycosyl, and dinucleoside methylenediphosphonates: direct synthesis and antiviral activity.

E. De Clercq, C. Grison, P. Coutrot, 2006, Carbohydrate research.

Synthesis and antiviral activity of 3'-C-branched-3'-deoxy analogues of adenosine.

T. M. Tsvetkova, E. De Clercq, J. Balzarini, 1996, Carbohydrate research.

Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.

E. De Clercq, J. Balzarini, C. Mcguigan, 2001, Bioorganic & medicinal chemistry letters.

SYNTHESIS AND IN VITRO CYTOTOXIC AND ANTIVIRAL ACTIVITIES OF 1-(2,5,6-TRIDEOXY-6-HALOGENOHEPT-5-ENOFURANURONONITRILE)THYMINE AND DERIVATIVES

E. De Clercq, J. Tronchet, M. Seman, 2002, Nucleosides, nucleotides & nucleic acids.

Sugar-modified conjugated diene analogues of adenosine and uridine: synthesis, interaction with S-adenosyl-L-homocysteine hydrolase, and antiviral and cytostatic effects.

E. De Clercq, R. Borchardt, C. A. Valdez, 2002, Journal of medicinal chemistry.

The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations.

E. De Clercq, K. Pavelić, M. Kralj, 2005, Journal of medicinal chemistry.

Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives

E. De Clercq, M. Bakht, M. Shahar Yar, 2009, Journal of enzyme inhibition and medicinal chemistry.

Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)

E. De Clercq, 2007, Advances in Antiviral Drug Design.

Chemotherapeutic agents for herpesvirus infections.

R. T. Walker, E. De Clercq, R. Walker, 1986, Progress in medicinal chemistry.

Synthesis and Antiviral Activity of the alpha-Analogues of 1,5-Anhydrohexitol Nucleosides (1,5-Anhydro-2,3-dideoxy-D-ribohexitol Nucleosides).

E. De Clercq, P. Herdewijn, J. Rozenski, 1997, The Journal of organic chemistry.

Spectroscopic and biological properties of palladium(II) complexes of ethyl 2-quinolylmethylphosphonate.

E. De Clercq, J. Balzarini, L. Tušek-Boz̆ić, 1998, Journal of inorganic biochemistry.

Nonnucleoside HIV-1 reverse transcriptase inhibitors: Part I. Synthesis and structure-activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues.

E. De Clercq, C. Pannecouque, J. Balzarini, 2003, Chemical & pharmaceutical bulletin.

SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus

E. De Clercq, C. Pannecouque, A. Vandamme, 1997, Antimicrobial agents and chemotherapy.

Thiosugars. X. Novel Nucleoside Analogues Derived from 4-Thio-L-lyxofuranose

E. De Clercq, J. Balzarini, J. Wirsching, 2003, Nucleosides, nucleotides & nucleic acids.

Thiosugars. Part 5: synthesis and biological activity of 1-(4-thio-L-arabinofuranosyl)-5-halopyrimidine nucleosides.

E. De Clercq, J. Balzarini, J. Wirsching, 2000, Bioorganic & medicinal chemistry letters.

A mercapto analogue of 5'-noraristeromycin.

E. De Clercq, J. Balzarini, Subha R. Das, 2002, Bioorganic & medicinal chemistry.

Configurationally restricted bismacrocyclic CXCR4 receptor antagonists.

Stephen J Archibald, Peter J Sadler, Christophe Pannecouque, 2006, Journal of medicinal chemistry.

Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.

E. De Clercq, E De Clercq, 2000, Molecular pharmacology.

Aryl-Substituted and Benzo-Annulated CycloSal-Derivatives of 2′,3′-Dideoxy-2′,3′-Didehydrothymidine Monophosphate — Correlation of Structure, Hydrolysis Properties and Anti-HIV Activity

E. De Clercq, L. Naesens, J. Balzarini, 2002, Antiviral chemistry & chemotherapy.

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.

E. De Clercq, D. Schols, M. Witvrouw, 1999, Journal of medicinal chemistry.

SYNTHESIS AND ANTI-HIV ACTIVITY OF THYMIDINE ANALOGUES BEARING A 4′-CYANOVINYL GROUP AND SOME DERIVATIVES THEREOF

E. De Clercq, J. Tronchet, M. Seman, 2001, Nucleosides, nucleotides & nucleic acids.

First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.

E. De Clercq, C. Pannecouque, C. Len, 2005, Journal of medicinal chemistry.

Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.

E. De Clercq, J. Dimmock, T. Lóránd, 2008, European journal of medicinal chemistry.

Anti‐influenza virus agents: Synthesis and mode of action

E. De Clercq, I. Lagoja, 2006, Medicinal research reviews.

Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases.

E. De Clercq, C. Pannecouque, L. Bannwarth, 2009, Biochemistry.

Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives.

E. De Clercq, J. Neyts, J. Balzarini, 2006, Journal of medicinal chemistry.

Antiviral Activity of Cyclosaligenyl Prodrugs of Acyclovir, Carbovir and Abacavir

E. De Clercq, J. Balzarini, C. Meier, 2001, Antiviral chemistry & chemotherapy.

Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP.

E. De Clercq, J. Balzarini, E. Clercq, 2000, Molecular pharmacology.

Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine).

E. De Clercq, L. Naesens, C. Perno, 1999, Molecular pharmacology.

Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine.

E. De Clercq, L. Naesens, J. Balzarini, 1999, Molecular pharmacology.

Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.

E. De Clercq, P. Herdewijn, J. Balzarini, 1989, The Journal of biological chemistry.

Synthesis and Antiviral Evaluation of Phosphoramidate Derivatives of (E)-5-(2-Bromovinyl)-2′-Deoxyuridine

E. De Clercq, J. Balzarini, C. Mcguigan, 2001, Antiviral chemistry & chemotherapy.

CycloSal-2'-ara(ribo)-fluoro-2',3'-dideoxyadenosine monophosphates--an effort to solve the structure-activity relationship of 2'-fluoro-ddA.

E. De Clercq, J. Balzarini, V. Marquez, 1999, Nucleosides & nucleotides.

Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.

R. T. Walker, E. De Clercq, J. Balzarini, 1990, Journal of medicinal chemistry.

Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.

E. De Clercq, M. Baba, T. Yokota, 1983, The Journal of infectious diseases.

Synthesis and anti-HIV1 biological activity of novel 5''-ATSAO compounds.

E. De Clercq, C. Pannecouque, J. Balzarini, 2008, Bioorganic & medicinal chemistry.

Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.

E. De Clercq, C. Pannecouque, J. Balzarini, 2008, Bioorganic & medicinal chemistry letters.

New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A.

E. De Clercq, S. Shuto, A. Matsuda, 1996, Journal of medicinal chemistry.

New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents.

E. De Clercq, S. Shuto, M. Hosoya, 1992, Journal of medicinal chemistry.

The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.

E. De Clercq, P. Herdewijn, R. Snoeck, 2000, Journal of medicinal chemistry.

Synthesis and anti-HIV properties of 1,2,4,6-thiatriazin-3-one 1,1-dioxide nucleosides.

E. De Clercq, J. Balzarini, M. Jimeno, 1998, Nucleosides & nucleotides.

Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV)

E. De Clercq, H. Mitsuya, S. Broder, 1986, International journal of cancer.

"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.

E. De Clercq, S. Asaftei, 2010, Journal of medicinal chemistry.

Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.

E. De Clercq, R. Pauwels, M. Hosoya, 1992, Molecular pharmacology.

Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.

E. De Clercq, F. Gago, J. Balzarini, 2005, Journal of medicinal chemistry.

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

Nuno R. Faria, Guangdi Li, E. De Clercq, 2020, Clinical & translational immunology.

Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds.

E. De Clercq, J. Dimmock, Rajendra K. Sharma, 2006, European journal of medicinal chemistry.

Cytotoxic Mannich Bases of 1-Arylidene-2-tetralones

E. De Clercq, R. Sharma, J. Dimmock, 2003, Journal of enzyme inhibition and medicinal chemistry.

Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.

E. De Clercq, J. Quail, J. Dimmock, 2002, Journal of medicinal chemistry.

Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.

L. Prasad, E. De Clercq, J. Quail, 1999, Journal of medicinal chemistry.

Synthesis, Protonation Behavior, Conformational Analysis, and Regioselective Enzymatic Acylation of the Novel Diamino Analogue of (E)-5-(2-Bromovinyl)-2′-deoxyuridine (BVDU)

E. De Clercq, I. Lavandera, S. Fernández, 2003, Nucleosides, nucleotides & nucleic acids.

A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951–2021)

Guangdi Li, E. De Clercq, 2021, Medicinal research reviews.

3'-C-branched 2'-deoxy-5-methyluridines: synthesis, enzyme inhibition, and antiviral properties.

E. De Clercq, M. Kukhanova, J. Balzarini, 1992, Journal of medicinal chemistry.

Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles.

E. De Clercq, J. Neyts, G. Fytas, 2006, Bioorganic chemistry.

5-Nitro-2'-deoxyuridine and 5-nitro-2'-deoxyuridine 5'-monophosphate: antiviral activity and inhibition of thymidylate synthetase in vivo.

E. De Clercq, J. Descamps, P. Torrence, 1978, Molecular pharmacology.

5-Substituted uracil arabinonucleosides as potential antiviral agents.

E. De Clercq, B. Bhooshan, J. Descamps, 1979, Journal of medicinal chemistry.

Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.

E. De Clercq, J. Lown,, R. Newman, 1989, Journal of medicinal chemistry.

Thymidylate synthetase‐positive and ‐negative murine mammary FM3A carcinoma cells as a useful system for detecting thymidylate synthetase inhibitors

E. De Clercq, T. Seno, D. Ayusawa, 1984, FEBS letters.

Antiviral activity of 5-methylthiomethyl-2'-deoxyuridine and other 5-substituted 2'-deoxyuridines.

E. De Clercq, J. Descamps, M. Mertes, 1979, Biochemical Pharmacology.

Oxovanadium(IV) cyclam and bicyclam complexes: potential CXCR4 receptor antagonists.

P. Sadler, E. De Clercq, C. Pannecouque, 2010, Inorganic chemistry.

Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa.

E. De Clercq, Y. Asakawa, L. Harinantenaina, 2007, Journal of natural products.

Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors.

E. De Clercq, M. Baba, E. Clercq, 1992, Antiviral research.

Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV).

E. De Clercq, M. Baba, A. Sato, 1988, Antiviral research.

Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].

E. De Clercq, R. Pauwels, M. Baba, 1987, Antiviral research.

Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.

E. De Clercq, H. Mitsuya, S. Broder, 1986, Biochemical and biophysical research communications.

Thymidylate synthetase-deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA.

E. De Clercq, T. Seno, D. Ayusawa, 1984, The Biochemical journal.

Role of thymidine kinase in the inhibitory activity of 5-substituted-2'-deoxyuridines on the growth of human and murine tumor cell lines.

R. T. Walker, E. De Clercq, P. Barr, 1982, Biochemical pharmacology.

Oxime and dithiolane derivatives of 5-formyl-2'-deoxyuridine and their 5'-phosphates: antiviral effects and thymidylate synthetase inhibition.

E. De Clercq, J. Descamps, C. Chang, 1980, Journal of medicinal chemistry.

Synthesis of 5-[(methylthio)methyl]-2'-deoxyuridine, the corresponding sulfoxide and sulfone, and their 5'-phosphates: antiviral effects and thymidylate synthetase inhibition.

E. De Clercq, J. Descamps, C. Chang, 1980, Journal of medicinal chemistry.

5-Propyl-2'-deoxyuridine: a specific anti-herpes agent

E. De Clercq, J. Descamps, D. Shugar, 1978, Antimicrobial Agents and Chemotherapy.

Deoxyribosyl exchange reactions leading to the in vivo generation and regeneration of the antiviral agents (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5-ethyl-2'-deoxyuridine and 5-(2-chloroethyl)-2'-deoxyuridine.

E. De Clercq, C. Desgranges, H. Bricaud, 1986, Biochemical pharmacology.

Antiviral, antitumor, and thymidylate synthetase inhibition studies of 5-substituted styryl derivatives of 2'-deoxyuridine and their 5'-phosphates.

E. De Clercq, J. Balzarini, J. Descamps, 1981, Biochemical pharmacology.

Antiviral activity of 5-thiocyanatopyrimidine nucleosides.

E. De Clercq, B. Witkop, P. Torrence, 1975, Biochemical pharmacology.

Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives

E. De Clercq, C. Pannecouque, E. Verbeken, 2007, Antimicrobial Agents and Chemotherapy.

A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors

E. De Clercq, C. Pannecouque, G. Pavlakis, 2005, Molecular Pharmacology.

Chemical studies of essential oils of Juniperus oxycedrus ssp. badia.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2002, Journal of ethnopharmacology.

A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors.

E. De Clercq, A. Vandamme, E. Clercq, 2001, Journal of virological methods.

Activities of Several Classes of Acyclic Nucleoside Phosphonates against Camelpox Virus Replication in Different Cell Culture Models

E. De Clercq, J. J. van den Oord, R. De vos, 2007, Antimicrobial Agents and Chemotherapy.

New developments in anti-HIV chemotherapy

E. De Clercq, 2001, Current medicinal chemistry.

Novel bicyclic sugar modified nucleosides: synthesis, conformational analysis and antiviral evaluation.

E. De Clercq, N. Kifli, J. Balzarini, 2004, Bioorganic & medicinal chemistry.

The multifunctional deoxynucleoside kinase of insect cells is a target for the development of new insecticides.

E. De Clercq, B. Degrève, J. Balzarini, 2000, Molecular pharmacology.

Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.

Peng Zhan, Jan Balzarini, Xuwang Chen, 2012, Bioorganic & medicinal chemistry.

Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents

E. De Clercq, C. Pannecouque, L. Naesens, 2012, Archives of Pharmacal Research.

Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.

E. De Clercq, C. Pannecouque, P. Zhan, 2011, European journal of medicinal chemistry.

The design of drugs for HIV and HCV.

E. De Clercq, Erik De Clercq, 2007, Nature reviews. Drug discovery.

Antifungal and antibacterial activities of diarylamidine derivatives

E. De Clercq, H. Eyssen, O. Dann, 1980, Antimicrobial Agents and Chemotherapy.

Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro.

E. De Clercq, S. Shigeta, F. Kawana, 1985, Antiviral research.

Exploring the active site of herpes simplex virus type‐1 thymidine kinase by X‐ray crystallography of complexes with aciclovir and other ligands

Frank Wien, Piet Herdewijn, Tomasz Ostrowski, 1998, Proteins.

New approaches toward anti-HIV chemotherapy.

E. De Clercq, 2005, Journal of medicinal chemistry.

In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine.

E. De Clercq, M. Nasisse, M. Davidson, 1989, American journal of veterinary research.

A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.

E. De Clercq, C. Pannecouque, T. Klimkait, 2000, Molecular pharmacology.

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

E. De Clercq, E. Clercq, D. Schols, 1997, Antiviral research.

Protective activity of lipid A analogue GLA‐60 against murine cytomegalovirus infection in mice

E. De Clercq, S. Ikeda, J. Neyts, 1993, Journal of medical virology.

Flow cytometric method for the detection of gpI antigens of varicella zoster virus and evaluation of anti-VZV agents.

E. De Clercq, J. Piette, B. Rentier, 1992, Journal of virological methods.

Differential Activity of Polyanionic Compounds and Castanospermine against HIV Replication and HIV-Induced Syncytium Formation Depending on Virus Strain and Cell Type

E. De Clercq, R. Pauwels, D. Schols, 1992 .

Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain.

E. De Clercq, M. Saijo, I. Kurane, 2002, Antiviral research.

Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method.

E. De Clercq, E. Kodama, S. Shigeta, 1996, Antiviral research.

Synthesis and Antiviral Activity of a Series of New Cyclohexenyl Nucleosides

E. De Clercq, P. Herdewijn, R. Busson, 2003, Antiviral chemistry & chemotherapy.

Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir.

E. De Clercq, J. Neyts, E. Clercq, 1998, Antiviral research.

Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus

E. De Clercq, J. Balzarini, D. C. Dao, 1996, Antimicrobial agents and chemotherapy.

Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.

E. De Clercq, O. Fodstad, J. Balzarini, 1999, Cancer research.

Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulencein Mice

E. De Clercq, G. Opdenakker, D. Gammon, 2006, Journal of Virology.

Inhibitory Activities of Three Classes of Acyclic Nucleoside Phosphonates against Murine Polyomavirus and Primate Simian Virus 40 Strains

E. De Clercq, G. Andrei, R. Snoeck, 2007, Antimicrobial Agents and Chemotherapy.

Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine against Orthopoxviruses in Cell Monolayers and in Organotypic Cultures

E. De Clercq, J. J. van den Oord, G. Andrei, 2006, Antimicrobial Agents and Chemotherapy.

6‐[2‐Phosphonomethoxy)Alkoxy]‐2,4‐Diaminopyrimidines: A New Class of Acyclic Pyrimidine Nucleoside Phosphonates with Antiviral Activity

E. De Clercq, C. Pannecouque, L. Naesens, 2004, Nucleosides, nucleotides & nucleic acids.

A case of human Orf in an immunocompromised patient treated successfully with cidofovir cream

E. De Clercq, Y. Vanrenterghem, R. De vos, 2001, Journal of medical virology.

Activity of a Sulfated Polysaccharide Extracted from the Red Seaweed Aghardhiella Tenera against Human Immunodeficiency Virus and Other Enveloped Viruses

E. De Clercq, R. Pauwels, S. Ikeda, 1994 .

Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses

E. De Clercq, R. Pauwels, M. Hosoya, 1990 .

Varicella-zoster virus in the human corneal endothelium: a case report.

E. De Clercq, L. Missotten, J. Descamps, 1980, Bulletin de la Societe belge d'ophtalmologie.

Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents.

E. De Clercq, E. Clercq, P. Maudgal, 1991, Current eye research.

Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.

E. De Clercq, O. P. van Bijsterveld, P. Maudgal, 1989, The British journal of ophthalmology.

Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine.

E. De Clercq, L. Missotten, E. Clercq, 1982, Archives of ophthalmology.

The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.).

E. Frison, E. De Clercq, J. Neyts, 2003, Antiviral research.

Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.

E. De Clercq, J. Neyts, E. Clercq, 1991, Antiviral research.

Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro.

E. De Clercq, M. Baba, T. Yokota, 1991, The Journal of infectious diseases.

Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.

E. De Clercq, J. Neyts, D. Schols, 1991, Journal of virological methods.

The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication

E. De Clercq, J. Neyts, J. Balzarini, 1994, Antimicrobial Agents and Chemotherapy.

Antiviral drug sensitivity in ocular herpes simplex virus infection.

E. De Clercq, D. Easty, S. Cook, 1990, The British journal of ophthalmology.

Absence of infectious retinitis after injection of human cytomegalovirus into rabbit eyes.

E. De Clercq, S. Spector, J. Neyts, 1995, The Journal of infectious diseases.

Antiviral agents acting as DNA or RNA chain terminators.

E. De Clercq, J. Neyts, E. Clercq, 2009, Handbook of experimental pharmacology.

Antivirals and antiviral strategies.

E. De Clercq, Erik De Clercq, 2004, Nature reviews. Microbiology.

Anti-herpes activity of deoxythymidine analogues: specific dependence on virus-induced deoxythymidine kinase.

E. De Clercq, J. Descamps, P. Torrence, 1977, Molecular pharmacology.

Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits.

E. De Clercq, P. Maudgal, 1991, Antiviral research.

Ocular penetration and efficacy of chloroethyldeoxyuridine against herpetic keratouveitis.

E. De Clercq, R. Bernaerts, M. Dieltiens, 1986, Investigative ophthalmology & visual science.

Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.

E. De Clercq, L. Missotten, P. Maudgal, 1984, Antiviral research.

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.

E. De Clercq, J. Wildiers, 1984, European journal of cancer & clinical oncology.

Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice.

E. De Clercq, D. Pavan-Langston, N. Park, 1983, Antiviral research.

The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.

E. De Clercq, E. Godehardt, D. Böhringer, 2002, Ophthalmology.

Herpes simplex acyclovir-resistant mutant in experimental keratouveitis.

E. De Clercq, D. Pavan-Langston, N. Park, 1983, Archives of ophthalmology.

Protection of Rabbits Against Local Vaccinia Virus Infection by Brucella abortus and Polyacrylic Acid in the Absence of Systemic Interferon Production

E. De Clercq, P. De Somer, 1973, Infection and immunity.

Increased Toxicity of Double-Stranded Ribonucleic Acid in Virus-Infected Animals

E. De Clercq, W. Stewart, P. De Somer, 1973, Infection and immunity.

The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice.

T. Merigan, M. Nuwer, E. De Clercq, 1970, The Journal of clinical investigation.

In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds

E. De Clercq, J. Descamps, S. Shigeta, 1982, Antimicrobial Agents and Chemotherapy.

In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?

E. De Clercq, G. Andrei, R. Snoeck, 2004, Antiviral research.

(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.

E. De Clercq, P. Maudgal, 1991, Investigative ophthalmology & visual science.

Comparative evaluation of BVDU ((E)-5-(2-bromovinyl)-2'-deoxyuridine) in the treatment of experimental herpes simplex keratitis in rabbits.

E. De Clercq, L. Missotten, J. Descamps, 1979, Bulletin de la Societe belge d'ophtalmologie.

Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds

E. De Clercq, E. D. Clercq, Rega, 1984, Antimicrobial Agents and Chemotherapy.

Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment of maintenance of latent herpes simplex virus infection in mice.

E. De Clercq, H. Field, E. D. Clercq, 1981, The Journal of general virology.

In vitro effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5'-amino-5-iodo-2',5'-dideoxyuridine and 2-deoxy-D-glucose on latent ganglionic herpes simplex virus infection.

E. De Clercq, D. Pavan-Langston, N. Park, 1984, Antiviral research.

Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.

E. De Clercq, D. Pavan-Langston, N. Park, 1982, The Journal of infectious diseases.

High efficiency latency and activation of herpes simplex virus in human cells.

E. De Clercq, F. Rapp, B. Wigdahl, 1982, Science.

Activation of herpes simplex virus (HSV) type 1 genome by temperature-sensitive mutants of HSV type 2.

E. De Clercq, F. Rapp, H. Isom, 1982, Virology.

Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro.

E. De Clercq, R. Tolman, E. Romanowski, 1991, Antiviral research.

Oral antiviral drugs in experimental herpes simplex keratitis

E. De Clercq, G. Kissling, E. Varnell, 1983, Antimicrobial Agents and Chemotherapy.

Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells.

E. De Clercq, J. Descamps, 1981, The Journal of biological chemistry.

(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis

E. De Clercq, R. Busson, L. Missotten, 1980, Antimicrobial Agents and Chemotherapy.

In search of a selective antiviral chemotherapy

E. De Clercq, E. Clercq, E. D. Clercq, 1997, Clinical microbiology reviews.

(E)-5-(2-bromovinyl)-2'-deoxyuridine not embryotoxic compared to related nucleoside analogues in chick embryos.

E. De Clercq, R. Jelínek, 1987, Folia morphologica.

Potent anti-viral 5-(2-bromovinyl) uracil nucleosides are inactive at inducing gene mutations in Salmonella typhimurium and V79 Chinese hamster cells and unscheduled DNA synthesis in primary rat hepatocytes.

E. De Clercq, J. Westendorf, H. Marquardt, 1985, Carcinogenesis.

Ocular penetration of (125I)IVDU, a radiolabeled analogue of bromovinyldeoxyuridine.

E. De Clercq, R. Busson, L. Missotten, 1985, Investigative ophthalmology & visual science.

The relationship between incorporation of E-5-(2-Bromovinyl)-2'-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity.

E. De Clercq, W. Prusoff, W. Mancini, 1983, The Journal of biological chemistry.

Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells.

E. De Clercq, W. Prusoff, M. S. Chen, 1982, The Journal of biological chemistry.

Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins.

R. T. Walker, E. De Clercq, Y. Cheng, 1981, Molecular pharmacology.

Preliminary results of oral BVDU treatment of herpes zoster ophthalmicus.

E. De Clercq, L. Missotten, J. Descamps, 1981, Bulletin de la Societe belge d'ophtalmologie.

Effects of E-5-(2-bromovinyl)-2'-deoxyuridine and other selective anti-herpes compounds on the induction of retrovirus particles in mouse BALB/3T3 cells.

E. De Clercq, H. Heremans, J. Descamps, 1981, Molecular pharmacology.

The Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication

E. De Clercq, P. Herdewijn, M. Froeyen, 2007, Journal of Virology.

Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: a new class of pestivirus inhibitors.

E. De Clercq, P. Herdewijn, J. Rozenski, 2006, Bioorganic & medicinal chemistry letters.

A Novel, Highly Selective Inhibitor of Pestivirus Replication That Targets the Viral RNA-Dependent RNA Polymerase

E. De Clercq, P. Herdewijn, M. Froeyen, 2006, Journal of Virology.

Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.

E. De Clercq, C. Pannecouque, J. Balzarini, 1998, Journal of medicinal chemistry.

Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine]

E. De Clercq, L. Naesens, C. Desloovere, 1998, Journal of medical virology.

Pretreatment with Topical 0.1% (S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine Inhibits Adenovirus Type 5 Replication in the New Zealand Rabbit Ocular Model

E. De Clercq, E. Romanowski, Y. Gordon, 1992, Cornea.

Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir

E. De Clercq, M. Saijo, K. Ishibashi, 2003, Antimicrobial Agents and Chemotherapy.

Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis.

E. De Clercq, D. Albert, T. Lin, 1981, Archives of ophthalmology.

Editorial overview: Antiviral strategies.

E. De Clercq, R. Schinazi, 2016, Current opinion in virology.

Experimental herpetic keratitis in rabbit corneal organ cultures.

L. A. Hatch, M. Creighton, E. De Clercq, 1984, British journal of experimental pathology.

An Odyssey in antiviral drug development—50 years at the Rega Institute: 1964–2014

E. De Clercq, 2015, Acta pharmaceutica Sinica. B.

Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.

E. De Clercq, P. Maudgal, 1991, Current eye research.

Experimental thymidine kinase-deficient HSV-1 keratitis: therapeutic attempts.

E. De Clercq, P. Maudgal, P. Huyghe, 1987, Current eye research.

Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.

E. De Clercq, P. Maudgal, P. Huyghe, 1987, Investigative ophthalmology & visual science.

Evaluation of bromovinyldeoxyuridine-related compounds in the treatment of experimental herpes simplex keratitis.

E. De Clercq, P. Maudgal, 1985, Archives of ophthalmology.

Susceptibility of bovid herpesvirus 1 to antiviral drugs: in vitro versus in vivo efficacy of (E)-5-(2-Bromovinyl)-2'-deoxyuridine

E. De Clercq, V. Misra, L. Babiuk, 1983, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of E-5-(2-Bromovinyl)-2′-Deoxyuridine in Mice

R. T. Walker, E. De Clercq, P. Barr, 1979, Antimicrobial Agents and Chemotherapy.

A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.

E. De Clercq, J. Neyts, E. Verbeken, 1999, Cancer research.

Specific therapies for human papilloma virus infections.

E. De Clercq, G. Andrei, R. Snoeck, 1998, Current opinion in infectious diseases.

New anti-HIV agents and targets.

E. De Clercq, Erik De Clercq, 2002, Medicinal research reviews.

Novel compounds in preclinical/early clinical development for the treatment of HIV infections

E. De Clercq, 2000, Reviews in medical virology.

Inhibition of visna virus replication and cytopathic effect in sheep choroid plexus cell cultures by selected anti-HIV agents.

E. De Clercq, J. Balzarini, Z. Debyser, 1995, Antiviral research.

Antitrypanosomal activity of phosphonylmethoxyalkylpurines.

E. De Clercq, R. Kaminsky, E. Zweygarth, 1994, The Journal of parasitology.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy

E. De Clercq, C. Pannecouque, Fener Chen, 2020, Molecules.

Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV‐1 RNase H inhibitors

Peng Zhan, Jacob Kongsted, Luis Menéndez-Arias, 2019, Chemical biology & drug design.

Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs

E. De Clercq, J. Balzarini, Z. Debyser, 1993, Antimicrobial Agents and Chemotherapy.

Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335

E. De Clercq, R. Pauwels, A. Vandamme, 1992, Antimicrobial Agents and Chemotherapy.

The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro.

E. De Clercq, M. Hosoya, J. Neyts, 1992, Antiviral research.

Specific HIV-1 reverse transcriptase inhibitors.

E. De Clercq, R. Pauwels, Z. Debyser, 1992, Journal of enzyme inhibition.

Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.

E. De Clercq, R. Pauwels, M. Nakajima, 1988, Antiviral research.

ACYCLIC/CARBOCYCLIC GUANOSINE ANALOGUES AS ANTI-HERPESVIRUS AGENTS

P Leyssen, E. De Clercq, L. Naesens, 2001 .

Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation.

E. De Clercq, C. Pannecouque, J. Balzarini, 2005, The Journal of antimicrobial chemotherapy.

E. De Clercq, J. Balzarini, P. Hatfield, 1984, Journal of medicinal chemistry.

Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo

E. De Clercq, A. Holý, I. Rosenberg, 1989, Antimicrobial Agents and Chemotherapy.

Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro

E. De Clercq, M. Baba, S. Shigeta, 1987, Antimicrobial Agents and Chemotherapy.

Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis.

E. De Clercq, I. Votruba, I. Rosenberg, 1987, Molecular pharmacology.

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

E. De Clercq, R. Pauwels, A. Bousseau, 1994, Proceedings of the National Academy of Sciences of the United States of America.

First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.

E. De Clercq, Dongwei Kang, Boshi Huang, 2018, Bioorganic & medicinal chemistry letters.

5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.

Peng Zhan, Xiao Ding, Luis Menéndez-Arias, 2018, European journal of medicinal chemistry.

Recent progress in the research of small molecule HIV-1 RNase H inhibitors.

E. De Clercq, P. Zhan, Xinyong Liu, 2014, Current medicinal chemistry.

Synthesis and biological activity of tricyclic analogues of 9-[[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine.

E. De Clercq, J. Balzarini, B. Golankiewicz, 2006, Bioorganic & medicinal chemistry.

The novel pyrimidine and purine derivatives of l-ascorbic acid: synthesis, one- and two-dimensional 1H and 13C NMR study, cytostatic and antiviral evaluation.

E. De Clercq, K. Pavelić, J. Plavec, 2005, Bioorganic & medicinal chemistry.

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Guangdi Li, E. De Clercq, D. Clercq, 2020, Nature Reviews Drug Discovery.

Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.

E. De Clercq, P. Zhan, Xinyong Liu, 2011, Current medicinal chemistry.

Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins.

E. De Clercq, R. Pauwels, L. Thiry, 1986, Biochemical and biophysical research communications.

Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI•Poly rC

T. Merigan, M. Nuwer, E. De Clercq, 1970, Infection and immunity.

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.

E. De Clercq, R. Pauwels, J. Le Pecq, 1996, Journal of medicinal chemistry.

The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication

E. De Clercq, J. Neyts, P. Leyssen, 2006, Molecular Pharmacology.

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections.

E. De Clercq, E De Clercq, 1995, Journal of medicinal chemistry.

Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.

E. De Clercq, E. Baitz-Gács, L. Otvös, 1990, Journal of medicinal chemistry.

Interferon inducing activity of polyinosinic acid.

E. De Clercq, B. Stollar, M. Thang, 1978, Journal of General Virology.

Effects of Ionenes on Interferon Induction by Poly(Inosinic Acid)·Poly(Cytidylic Acid)

E. De Clercq, B. Janik, R. Sommer, 1977, Antimicrobial Agents and Chemotherapy.

Are cytotoxicity and interferon inducing activity of poly(I).poly(C) invariably linked in interferon-treated L cells.

E. De Clercq, P. De Somer, 1975, The Journal of general virology.

Immunochemical measurement of conformational heterogeneity of poly(inosinic acid).

E. De Clercq, B. Stollar, J. Drocourt, 1978, European journal of biochemistry.

A continuous high molecular weight base‐paired structure is not an absolute requirement for a potential polynucleotide inducer of interferon

E. De Clercq, B. Stollar, L. Bachner, 1977, FEBS letters.

Relationship of cytotoxicity and interferon-inducing activity of polyriboinosinic acid. Polyribocytidylic acid to the molecular weights of the homopolymers.

E. De Clercq, W. Stewart, 1974, The Journal of general virology.

Interferon induction by synthetic polynucleotides: importance of purine N-7 and strandwise rearrangement.

E. De Clercq, B. Witkop, P. Torrence, 1974, Proceedings of the National Academy of Sciences of the United States of America.

Mechanism of the Antiviral Activity Resulting from Sequential Administration of Complementary Homopolyribonucleotides to Cell Cultures

E. De Clercq, P. De Somer, 1972, Journal of virology.

Interferon inducing activity of (A)n.(U)n complexes of varying chain length.

E. De Clercq, B. Janik, R. Sommer, 1978, Biochimica et biophysica acta.

Interferon induction by two 2'-modified double-helical RNAs, poly(2'-fluoro-2'-deoxyinosinic acid) x poly(cytidylic acid) and poly(2'-chloro-2'-deoxyinosinic acid) x poly(cytidylic acid).

E. De Clercq, M. Ikehara, B. Stollar, 1980, European journal of biochemistry.

Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.

E. De Clercq, J. Balzarini, S. Karki, 2007, Bioorganic & medicinal chemistry.

Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.

E. De Clercq, C. Pannecouque, Li Ding, 2022, Journal of medicinal chemistry.

Design, synthesis, and antiviral evaluation of novel hydrazone‐substituted thiophene[3,2‐d]pyrimidine derivatives as potent human immunodeficiency virus‐1 inhibitors

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, Chemical biology & drug design.

Antiviral Activity of N4-Aminocytidine Derivatives Related to AZT

E. De Clercq, J. Balzarini, D. Loakes, 1995 .

Synthesis and cytotoxic activity of 6-vinyl- and 6-ethynyluridine and 8-vinyl-and 8-ethynyladenosine.

E. De Clercq, J. Balzarini, S. Manfredini, 1995, Journal of medicinal chemistry.

Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

E. De Clercq, J. Balzarini, A. Karlsson, 1993, Molecular pharmacology.

Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.

R. T. Walker, E. De Clercq, M. Baba, 1991, Molecular pharmacology.

Nonnucleoside HIV-1 reverse-transcriptase inhibitors, part 5. Synthesis and anti-HIV-1 activity of novel 6-naphthylthio HEPT analogues.

E. De Clercq, C. Pannecouque, J. Balzarini, 2005, Chemical & pharmaceutical bulletin.

Synthesis, Biological Activity, Pharmacokinetic Properties and Molecular Modelling Studies of Novel 1H,3H-Oxazolo[3,4-a]Benzimidazoles: Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

E. De Clercq, C. Pannecouque, G. De Sarro, 2001, Antiviral chemistry & chemotherapy.

Synthesis of 6-Arylthio Analogs of 2′,3′-Dideoxy-3′-Fluoroguanosine and Their Effect against Hepatitis B Virus Replication

E. De Clercq, J. Neyts, T. Maruyama, 2006, Nucleosides, nucleotides & nucleic acids.

Synthesis and Antiviral Properties of Aza-Analogues of Acyclovir

E. De Clercq, Mariola Koszytkowska-Stawińska, W. Sas, 2007, Nucleosides, nucleotides & nucleic acids.

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti‐HIV‐1 Agents

E. De Clercq, Lingzi Zhang, Huiqing Liu, 2015, Chemical biology & drug design.

Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro

Shinobu, E. De Clercq, E. Clercq, 1990, Antimicrobial Agents and Chemotherapy.

The interaction of polyxanthylic acid with polyadenylic acid.

E. De Clercq, B. Witkop, P. Torrence, 1977, Biochimica et biophysica acta.

Triple-helical polynucleotides. Mixed triplexes of the poly(uridylic acid)-poly(adenylic acid)-poly(uridylic acid) class.

E. De Clercq, B. Witkop, P. Torrence, 1976, Biochemistry.

A potent interferon inducer derived from poly (7-deazainosinic acid).

E. De Clercq, B. Witkop, P. Torrence, 1974, Biochemistry.

Synthesis and biological evaluation of dinucleoside methylphosphonates of 3'-azido-3'-deoxythymidine and 2', 3'-dideoxycytidine.

E. De Clercq, J. Balzarini, E. Clercq, 1990, Antiviral research.

Antimetabolic activities of 2-fluoro-L-histidine.

E. De Clercq, A. Billiau, K. Kirk, 1978, Biochemical and biophysical research communications.

Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.

E. De Clercq, P. Herdewijn, S. Ikeda, 1993, Journal of medicinal chemistry.

Mouse adenovirus type 1 attachment is not mediated by the coxsackie‐adenovirus receptor

E. De Clercq, L. Naesens, D. Daelemans, 2006, FEBS letters.

In Vivo Release of Previously Cleared Interferon by Cycloheximide

T. Merigan, M. Nuwer, E. De Clercq, 1972, Infection and immunity.

Stimulation or inhibition of interferon production depending on time of cycloheximide administration.

T. Merigan, E. De Clercq, 1970, Virology.

Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse.

T. Merigan, E. De Clercq, 1971, The Journal of infectious diseases.

Induction of interferon by nonviral agents.

T. Merigan, E. De Clercq, 1970, Archives of internal medicine.

Nonviral Interferon Inducers

T. Merigan, E. De Clercq, G. H. Bausek, 1970, The Journal of general physiology.

Current concepts of interferon and interferon induction.

T. Merigan, E. De Clercq, 1970, Annual review of medicine.

Recovery of Cell-Bound Interferon

E. De Clercq, W. Stewart, P. De Somer, 1972, Journal of virology.

Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.

E. De Clercq, J. Balzarini, E. Clercq, 1999, Biochemical pharmacology.

Strategies in the design of antiviral drugs

E. De Clercq, Erik De Clercq, 2002, Nature reviews. Drug discovery.

SVLM21, a mutant of Sindbis virus able to grow in Aedes albopictus cells in the absence of methionine, shows increased sensitivity to S-adenosylhomocysteine hydrolase inhibitors such as neplanocin A.

V. Stollar, E. De Clercq, R. Durbin, 1988, Virology.

Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.

E. De Clercq, A. Vandamme, K. Van Laethem, 1997, Molecular pharmacology.

Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection

E. De Clercq, J. Balzarini, D. Schols, 2004, Antimicrobial Agents and Chemotherapy.

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

E. De Clercq, R. Pauwels, M. Baba, 1988, Antimicrobial Agents and Chemotherapy.

Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)

E. De Clercq, R. Snoeck, J. Noel, 2000, Journal of medical virology.

Novel DNA groove binding alkylators: design, synthesis, and biological evaluation.

E. De Clercq, J. Lown,, R. Newman, 1988, Journal of medicinal chemistry.

Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.

E. De Clercq, J. de Rudder, J. Imbach, 1986, Journal of medicinal chemistry.

Chemoenzymatic synthesis and antiviral evaluation of conformationally constrained and 3'-methyl-branched carbanucleosides using both enantiomers of the same building block.

E. De Clercq, G. Audran, Y. Aubin, 2008, Bioorganic & medicinal chemistry.

Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

E. De Clercq, P. Herdewijn, C. Desgranges, 1984, Nucleic acids research.

New neplanocin analogues. VIII. Synthesis and biological activity of 6'-C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A.

E. De Clercq, S. Shuto, A. Matsuda, 1997, Chemical & pharmaceutical bulletin.

Homocysteine potentiates the antiviral and cytostatic activity of those nucleoside analogues that are targeted at S-adenosylhomocysteine hydrolase.

E. De Clercq, J. Balzarini, M. Cools, 1989, Biochemical pharmacology.

Synthesis, cytostatic activity and inhibition of ribonucleotide reductase by 5'-phosphoramidates and 5'-diphosphates, of 2'-O-allyl-arabinofuranosyl nucleosides.

E. De Clercq, J. Balzarini, A. Karlsson, 1999, Nucleosides & nucleotides.

Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine.

E. De Clercq, P. Herdewijn, G. Janssen, 1989, Antiviral research.

Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase.

E. De Clercq, W. Bentrude, J. Béres, 1987, Molecular pharmacology.

Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.

E. De Clercq, J. Rozenski, J. Balzarini, 1995, Journal of medicinal chemistry.

3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.

E. De Clercq, R. Pauwels, P. Herdewijn, 1989, Journal of medicinal chemistry.

The discovery of antiviral agents: Ten different compounds, ten different stories

E. De Clercq, 2008, Medicinal research reviews.

Inhibitors of infectious pancreatic necrosis virus (IPNV) replication.

E. De Clercq, A. Sandino, M. López-Lastra, 1996, Antiviral research.

A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1.

E. De Clercq, J. Vandekerckhove, J. Balzarini, 1996, Journal of virological methods.

Synergism in the antitumor effects of type 1 and type II interferon in mice inoculated with leukemia L1210 cells.

E. De Clercq, Z. Zhang, K. Huygen, 1982, Cancer letters.

Specificity of interferon-induced enhancement of toxicity for double-stranded ribonucleic acids.

E. De Clercq, W. Stewart, P. De Somer, 1973, The Journal of general virology.

Cellular Alteration by Interferon: a Virus-Free System for Assaying Interferon

E. De Clercq, W. Stewart, P. De Somer, 1972, Journal of virology.

Human Fibroblast Interferon for Clinical Trials: Pharmacokinetics and Tolerability in Experimental Animals and Humans

E. De Clercq, A. Billiau, H. Heremans, 1979, Antimicrobial Agents and Chemotherapy.

Purification of interferon by adsorption chromatography on controlled pore glass.

E. De Clercq, A. Billiau, P. De Somer, 1976, The Journal of general virology.

Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro.

E. De Clercq, R. Pauwels, G. Molema, 1990, Biochemical pharmacology.

Alkyl esters of 3-adenin-9-yl-2-hydroxypropanoic acid: a new class of broad-spectrum antiviral agents.

E. De Clercq, A. Holý, 1985, Journal of medicinal chemistry.

Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-halogenovinyl)-2'-deoxyuridines: dependence on specific phosphorylation by viral thymidine kinase.

E. De Clercq, P. Herdewijn, A. Verbruggen, 1985, Biochemical and biophysical research communications.

Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].

E. De Clercq, R. Busson, H. Vanderhaeghe, 1983, Journal of medicinal chemistry.

Chemo-enzymatic Synthesis of 3-Deoxy-β-D-ribofuranosyl Purines and Study of Their Biological Properties

E. De Clercq, J. Balzarini, V. Barai, 2003, Nucleosides, nucleotides & nucleic acids.

Database Searching for Thymidine and Thymidylate Kinase Inhibitors Using Three-dimensional Structure-based Methods

M. Delarue, D. Manallack, E. De Clercq, 2002, Journal of enzyme inhibition and medicinal chemistry.

Synthesis and antiviral activity of 3'-heterocyclic substituted 3'-deoxythymidines.

E. De Clercq, P. Herdewijn, G. Janssen, 1990, Journal of medicinal chemistry.

5′-Nor Carbocyclic 5′-Deoxy-5′-(Isobutylthio)Adenosine and a 2′,3′-Dideoxy-2′,3′-Didehydro Derivative

E. De Clercq, J. Balzarini, Subha R. Das, 2001, Antiviral chemistry & chemotherapy.

Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

E. De Clercq, J. Balzarini, A. Karlsson, 2000, The Biochemical journal.

Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes.

R. T. Walker, E. De Clercq, J. Balzarini, 2000, The Biochemical journal.

Synthesis and anti-HIV-1 Activity of [1-[2′,5′-Bis-O-(Tert-Butyldimethylsilyl)-β-L-Ribofuranosyl]Thymine]-3′-Spiro-5″-(4″-Amino-1″,2″-Oxathiole-2″,2″-Dioxide) (L-TSAO-T), the L-enantiomer of the Highly Specific HIV-1 Reverse Transcriptase Inhibitor TSAO-T

E. De Clercq, J. Balzarini, M. Camarasa, 1995 .

Perspectives for the treatment of hepatitis B virus infections.

E. De Clercq, 1999, International journal of antimicrobial agents.

Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).

R T Walker, R. T. Walker, S Shigeta, 1991, Journal of medicinal chemistry.

The regulation of HIV‐1 transcription: Molecular targets for chemotherapeutic intervention

E. De Clercq, J. Balzarini, M. Stevens, 2006, Medicinal research reviews.

Synthesis, antiviral and cytostatic activities of carbocyclic nucleosides incorporating a modified cyclopentane ring. Part 2: Adenosine and uridine analogues.

E. De Clercq, X. García‐Mera, J. Neyts, 1998, Nucleosides & nucleotides.

Synthesis, conformational analysis and antiviral and antitumoral activity of new 1,2-disubstituted carbocyclic nucleosides.

Jan Balzarini, Lourdes Santana, Marta Teijeira, 2002, European journal of medicinal chemistry.

Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.

E. De Clercq, J. Balzarini, M. Camarasa, 2005, Journal of medicinal chemistry.

3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.

E. De Clercq, J. Balzarini, E. Clercq, 1992, Journal of medicinal chemistry.

Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues.

E. De Clercq, J. Balzarini, M. Camarasa, 1994, Journal of medicinal chemistry.

Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances.

E. De Clercq, 1998, Nucleosides & nucleotides.

Antiviral enantiomeric preference for 5'-noraristeromycin.

E. De Clercq, S. Ikeda, J. Balzarini, 1994, Journal of medicinal chemistry.

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

E. De Clercq, C. Perno, J. Balzarini, 1994, Antiviral research.

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection.

E. De Clercq, J. Balzarini, A. Holý, 1993, Antiviral research.

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

E. De Clercq, E. Clercq, T. Yokota, 1991, Antimicrobial Agents and Chemotherapy.

Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.

E. De Clercq, E. Kern, E. Mayer, 1991, Antiviral research.

Synthesis and antiviral properties of carbocyclic 3'-oxa-2',3'-dideoxyguanosine and its 7-deazaguanosine analogue.

E. De Clercq, J. Balzarini, S. Siddiqi, 1993, Antiviral research.

Approved HIV reverse transcriptase inhibitors in the past decade

Guangdi Li, E. De Clercq, Yali Wang, 2021, Acta pharmaceutica Sinica. B.

TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.

E. De Clercq, J. Balzarini, M. Camarasa, 1992, Journal of medicinal chemistry.

Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.

R. T. Walker, E. De Clercq, P. Herdewijn, 1986, Journal of medicinal chemistry.

Hiv-1 Specific Reverse Transcriptase Inhibitors: why are Tsao-Nucleosides so Unique?

E. De Clercq, F. Gago, J. Balzarini, 2000 .

Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity.

E. De Clercq, J. Balzarini, M. Camarasa, 1996, Antiviral research.

Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety.

E. De Clercq, J. Balzarini, M. Camarasa, 1995, Antiviral research.

Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).

E. De Clercq, P. Barr, J. Balzarini, 1992, The Journal of biological chemistry.

Biochemical aspects of the selective antiherpes activity of nucleoside analogues.

E. De Clercq, 1984, Biochemical pharmacology.

Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.

E. De Clercq, J. Balzarini, C. Bohman, 1993, The Journal of biological chemistry.

Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpe

E. De Clercq, J. Balzarini, H. Griengl, 1990, Molecular pharmacology.

Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.

E. De Clercq, J. Balzarini, 1989, Methods and findings in experimental and clinical pharmacology.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.

E. De Clercq, Erik De Clercq, 2004, Chemistry & biodiversity.

Non‐nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV‐1) infections: Strategies to overcome drug resistance development

E. De Clercq, E de Clercq, 1996, Medicinal research reviews.

Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.

I. Gilbert, E. De Clercq, J. Balzarini, 1999, Journal of medicinal chemistry.

The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.

E. De Clercq, J. Balzarini, C. Mcguigan, 1999, Journal of medicinal chemistry.

Estimation of the lipophilicity of anti-HIV nucleoside analogues by determination of the partition coefficient and retention time on a Lichrospher 60 RP-8 HPLC column.

E. De Clercq, J. Balzarini, E De Clercq, 1989, Biochemical and biophysical research communications.

Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

Thiosugars. XII. Synthesis of New 3′‐O‐Substituted 2′,5′‐Anhydro‐2′‐thio‐α‐d‐pentofuranosyl Nucleoside Analogues

E. De Clercq, J. Balzarini, J. Wirsching, 2004, Nucleosides, nucleotides & nucleic acids.

Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity.

E. De Clercq, K. Pavelić, M. Kralj, 2006, Molecules.

Anno 2021: Which antivirals for the coming decade?

E. De Clercq, P. Herdewijn, E. Groaz, 2021, Annual Reports in Medicinal Chemistry.

N-3 Substituted TSAO Derivatives as a Probe to Explore the Dimeric Interface of HIV-1 Reverse Transcriptase

E. De Clercq, J. Balzarini, M. Camarasa, 2003, Nucleosides, Nucleotides & Nucleic Acids.

Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine

E. De Clercq, J. Montgomery, Y. Shealy, 1990, Biochemical Pharmacology.

Role of thymidine kinase and thymidylate synthetase in the cytostatic, antimetabolic, and antitumor effects of the carbocyclic analogue of 5-nitro-2'-deoxyuridine. A comparison with 5-nitro-2'-deoxyuridine.

E. De Clercq, P. Herdewijn, J. Balzarini, 1985, Molecular pharmacology.

Novel carbocyclic nucleosides containing a cyclobutyl ring. Guanosine and adenosine analogues.

E. De Clercq, J. Balzarini, R. Snoeck, 1998, Nucleosides and Nucleotides.

2'-Fluorinated isonucleosides. 1. Synthesis and biological activity of some methyl 2'-deoxy-2'-fluoro-2'-pyrimidinyl-D-arabinopyranosides.

E. De Clercq, R. Bernacki, M. Bobek, 1989, Journal of Medicinal Chemistry.

Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.

E. De Clercq, F. Gago, K. Van Laethem, 2006, Antiviral research.

Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.

E. De Clercq, Á. Díaz‐Ortiz, J. Balzarini, 1989, Journal of Medicinal Chemistry.

Synthesis of 3' '-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach.

E. De Clercq, F. Gago, J. Balzarini, 2002, Journal of medicinal chemistry.

Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase.

E. De Clercq, J. Balzarini, M. Camarasa, 2001, Bioorganic & Medicinal Chemistry Letters.

Exploitation of the Low Fidelity of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase and the Nucleotide Composition Bias in the HIV-1 Genome To Alter the Drug Resistance Development of HIV

Jan Balzarini, Anna Karlsson, E. De Clercq, 2001, Journal of Virology.

4″-H-TSAO-T, A NOVEL PROTOTYPE IN THE HIV-1 SPECIFIC TSAO FAMILY

E. De Clercq, J. Balzarini, M. Camarasa, 2001, Nucleosides, nucleotides & nucleic acids.

“SECOND GENERATION” OF TSAO COMPOUNDS DIRECTED AGAINST HIV-1 TSAO-RESISTANT STRAINS

E. De Clercq, J. Balzarini, M. Camarasa, 2001, Nucleosides, nucleotides & nucleic acids.

Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.

A. Aertsen, E. De Clercq, A. Vandamme, 2001, Virology.

Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

R. Esnouf, E. De Clercq, B. Clotet, 2000, AIDS research and human retroviruses.

TSAO-T Analogues Bearing Amino Acids at Position N-3 of Thymine: Synthesis and Anti-Human Immunodeficiency Virus Activity

E. De Clercq, J. Balzarini, C. Chamorro, 2000, Antiviral chemistry & chemotherapy.

Synthesis of Novel 5″-Substituted Tsao-T Analogues with Anti-Hiv-1 Activity

E. De Clercq, J. Balzarini, M. Camarasa, 2000 .

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

R. Esnouf, E. De Clercq, J. Balzarini, 1998, AIDS research and human retroviruses.

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1

R. Esnouf, E. De Clercq, A. Vandamme, 1997, Journal of virology.

Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.

E. De Clercq, L. Naesens, R. Pohl, 2007, Journal of medicinal chemistry.

In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.

E. De Clercq, G. Andrei, K. Hostetler, 2007, Antiviral research.

Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region.

E. De Clercq, J. Balzarini, M. Camarasa, 1999, Journal of Medicinal Chemistry.

Local treatment of HPV‐induced skin lesions by Cidofovir

E. De Clercq, M. Van Ranst, J. J. van den Oord, 2002, Journal of medical virology.

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication

E. De Clercq, R. Snoeck, A. Holý, 1988, Antimicrobial Agents and Chemotherapy.

Acyclic nucleoside phosphonates: a new dimension to the chemotherapy of DNA virus and retrovirus infections.

E. De Clercq, 1998, Journal of medical microbiology.

Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.

E. De Clercq, 1990, Drugs under experimental and clinical research.

New acquisitions in the development of anti-HIV agents.

E. De Clercq, 1989, Antiviral research.

New antivirals - mechanism of action and resistance development.

E. De Clercq, L. Naesens, J. Balzarini, 1998, Current opinion in microbiology.

3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.

E. De Clercq, S. Ikeda, J. Balzarini, 1995, Journal of medicinal chemistry.

Ebola virus (EBOV) infection: Therapeutic strategies

E. De Clercq, 2014, Biochemical Pharmacology.

Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.

E. De Clercq, J. Neyts, 2003, Antiviral research.

7‐Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase

R. Esnouf, E. De Clercq, J. Neyts, 1998, FEBS letters.

Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.

E. De Clercq, S. Ikeda, R. Snoeck, 1994, Journal of medicinal chemistry.

Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.

E. De Clercq, P. Herdewijn, J. Balzarini, 1991, The Journal of biological chemistry.

Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-Ester Prodrug of 9-(2- Phosphonylmethoxyethyl)Adenine in an In Vitro Cell Culture System of the Intestinal Mucosa (Caco-2)

E. De Clercq, L. Naesens, P. Annaert, 1997, Pharmaceutical Research.

Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.

E. De Clercq, G. Janssen, J. Balzarini, 1990, Journal of medicinal chemistry.

2',3'-didehydro-2',3'-dideoxy-5-chlorocytidine is a selective anti-retrovirus agent.

E. De Clercq, P. Herdewijn, A. Aerschot, 1989, Biochemical and biophysical research communications.

5-Chloro-substituted derivatives of 2', 3'-didehydro-2',3'-dideoxyuridine, 3'-fluoro-2',3'-dideoxyuridine and 3'-azido-2',3'-dideoxyuridine as anti-HIV agents.

E. De Clercq, P. Herdewijn, J. Balzarini, 1989, Biochemical pharmacology.

Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

E. De Clercq, T. Harrer, M. Van Ranst, 1999, Journal of Acquired Immune Deficiency Syndromes.

Potent antitumor activity of the acyclic nucleoside phosphonate 9‐(2‐phosphonylmethoxyethyl)adenine in choriocarcinoma‐bearing rats

E. De Clercq, L. Naesens, B. Degrève, 1998, International journal of cancer.

Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus.

E. De Clercq, L. Naesens, J. Balzarini, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system.

E. De Clercq, C. Perno, J. Balzarini, 1994, Antiviral research.

9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.

E. De Clercq, L. Naesens, H. Niphuis, 1991, AIDS.

Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine.

E. De Clercq, H. Niphuis, J. Balzarini, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effects of 9‐(2‐Phosphonylmethoxyethyl)adenine and 3′‐azido‐2′,3′‐dideoxythymidine on tumor development in mice inoculated intracerebrally with moloney murine sarcoma virus

E. De Clercq, L. Naesens, J. Balzarini, 1990, International journal of cancer.

The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death

E. De Clercq, 2022, Viruses.

Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection.

E. De Clercq, L. Naesens, J. Balzarini, 1992, Clinical chemistry.

Inhibition of African swine fever virus DNA synthesis by (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.

E. De Clercq, E. Tabarés, O. Arzuza, 1988, Biochemical and biophysical research communications.

Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

E. De Clercq, R. Pauwels, P. Herdewijn, 1986, Biochemical and biophysical research communications.

Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates

E. De Clercq, C. Pannecouque, C. Perno, 2002, Antimicrobial Agents and Chemotherapy.

Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model.

E. De Clercq, L. Naesens, J. Balzarini, 1998, Biochemical pharmacology.

In vitro and in vivo inhibitory activity of the differentiation-inducing agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against rat choriocarcinoma.

E. De Clercq, L. Naesens, B. Degrève, 1998, Advances in experimental medicine and biology.

Comparative Anti-Retrovirus and Anti-Hepadnavirus Activity of Three Different Classes of Nucleoside Phosphonate Derivatives

E. De Clercq, J. Balzarini, R. Heijtink, 1994 .

Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

E. De Clercq, J. Neyts, J. Balzarini, 1990, Virology.

Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.

E. De Clercq, S. Spruance, S. Sacks, 1985, Antiviral research.

Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice

R. T. Walker, E. De Clercq, P. Barr, 1979, Antimicrobial Agents and Chemotherapy.

Selective inhibitory effects of (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl) adenine and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil on seal herpesvirus (phocid herpesvirus 1) infection in vitro.

E. De Clercq, A. Osterhaus, J. Groen, 1987, Antiviral research.

The race for interferon‐free HCV therapies: a snapshot by the spring of 2012

E. De Clercq, 2012, Reviews in medical virology.

Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue.

E. De Clercq, M. Van Ranst, N. Clumeck, 1995, The New England journal of medicine.

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

E. De Clercq, 2016, Biochemical pharmacology.

Antiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues

E. De Clercq, L. Naesens, J. Balzarini, 2005, Antimicrobial Agents and Chemotherapy.

Differential inhibitory effects of several pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases.

E. De Clercq, P. Herdewijn, J. Balzarini, 1989, Molecular Pharmacology.

Synthesis, X-ray crystal structural study, antiviral and cytostatic evaluations of the novel unsaturated acyclic and epoxide nucleoside analogues.

E. De Clercq, K. Pavelić, M. Kralj, 2006, Bioorganic & medicinal chemistry.

Inhibitory Activity of (E)‐5‐(2‐Bromovinyl)‐2′‐Deoxyuridine on the Salmonid Herpesviruses, Oncorhynchus masou Virus (OMV) and Herpesvirus salmonis

E. De Clercq, T. Nishizawa, M. Yoshimizu, 1988, Microbiology and immunology.

Structure-Activity Relationship Studies on a Novel Family of Specific HIV-1 Reverse Transcriptase Inhibitors

E. De Clercq, J. Balzarini, M. Camarasa, 2003, Antiviral chemistry & chemotherapy.

Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy

E. De Clercq, J. Balzarini, E. Clercq, 1993, Journal of virology.

Antiviral Activity of Bicyclic Pyrimidine Nucleosides

E. De Clercq, J. Balzarini, D. Loakes, 1995 .

Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.

E. De Clercq, F. Gago, J. Balzarini, 1998, Journal of medicinal chemistry.

The 2',3'-dideoxyriboside of 2,6-diaminopurine and its 2',3'-didehydro derivative inhibit the deamination of 2',3'-dideoxyadenosine, an inhibitor of human immunodeficiency virus (HIV) replication.

E. De Clercq, P. Herdewijn, J. Balzarini, 1987, Biochemical and biophysical research communications.

Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.

E. De Clercq, J. Balzarini, C. Mcguigan, 2004, Journal of Medicinal Chemistry.

Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase.

E. De Clercq, S. Kit, H. Ichimura, 1987, Antiviral research.

Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice

E. De Clercq, Z. Zhang, I. Sim, 1982, Antimicrobial Agents and Chemotherapy.

Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.

E. De Clercq, J. Balzarini, M. Camarasa, 1994, The Journal of biological chemistry.

Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Biochemical and biophysical research communications.

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

E. De Clercq, L. Vrang, A. Vandamme, 1993, Virology.

Oxathiin Carboxanilide Derivatives: A Class of Non-Nucleoside HIV-1-Specific Reverse Transcriptase Inhibitors (NNRTIs) that are Active against Mutant HIV-1 Strains Resistant to other NNRTIs

W. A. Harrison, E. De Clercq, J. Balzarini, 1995 .

Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains

E. De Clercq, M. Baba, J. Balzarini, 1995, Antimicrobial agents and chemotherapy.

The Phenylmethylthiazolylthiourea Nonnucleoside Reverse Transcriptase (RT) Inhibitor MSK-076 Selects for a Resistance Mutation in the Active Site of Human Immunodeficiency Virus Type 2 RT

D. Stammers, E. De Clercq, L. Bird, 2004, Journal of Virology.

Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.

R. Esnouf, E. De Clercq, J. Balzarini, 2004, Molecular pharmacology.

Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, G. Klarmann, B. Preston, 2002, Molecular pharmacology.

Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT.

R. Esnouf, E. De Clercq, J. Balzarini, 2001, Virology.

Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase*

R. Esnouf, E. De Clercq, J. Balzarini, 1998, The Journal of Biological Chemistry.

Preclinical studies on thiocarboxanilide UC‐781 as a virucidal agent

L. van Damme, E. De Clercq, L. Naesens, 1998, AIDS.

A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.

R. Esnouf, E. De Clercq, A. Vandamme, 1998, The Journal of general virology.

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, A. Karlsson, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication

E. De Clercq, E. Kodama, A. Igarashi, 1996, Microbiology and immunology.

9-Beta-D-arabinofuranosyladenine 5'-monophosphate (araAMP) is converted directly to its antivirally active 5'-triphosphate form by 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase.

E. De Clercq, J. Balzarini, 1990, Biochemical and biophysical research communications.

A Comparative Study of 5-ethyl-2′-Deoxyuridine and Selected Lipophilic 5,6-Dihydro Double/Triple Prodrugs

E. De Clercq, K. Morin, L. Wiebe, 1995 .

Differential Intracellular Compartmentalization of Herpetic Thymidine Kinases (TKs) in TK Gene-Transfected Tumor Cells: Molecular Characterization of the Nuclear Localization Signal of Herpes Simplex Virus Type 1 TK

E. De Clercq, B. Degrève, J. Balzarini, 1998, Journal of Virology.

Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.

E. De Clercq, J. Balzarini, J. Imbach, 1997, Journal of medicinal chemistry.

Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.

E. De Clercq, B. Rosenwirth, H. Griengl, 1988, Journal of medicinal chemistry.

Thymidine Phosphorylase is Noncompetitively Inhibited by 5′-O-Trityl-Inosine (KIN59) and Related Compounds

E. De Clercq, J. Balzarini, S. Liekens, 2006, Nucleosides, nucleotides & nucleic acids.

The Nucleoside Derivative 5′-O-Trityl-inosine (KIN59) Suppresses Thymidine Phosphorylase-triggered Angiogenesis via a Noncompetitive Mechanism of Action*

E. De Clercq, D. Ribatti, J. Balzarini, 2004, Journal of Biological Chemistry.

New treatments for genital herpes

E. De Clercq, R. Snoeck, 2002, Current opinion in infectious diseases.

Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro

E. De Clercq, S. D. Smith, A. Arvin, 1983, Antimicrobial Agents and Chemotherapy.

Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus

E. De Clercq, B. Rosenwirth, 1985, Antimicrobial Agents and Chemotherapy.

Synthesis and Antiviral Activity of 1,3-Disubstituted Uracils against HIV-1 and HCMV

E. De Clercq, C. Pannecouque, J. Balzarini, 2003, Antiviral chemistry & chemotherapy.

1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity

R. Esnouf, E. De Clercq, C. Pannecouque, 1998, Antimicrobial Agents and Chemotherapy.

Design and Synthesis of Phosphonoacetic Acid (PPA) Ester and Amide Bioisosters of Ribofuranosylnucleoside Diphosphates as Potential Ribonucleotide Reductase Inhibitors and Evaluation of Their Enzyme Inhibitory, Cytostatic and Antiviral Activity

E. De Clercq, M. Ferrone, S. Pricl, 2003, Antiviral chemistry & chemotherapy.

In vitro and in vivo antiviral activity of 2'-fluorinated arabinosides of 5-(2-haloalkyl)uracil.

E. De Clercq, B. Rosenwirth, H. Griengl, 1987, Antiviral research.

5'-O-phosphonomethyl-2',3'-dideoxynucleosides: synthesis and anti-HIV activity.

J. Hoogmartens, E. De Clercq, P. Herdewijn, 1990, Journal of medicinal chemistry.

Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.

E. De Clercq, J. Balzarini, W. Bentrude, 1992, Journal of medicinal chemistry.

Thienothiadiazine 2,2-Dioxide Acyclonucleosides: Synthesis and Antiviral Activity

E. De Clercq, J. Balzarini, R. Snoeck, 2000, Antiviral chemistry & chemotherapy.

New 1,2,6-thiadiazine dioxide acyclonucleosides: synthesis and antiviral evaluation.

E. De Clercq, S. Conde, P. Goya, 1995, Bioorganic & medicinal chemistry.

Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.

E. De Clercq, J. Balzarini, C. Mcguigan, 2000, Bioorganic & medicinal chemistry letters.

Simple mono-derivatisation of the aryl moiety of D4A and DDA-based phosphoramidate prodrugs significantly enhances their anti-HIV potency in cell culture.

E. De Clercq, J. Balzarini, C. Mcguigan, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.

E. De Clercq, S. Ikeda, G. Fytas, 1994 .

Activity of several S-adenosylhomocysteine hydrolase inhibitors against African swine fever virus replication in Vero cells.

E. De Clercq, E. Clercq, C. Gil-Fernández, 1993, Antiviral research.

Phosphonylmethoxyalkylpurines and -pyrimidines as inhibitors of African swine fever virus replication in vitro.

E. De Clercq, E. Clercq, A. Holý, 1987, Antiviral research.

Comparative efficacy of broad-spectrum antiviral agents as inhibitors of African swine fever virus replication in vitro.

E. De Clercq, E. Clercq, C. Gil-Fernández, 1987, Antiviral research.

Synthesis and Evaluation of 5-Halo 2′,3′-Didehydro-2′,3′-Dideoxynucleosides and their Blocked Phosphoramidates as Potential Anti-Human Immunodeficiency virus Agents: An Example of ‘Kinase Bypass’

E. De Clercq, J. Balzarini, S. Velázquez, 1997 .

The antiviral activity of 9-beta-D-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine.

E. De Clercq, J. Balzarini, 1989, Biochemical and Biophysical Research Communications - BBRC.

Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.

E. De Clercq, J. de Rudder, J. Imbach, 1987, Journal of Medicinal Chemistry.

Selective inhibition of human immunodeficiency virus (HIV) by 3'-azido-2', 3'-dideoxyguanosine in vitro.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Biochemical and biophysical research communications.

Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity.

R T Walker, R. T. Walker, S Shigeta, 1992, Journal of medicinal chemistry.

5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine.

E. De Clercq, R. Pauwels, P. Herdewijn, 1989, Molecular pharmacology.

Synthesis and Antiviral Activity of Some 5′-N-Phthaloyl-3′-Azido-2′,3′-Dideoxythymidine Analogues

E. De Clercq, J. Balzarini, B. Kamińska, 2003, Antiviral chemistry & chemotherapy.

Moloney Sarcoma Virus-Induced Tumors in Mice: Inhibition or Stimulation by (Poly rI)·(Poly rC) 1

T. Merigan, E. De Clercq, 1971 .

Antiviral activity of polynucleotides: Role of the 2′‐hydroxyl and a pyrimidine 5‐methyl

E. De Clercq, B. Zmudzka, D. Shugar, 1972, FEBS letters.

Antiviral activity of polynucleotides: poly(2'-fluoro-2'-deoxyuridylic acid).

E. De Clercq, B. Janik, 1973, Biochimica et biophysica acta.

Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.

R. T. Walker, E. De Clercq, A. S. Jones, 1981, Journal of Medicinal Chemistry.

Xylotubercidin against herpes simplex virus type 2 in mice

E. De Clercq, M. Robins, Erikde CLERCQl, 1986, Antimicrobial Agents and Chemotherapy.

Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2'-deoxycytidine in combination with deaminase inhibitors.

E. De Clercq, S. V. Gupta, P. Aduma, 1990, Antiviral research.

Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, J. Balzarini, J. Descamps, 1983, The Biochemical journal.

Relationship between structure and antiviral activity of 5-methoxymethyl-2′-deoxyuridine and 5-methoxymethyl-1-(2′-deoxy-β-d-lyxofuranosyl)uracil

L. Delbaere, E. De Clercq, O. El-Kabbani, 1987 .

Specific targets for antiviral drugs.

E. De Clercq, 1982, The Biochemical journal.

Metabolic fate of (E)-5-(2-bromovinyl)-2'-deoxyuridine in herpes simplex virus- and mock-infected cells

E. De Clercq, E. Clercq, S. Sacks, 1984, Antimicrobial Agents and Chemotherapy.

Biotransformation of 5-(2-chloroethyl)-2'-deoxyuridine in male NMRI mice.

E. De Clercq, I. Szinai, 1989, Drug metabolism and disposition: the biological fate of chemicals.

Mutagenic and antimutagenic effects of 5-substituted 2'-deoxyuridines depending on the nature of the 5-substituent.

E. De Clercq, J. Westendorf, H. Marquardt, 1988, Arzneimittel-Forschung.

5-(2-Chloroethyl)-2'-deoxyuridine: a potent and selective inhibitor of herpes viruses in vitro and in vivo.

E. De Clercq, B. Rosenwirth, H. Griengl, 1985, Antiviral research.

Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug.

E. De Clercq, 1986, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

High-performance liquid chromatographic analysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine and its metabolites in serum, urine and herpes simplex virus type-1 infected cells.

E. De Clercq, S. Sacks, N. Ayisi, 1986, Journal of chromatography.

Incorporation of carbocyclic (E)-5-(2-iodovinyl)-2'-deoxyuridine (C-IVDU) into DNA of herpes simplex virus-infected cells.

E. De Clercq, P. Herdewijn, A. Verbruggen, 1985, Antiviral research.

Discovery of type II (covalent) inactivation of S-adenosyl-L-homocysteine hydrolase involving its "hydrolytic activity": synthesis and evaluation of dihalohomovinyl nucleoside analogues derived from adenosine.

E. De Clercq, R. Borchardt, J. Balzarini, 1998, Journal of medicinal chemistry.

Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice

E. De Clercq, C. Pannecouque, J. Balzarini, 1997, Antimicrobial agents and chemotherapy.

Interferon induction by platinum(II)-poly(I).poly(C) complexes.

E. De Clercq, W. Guschlbauer, D. Hermann, 1983, Biochimica et biophysica acta.

Interferon induction by poly(inosinic acid).poly(cytidylic acid) segmented by spin-labels.

P. W. Langemeier, E. De Clercq, P. Torrence, 1981, Biochemistry.

Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir.

E. De Clercq, J. Neyts, S. Liekens, 1998, Cancer research.

Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs.

E. De Clercq, M. Luczak, 1976, The Journal of infectious diseases.

Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase

R. Esnouf, E. De Clercq, B. Degrève, 2000, FEBS letters.

Establishment of mutant murine mammary carcinoma FM3A cell strains transformed with the herpes simplex virus type 2 thymidine kinase gene.

E. De Clercq, T. Seno, D. Ayusawa, 1986, Cell structure and function.

Synthesis and Antiviral Activity of Acyclic Derivatives of 5‐Ethyl‐2′‐Deoxyuridine

E. De Clercq, G. Kiefer, Klaus Keppeler, 1986, Archiv der Pharmazie.

Differential binding affinities of sugar-modified derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine for herpes simplex virus-induced and human cellular deoxythymidine kinases.

E. De Clercq, Y. Cheng, G. Dutschman, 1984, Biochemical pharmacology.

Differential metabolism of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by equine herpesvirus type 1- and herpes simplex virus-infected cells.

E. De Clercq, S. Kit, H. Ichimura, 1987, Antiviral research.

Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture.

E. De Clercq, M. Baba, S. Shigeta, 1984, The Tohoku journal of experimental medicine.

Differential metabolism of (E)-5-(2-bromovinyl)-2'-deoxyuridine in wild-type and drug-resistant herpes simplex virus-infected cells.

E. De Clercq, S. Sacks, N. Ayisi, 1985, Antiviral research.

Establishment of mutant FM3A murine mammary carcinoma cell strains transformed with the herpes simplex virus type 1 thymidine kinase gene.

E. De Clercq, T. Seno, D. Ayusawa, 1985, Japanese journal of cancer research : Gann.

The 5'-monophosphates of 5-propyl- and 5-ethyl-2'-deoxyuridine do not inhibit the replication of deoxythymidine kinase deficient (TK-) mutants of herpes simplex virus.

E. De Clercq, D. Shugar, T. Kulikowski, 1980, Biochemical pharmacology.

Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.

E. De Clercq, T. Yokota, K. Konno, 1984, Molecular pharmacology.

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

S Shigeta, E. De Clercq, M. Baba, 1994, Antimicrobial Agents and Chemotherapy.

Synthesis and Biological Activity of a Series of Methylene-Expanded Oxetanocin Nucleoside Analogues

E. De Clercq, J. Balzarini, M. Jung, 2002 .

Stereoselective synthesis of sugar-modified enyne analogues of adenosine and uridine. Interaction with S-adenosyl-L-homocysteine hydrolase and antiviral and cytotoxic effects.

E. De Clercq, R. Borchardt, S. Wnuk, 2004, Journal of medicinal chemistry.

Doubly homologated dihalovinyl and acetylene analogues of adenosine: synthesis, interaction with S-adenosyl-L-homocysteine hydrolase, and antiviral and cytostatic effects.

E. De Clercq, R. Borchardt, C. A. Valdez, 2000, Journal of medicinal chemistry.

Interferon induction by mismatched analogues of polyinosinic acid . polycytidylic acid [(Ix,U)n.(C)n].

E. De Clercq, B. Bhooshan, P. Torrence, 1979, Nucleic Acids Research.

Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides.

T. Merigan, E. De Clercq, R. Wells, 1971, Journal of molecular biology.

Failure of duplexes based on polylaurusin (poly(L), "Polyformycin B") to induce interferon.

E. De Clercq, B. Witkop, P. Torrence, 1975, Biochemical and Biophysical Research Communications - BBRC.

Poly(rI) more important than poly(rC) in the interferon induction process by poly(rI)-poly(rC).

E. De Clercq, W. Stewart, P. De Somer, 1973, Virology.

New AZT Analogues Having 5′-Alkylsulfonyl Groups: Synthesis and Anti-HIV Activity

E. De Clercq, C. Pannecouque, N. Al-Masoudi, 2007, Nucleosides, Nucleotides & Nucleic Acids.

Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.

E. De Clercq, H. Rogniaux, A. van Dorsselaer, 2001, Journal of medicinal chemistry.

E. De Clercq, P. Barr, J. Balzarini, 1983, Journal of medicinal chemistry.

Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.

E. De Clercq, B. Golankiewicz, G. Andrei, 1994, Journal of medicinal chemistry.

Synthesis and antiviral activity of novel N-substituted derivatives of acyclovir.

E. De Clercq, B. Golankiewicz, J. Boryski, 1988, Journal of medicinal chemistry.

Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.

R. T. Walker, E. De Clercq, J. Balzarini, 1990, Journal of medicinal chemistry.

Potent inhibitory effects of the 5'-triphosphates of (E)-5-(2-bromovinyl)-2'-deoxyuridine and (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on DNA polymerase gamma.

E. De Clercq, E. Clercq, K. Ono, 1990, European journal of biochemistry.

Polyacetal Carboxylic Acids: a New Group of Antiviral Polyanions

E. De Clercq, A. Billiau, E. Schonne, 1970, Journal of virology.

Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth‐inhibitory properties of (E)‐5‐(2‐bromovinyl)‐2'‐deoxyuridine and related compounds

E. De Clercq, T. Seno, D. Ayusawa, 1985, FEBS letters.

Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid.

E. De Clercq, J. Balzarini, K. Ono, 1988, European journal of biochemistry.

Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives.

R. T. Walker, E. De Clercq, R. Pauwels, 1992, Antiviral research.

Influence of various 2- and 2'-substituted polyadenylic acids on murine leukemia virus reverse transcriptase.

E. De Clercq, M. Hattori, M. Ikehara, 1979, Cancer letters.

New developments in anti-HIV chemotherapy.

E. De Clercq, 2002, Biochimica et biophysica acta.

The human immunodeficiency virus(HIV) inhibitor 9‐(2‐phosphonylmethoxyethyl)adenine (pmea) is a strong inducer of differentiation of several tumor cell lines

E. De Clercq, J. Balzarini, A. Verstuyf, 1995, International journal of cancer.

The cytostatic activity of 5‐(1‐azidovinyl)‐2′‐deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene‐transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (λ = 254 nm) exposure

E. De Clercq, J. Balzarini, G. Andrei, 1995, FEBS letters.

Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.

E. De Clercq, P. Herdewijn, R. Snoeck, 1991, Journal of medicinal chemistry.

Synthesis, antimycobacterial, antiviral, antimicrobial activity and QSAR studies of N(2)-acyl isonicotinic acid hydrazide derivatives.

B. Narasimhan, P. Yogeeswari, D. Sriram, 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).

Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.

E. De Clercq, B. Golankiewicz, G. Andrei, 2009, European journal of medicinal chemistry.

Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

F. Chen, E. De Clercq, C. Pannecouque, 2023, Bioorganic chemistry.

Prodrugs of 5‐Ethyl‐2′‐deoxyuridine, II Syntheses and Antiviral Activities of 5′‐ and 3′‐Ester Derivatives

E. De Clercq, G. Kiefer, Klaus Keppeler, 1986, Archiv der Pharmazie.

Syntheses and Antiviral Activities of Some 5′‐O‐Acyl Derivatives

E. De Clercq, G. Kiefer, Klaus Keppeler, 1985, Archiv der Pharmazie.

Synthesis and antiviral activity of acyclic nucleosides with a 3(S),5-dihydroxypentyl or 4(R)-methoxy-3(S),5-dihydroxypentyl side chain.

J. Hoogmartens, E. De Clercq, P. Herdewijn, 1992, Journal of medicinal chemistry.

Potent and selective activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside, 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside, and 3'-fluoro-2',3'-dideoxyguanosine against human immunodeficiency virus.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Molecular pharmacology.

Regression of autochthonous Moloney sarcoma virus-induced tumors in mice treated with polyriboinosinic acid-polyribocytidylic acid.

E. De Clercq, W. Stewart, 1974, Journal of the National Cancer Institute.

Synthesis and biological properties of 2'-deoxy-5-vinyluridine and 2'deoxy-5-vinylcytidine.

R. T. Walker, E. De Clercq, J. Balzarini, 1982, Nucleic acids research.

Mechanism of action of 5-(2-chloroethyl)-2'-deoxyuridine, a selective inhibitor of herpes simplex virus replication.

E. De Clercq, B. Rosenwirth, R. Bernaerts, 1990, Molecular pharmacology.

Synthesis of 1‐(2‐deoxy‐β‐D‐ribofuranosyl)‐2,4‐ difluoro‐5‐(2‐halo‐1‐hydroxyethyl)benzenes and related derivatives: “thymine replacement” analogs of deoxythymidine for evaluation as antiviral and anticancer agents

E. De Clercq, J. Balzarini, L. Wiebe, 2001 .

Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.

E. De Clercq, M. Bobek, I. Kavai, 1987, Journal of medicinal chemistry.

Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line.

E. De Clercq, T. Seno, D. Ayusawa, 1985, Methods and findings in experimental and clinical pharmacology.

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.

J Desmyter, E. De Clercq, R. Pauwels, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of a varicella-zoster virus variant with altered thymidine kinase activity

E. De Clercq, T. Yokota, K. Konno, 1986, Antimicrobial Agents and Chemotherapy.

New trends in antiviral chemotherapy.

E. De Clercq, 1979, Archives internationales de physiologie et de biochimie.

Therapy of varicella-zoster virus infection--mechanism of action of (E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, T. Yokota, S. Shigeta, 1985, Antiviral research.

Optimal Treatment Regimens for 5′‐Deoxy‐5‐fluorouridine, with or without (E)‐5‐(2‐Bromovinyl)‐2′‐deoxyuridine, against Various Tumors in Mice

E. De Clercq, M. Iigo, M. Miwa, 1990, Japanese journal of cancer research : Gann.

The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, S. Nishimura, M. Iigo, 1987, Japanese journal of cancer research : Gann.

Synthesis, Solution Conformation and Anti-HIV Activity of Novel 3-Substituted-2′,3′-Dideoxy-5-Hydroxymethyl-Uridines and Their 4,5-Substituted Analogues

E. De Clercq, J. Poznański, J. Balzarini, 2003, Antiviral chemistry & chemotherapy.

Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.

R. T. Walker, E. De Clercq, J. Balzarini, 1984, Journal of medicinal chemistry.

Synthesis and biological evaluation of phosphonopyrimidine and phosphonopurine ribonucleosides.

E. De Clercq, J. Balzarini, T. Maruyama, 1987, Chemical & pharmaceutical bulletin.

2′-Deoxyuridines with a 5-Heteroaromatic Substituent: Synthesis and Biological Evaluation

E. De Clercq, C. Pannecouque, P. Herdewijn, 1995 .

Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.

E. De Clercq, J. Descamps, D. Shugar, 1979, Journal of medicinal chemistry.

3-Benzamido, ureido and thioureidoimidazo[1,2-a]pyridine derivatives as potential antiviral agents.

E. De Clercq, C. Pannecouque, A. Kherbeche, 2001, Chemical & pharmaceutical bulletin.

Synthesis of imidazo[1,2-a]pyridines as antiviral agents.

E. De Clercq, J. Balzarini, M. Witvrouw, 1998, Journal of medicinal chemistry.

Analogues of Acyclic Nucleosides Derived from Tris-(Hydroxymethyl)Phosphine Oxide or Bis-(Hydroxymethyl)Phosphinic Acid Coupled to DNA Nucleobases

W. Stec, E. De Clercq, B. Nawrot, 2004, Antiviral chemistry & chemotherapy.

Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus.

E. De Clercq, J. Balzarini, R. Snoeck, 2002, Bioorganic & medicinal chemistry.

Potential use of antiviral agents in polio eradication.

E. De Clercq, J. Neyts, B. Rombaut, 2008, Emerging infectious diseases.

The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C

E. De Clercq, B. Coutard, J. Neyts, 2008, Journal of Virology.

Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.

E. De Clercq, C. Pannecouque, J. Balzarini, 2013, Bioorganic & Medicinal Chemistry.

Synthesis and antiviral activity of 6-chloropurine arabinoside and its 2'-deoxy-2'-fluoro derivative.

E. De Clercq, M. Witvrouw, Y. Takahashi, 1996, Chemical & pharmaceutical bulletin.

Chemoenzymatic Syntheses of Homo‐ and Heterodimers of AZT and d4T, and Evaluation of Their Anti‐HIV Activity

E. De Clercq, C. Pannecouque, J. Vasseur, 2004, Nucleosides, nucleotides & nucleic acids.

Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds

E. De Clercq, R. Snoeck, G. Andrei, 1995, Antimicrobial agents and chemotherapy.

Synthesis and Antiviral Evaluation of 2′-C-Methyl Analogues of 5-Alkynyl- and 6-Alkylfurano- and Pyrrolo[2,3-d]Pyrimidine Ribonucleosides

E. De Clercq, J. Neyts, K. Izawa, 2009, Nucleosides, nucleotides & nucleic acids.

Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2020, Bioorganic & medicinal chemistry.

Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.

E. De Clercq, C. Pannecouque, P. Zhan, 2019, Bioorganic & medicinal chemistry.

Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues

E. De Clercq, C. Pannecouque, B. Clotet, 2000, Antimicrobial Agents and Chemotherapy.

Discovery of Dihydro‐Alkyloxy‐Benzyl‐Oxopyrimidines as Promising Anti‐Influenza Virus Agents

E. De Clercq, L. Naesens, Xinyong Liu, 2011, Chemical biology & drug design.

Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2007, European journal of medicinal chemistry.

Synthesis and biological evaluation of 1,2-disubstituted carbonucleosides of 6-substituted purine and 8-azapurine.

E Uriarte, L. Santana, E. Uriarte, 1999, Nucleosides & nucleotides.

Novel Carbocyclic Nucleosides Containing a Cyclopentyl Ring. Adenosine and Uridine Analogues

E. De Clercq, J. Balzarini, G. Andrei, 1997, Archiv der Pharmazie.

Metabolism of the carbocyclic analogue of (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells. Incorporation of C-IVDU into DNA.

E. De Clercq, P. Herdewijn, A. Verbruggen, 1985, The Journal of biological chemistry.

Novel carbocyclic nucleosides containing a cyclobutyl ring: adenosine analogues.

E. De Clercq, J. Balzarini, C. López, 2001, Chemical & pharmaceutical bulletin.

MODIFIED CYCLOBUTANE CARBONUCLEOSIDES: SYNTHESIS AND EVALUATION OF THEIR ANTIVIRAL ACTIVITY

E. De Clercq, J. Balzarini, C. López, 2001, Nucleosides, nucleotides & nucleic acids.

A CYCLOBUTANE CARBONUCLEOSIDE WITH MARKED SELECTIVITY AGAINST TK+ AND TK− VARICELLA ZOSTER VIRUS

E. De Clercq, J. Balzarini, C. López, 2001, Nucleosides, nucleotides & nucleic acids.

Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.

E. De Clercq, A. Verbruggen, T. Yokota, 1987, Molecular pharmacology.

Clinical significance of chemokine receptor antagonists

Guangdi Li, E. De Clercq, Miao Miao, 2020, Expert opinion on drug metabolism & toxicology.

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Guangdi Li, E. De Clercq, Yali Wang, 2019, Expert opinion on drug metabolism & toxicology.

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

E. De Clercq, 2019, Antiviral chemistry & chemotherapy.

Tanovea® for the treatment of lymphoma in dogs.

E. De Clercq, 2018, Biochemical pharmacology.

Curious discoveries in antiviral drug development: the role of serendipity.

E. De Clercq, 2015, Medicinal research reviews.

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

E. De Clercq, 1999, Farmaco.

Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside

E. De Clercq, J. Balzarini, A. Karlsson, 1993, Molecular pharmacology.

Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.

E. De Clercq, J. Mellors, J. Balzarini, 2004, Journal of medicinal chemistry.

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.

D I Stuart, R M Esnouf, D. Stuart, 1997, Biochemical and biophysical research communications.

Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

E. De Clercq, C. Perno, J. Balzarini, 1996, Molecular pharmacology.

Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.

E. De Clercq, E. Emini, J. Balzarini, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Anti-HIV-1 Activity of Benzothiadiazine Dioxide

E. De Clercq, C. Pannecouque, C. Pérez, 2001, Antiviral chemistry & chemotherapy.

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

E. De Clercq, E. De Clercq, 2003, Expert review of anti-infective therapy.

Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents.

E. De Clercq, A. Jha, J. Balzarini, 2009, Bioorganic & medicinal chemistry letters.

Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a potent inhibitor of herpesvirus replication.

E. De Clercq, J. Neyts, J. Balzarini, 1998, Molecular pharmacology.

In search of effective anti-HHV-6 agents.

E. De Clercq, L. Naesens, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Translation of mouse interferon mRNA in Xenopus laevis oocytes and in rabbit reticulocyte lysates.

E. De Clercq, B. Lebleu, I. Braude, 1978, Biochemical and biophysical research communications.

Preparation and biological properties of a highly active poly(G) X poly(C) inducer of interferon.

E. De Clercq, P. Torrence, 1984, Antiviral research.

Polyadenylic-polyxanthylic-polyuridylic acid triple helix.

E. De Clercq, P. Torrence, 1977, Biochemistry.

Interferon production in rabbit kidney cell cultures exposed to poly (I). poly (C) adsorbed to rabbit red blood cells.

E. De Clercq, P. De Somer, P. Desomer, 1974, The Journal of general virology.

Rodent models for the study of therapy against flavivirus infections.

E. De Clercq, J. Neyts, P. Leyssen, 2004, Antiviral research.

Anti-complement activity of polynucleotides.

E. De Clercq, P. De Somer, B. Witkop, 1975, Biochemical and biophysical research communications.

Antiviral activity of polynucleotides: poly 2′‐o‐ethyladenylic acid and poly 2′‐o‐ethyluridylic acid

E. De Clercq, F. Rottman, D. Shugar, 1974, FEBS letters.

Interferon induction by polynucleotides: structure-function relationship.

E. De Clercq, 1977, Texas reports on biology and medicine.

Purification of mouse interferon by sequential chromatography.

E. De Clercq, I. Braude, 1979, Journal of chromatography.

Antiviral Activity of Polyribocytidylic Acid in Cells Primed with Polyriboinosinic Acid

E. De Clercq, P. De Somer, 1971, Science.

Synthesis and Biological Evaluation of New 5,6-dichlorobenzimidazole Nucleoside Derivatives

E. De Clercq, J. Balzarini, J. Imbach, 1994 .

Synthesis and antiviral activity of carbocyclic oxetanocin analogues (C-OXT-A, C-OXT-G) and related compounds. II.

E. De Clercq, M. Hosoya, J. Balzarini, 1993, Chemical & pharmaceutical bulletin.

E. De Clercq, P. Herdewijn, J. Balzarini, 1989, Journal of medicinal chemistry.

Synthesis and Fluorescent Properties of 6-(4-Biphenylyl)-3,9-dihydro-9-oxo-5H-imidazo[1,2-A]purine Analogues of Acyclovir and Ganciclovir

E. De Clercq, J. Balzarini, T. Goslinski, 2003, Nucleosides, nucleotides & nucleic acids.

Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir.

E. De Clercq, J. Balzarini, T. Goslinski, 2002, Journal of medicinal chemistry.

Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.

E. De Clercq, T. Goslinski, B. Golankiewicz, 2001, Journal of medicinal chemistry.

(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection

E. De Clercq, L. Naesens, J. Balzarini, 1995, Antimicrobial agents and chemotherapy.

Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine

E. De Clercq, J. Pagano, M. Smith, 1989, Antimicrobial Agents and Chemotherapy.

Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo

E. De Clercq, E. Clercq, C. Bruggeman, 1991, Antimicrobial Agents and Chemotherapy.

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice

E. De Clercq, A. Holý, 1991, Antimicrobial Agents and Chemotherapy.

The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents.

E. De Clercq, L. Naesens, J. Balzarini, 1995, Postepy biochemii.

Recovery of Humoral Immunity Is Critical for Successful Antiviral Therapy in Disseminated Mouse Adenovirus Type 1 Infection

E. De Clercq, L. Naesens, E. Verbeken, 2008, Antimicrobial Agents and Chemotherapy.

Role of the human herpesvirus 6 u69-encoded kinase in the phosphorylation of ganciclovir.

C. Manichanh, E. De Clercq, L. Naesens, 2002, Molecular pharmacology.

A Cutting‐Edge View on the Current State of Antiviral Drug Development

E. De Clercq, 2013, Medicinal research reviews.

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.

W. Freeman, E. De Clercq, F. Rahhal, 1997, Ophthalmology.

Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.

E. De Clercq, J. Neyts, 1994, Biochemical pharmacology.

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.

E. De Clercq, J. Neyts, J. Balzarini, 1991, Antiviral research.

Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice.

P. Delvenne, E. De Clercq, J. Piette, 1998, Oncology research.

Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent

R. Ptak, E. De Clercq, B. Rosenwirth, 2008, Antimicrobial Agents and Chemotherapy.

Antiviral Research at the Rega Institute (KU Leuven), Now 50 Years Old

E. De Clercq, 2004, Antiviral chemistry & chemotherapy.

Anti-HIV and anti-HCMV Activities of New Aurintricarboxylic Acid Analogues

E. De Clercq, J. Neyts, M. Witvrouw, 1995 .

Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.

W. Freeman, E. De Clercq, J. Arevalo, 1995, Ophthalmology.

Dipyridamole Potentiates the Activity of Various Acyclic Nucleoside Phosphonates against Varicella-Zoster Virus, Herpes Simplex Virus and Human Cytomegalovirus

E. De Clercq, J. Balzarini, G. Andrei, 1994 .

Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

E. De Clercq, C. Wiley, J. Connor, 1992, Investigative ophthalmology & visual science.

Sulphated Cyclodextrins are Potent anti-HIV Agents Acting Synergistically with 2′,3′-dideoxynucleoside Analogues

A. Van Schepdael, E. De Clercq, R. Pauwels, 1991 .

BENZYL-FUNCTIONALIZED cycloSal-d4T MONOPHOSPHATES

E. De Clercq, J. Balzarini, C. Ducho, 2001, Nucleosides, nucleotides & nucleic acids.

Effect of 5-Iodo-2′-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice

E. De Clercq, J. Neyts, E. Verbeken, 2002, Antimicrobial Agents and Chemotherapy.

In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine

E. De Clercq, J. Neyts, E. Clercq, 1995, Antimicrobial agents and chemotherapy.

Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines.

E. De Clercq, 1980, Methods and findings in experimental and clinical pharmacology.

Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia

E. De Clercq, J. Neyts, E. Verbeken, 2004, Antimicrobial Agents and Chemotherapy.

Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?

E. De Clercq, 1997, International journal of antimicrobial agents.

Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines.

E. De Clercq, 1991, Biochemical pharmacology.

Ribavirin Derivatives with a Hexitol Moiety: Synthesis and Antiviral Evaluation

E. De Clercq, P. Herdewijn, R. Busson, 2003, Antiviral chemistry & chemotherapy.

Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism.

E. De Clercq, L. Naesens, P. Annaert, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.

E. De Clercq, T. Seno, D. Ayusawa, 1987, Molecular pharmacology.

Enzymatic activities induced by interferon in human fibroblast cell lines differing in their sensitivity to the anticellular activity of interferon.

E. De Clercq, A. Fuse, J. Content, 1981, Virology.

Antiviral activity of a chemically stabilized 2‐5A analog upon microinjection into HeLa cells

E. De Clercq, G. Huez, P. Defilippi, 1986, FEBS letters.

Structure--activity relationships for and potentiation of the antimitogenic activity of 2-5A core derived from 2-5A, a mediator of interferon action.

E. De Clercq, J. Balzarini, P. Torrence, 1983, Journal of medicinal chemistry.

Oligo(2'-5')adenylate synthetase in human lymphoblastoid cells.

E. De Clercq, R. Friedman, K. Zoon, 1980, Biochemical and biophysical research communications.

Human viral diseases: what is next for antiviral drug discovery?

E. De Clercq, 2012, Current opinion in virology.

In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil.

E. De Clercq, L. Naesens, E. Clercq, 2000, Journal of pharmaceutical sciences.

Conversion of acyclic nucleoside phosphonates to their diphosphate derivatives by 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase.

E. De Clercq, J. Balzarini, 1991, Advances in experimental medicine and biology.

Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?

E. De Clercq, J. Neyts, G. Fytas, 2003, Antiviral chemistry & chemotherapy.

Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy

E. De Clercq, L. Naesens, L. de Bolle, 2005, Clinical Microbiology Reviews.

Stereospecific synthesis and antiviral activities of beta-L-2',3'-dideoxy-5-chloropyrimidine nucleoside derivatives.

E. De Clercq, J. Balzarini, J. Imbach, 1999, Nucleosides & nucleotides.

2'-Azido-2',3'-dideoxythymidine: synthesis and crystal structure of a 2'-substituted dideoxynucleoside.

E. De Clercq, P. Herdewijn, J. Balzarini, 1990, Antiviral Research.

Analogues Classes of Nucleoside and Nucleotide Antiadenovirus Activities of Several

E. De Clercq, L. Naesens, J. Balzarini, 2005 .

Anti-Human Immunodeficiency Virus Drug Combination Strategies

E. De Clercq, A. Vandamme, A-M Vandamme, 1998, Antiviral chemistry & chemotherapy.

Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.

E. De Clercq, C. Pannecouque, E. Clercq, 2000, Molecular pharmacology.

Monitoring drug resistance for herpesviruses.

E. De Clercq, G. Opdenakker, R. Snoeck, 2000, Methods in molecular medicine.

Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.

E. De Clercq, M. Baba, M. Makino, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication

E. De Clercq, Marian C. Horzinek, J. Balzarini, 1999, Journal of Virology.

In vitro Activity of Acyclic Nucleoside Phosphonate Derivatives against Feline Immunodeficiency Virus in Crandell Feline Kidney Cells and Feline Peripheral Blood Lymphocytes

N. Pedersen, E. De Clercq, J. Balzarini, 1994 .

Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.

E. De Clercq, J. Balzarini, S. Hatse, 1996, Molecular pharmacology.

Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro.

E. De Clercq, A. Billiau, E. Schonne, 1968, Journal of virology.

Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120

E. De Clercq, J. Anné, K. De Vreese, 1997, Antimicrobial agents and chemotherapy.

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

E. De Clercq, A. Vandamme, M. Witvrouw, 1996, Antiviral research.

Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice.

E. De Clercq, S. Ikeda, J. Neyts, 1993, The Journal of general virology.

Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection.

E. De Clercq, J. Balzarini, S. Velázquez, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.

E. De Clercq, K. Van Laethem, J. Balzarini, 2006, The Journal of antimicrobial chemotherapy.

Potentiating effect of ribavirin on the anti-retrovirus activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside in vitro and in vivo.

E. De Clercq, P. Herdewijn, J. Balzarini, 1989, Antiviral research.

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

E. De Clercq, P. Augustijns, R. Mols, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Treatment of Visna Virus Infection in Lambs with the Acyclic Nucleoside Phosphonate Analogue 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA)

E. De Clercq, L. Naesens, G. Georgsson, 1998, Antiviral chemistry & chemotherapy.

Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes.

E. De Clercq, J. Balzarini, E. Clercq, 1992, The Biochemical journal.

Organotypic Epithelial Raft Cultures as a Model for Evaluating Compounds against Alphaherpesviruses

E. De Clercq, J. J. van den Oord, C. de Wolf‐Peeters, 2005, Antimicrobial Agents and Chemotherapy.

Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.

E. De Clercq, 1991, International journal of immunopharmacology.

Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

E. De Clercq, A. Vandamme, S. Van Dooren, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Activities of Masked 2′,3′-Dideoxynucleoside Monophosphate Derivatives against Human Immunodeficiency Virus in Resting Macrophages

E. De Clercq, J. Balzarini, C. Mcguigan, 2000, Antimicrobial Agents and Chemotherapy.

Neutralization of Interferon Activity in Homologous and Heterologous Cells with Homologous and Heterologous Antibody

E. De Clercq, I. Braude, P. Desomer, 1980, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Anti-HIV activity of dextran sulphate as determined under different experimental conditions.

E. De Clercq, M. Baba, N. Yamamoto, 1989, Antiviral research.

Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase.

E. De Clercq, J. Balzarini, C. Mcguigan, 2004, Biochemical and biophysical research communications.

Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.

E. De Clercq, A. Ghanem, W. Higuchi, 1998, Journal of pharmaceutical sciences.

Antiviral Activity of a Keggin Polyoxotungstate PM-19 against Herpes Simplex Virus in Mice

E. De Clercq, S. Ikeda, T. Yamase, 1994 .

A new topical treatment for resistant herpes simplex infections.

E. De Clercq, N. Clumeck, G. Andrei, 1993, The New England journal of medicine.

Perspectives for the Treatment of Infections withFlaviviridae

E. De Clercq, J. Neyts, P. Leyssen, 2000, Clinical Microbiology Reviews.

Antiviral drugs: current state of the art.

E. De Clercq, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Antiviral effects of dihydroxypropyladenine [RS)-DHPA) and bromovinyldeoxyuridine (BVDU) on plant viruses.

E. De Clercq, G. De Fazio, M. Vicente, 1987, Antiviral research.

SYNTHESIS AND BIOLOGICAL EVALUATION OF ISONUCLEOSIDES DERIVED FROM METHYL 3,5-ANHYDRO-2-O-(2-FLUOROBENZYL)-d-XYLOFURANOSIDES

E. De Clercq, J. Balzarini, J. Wirsching, 2002, Nucleosides, nucleotides & nucleic acids.

Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome.

E. De Clercq, N. Clumeck, Y. Van Laethem, 2001, Archives of internal medicine.

Novel bicyclic furanopyrimidines with dual anti-VZV and -HCMV activity.

E. De Clercq, A. Brancale, J. Balzarini, 2003, Bioorganic & medicinal chemistry letters.

Anti-Varicella—Zoster Virus Bicyclic Nucleosides: Replacement of Furo by Pyrro Base Reduces Antiviral Potency

E. De Clercq, J. Balzarini, C. Mcguigan, 2000, Antiviral chemistry & chemotherapy.

Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.

E. De Clercq, J. Balzarini, 1983, Molecular pharmacology.

Antiviral activity of 5-substituted pyrimidine nucleoside analogues

E. De Clercq, 1983 .

Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs

E. De Clercq, Dongwei Kang, Boshi Huang, 2019, Acta pharmaceutica Sinica. B.

Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates.

E. De Clercq, C. Pannecouque, P. Zhan, 2012, International journal of biological macromolecules.

Novel Nucleoside Phosphoramidates as Inhibitors of HIV: Studies on the Stereochemical Requirements of the Phosphoramidate Amino Acid

E. De Clercq, J. Balzarini, C. Mcguigan, 1996 .

Phosphoramidates as Potent Prodrugs of anti-HIV Nucleotides: Studies in the Amino Region

E. De Clercq, J. Balzarini, C. Mcguigan, 1996 .

Glycosyl-oxycarbonylaminosulfonyl-2',3'-dideoxynucleoside derivatives as lipophilic nucleotide mimics. Synthesis and anti-HIV activity.

E. De Clercq, J. Balzarini, M. Camarasa, 1993, Bioorganic & medicinal chemistry.

SYNTHESIS AND FLUORESCENT PROPERTIES OF THE TRICYCLIC ANALOGUES OF ACYCLOVIR LINKED WITH NITROGEN HETBROCYCLIC UNITS

E. De Clercq, J. Balzarini, T. Goslinski, 2005, Nucleosides, nucleotides & nucleic acids.

5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.

E. De Clercq, J. Balzarini, C. Decedue, 1987, Journal of medicinal chemistry.

Synthesis and Anti-Varicella-Zoster Virus Activity of Some Novel Bicyclic Nucleoside Inhibitors: Effect of Enhanced Aqueous Solubility

E. De Clercq, A. Brancale, J. Balzarini, 2000, Antiviral chemistry & chemotherapy.

Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus.

E. De Clercq, P. Herdewijn, J. Balzarini, 1994, The Journal of biological chemistry.

Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds.

E. De Clercq, R. Pauwels, M. Baba, 1989, Journal of virological methods.

THE JOURNEY TOWARDS ELUCIDATING THE ANTI-HCMV ACTIVITY OF ALKYLATED BICYCLIC FURANO PYRIMIDINES

E. De Clercq, O. Bidet, J. Balzarini, 2005, Nucleosides, nucleotides & nucleic acids.

SYNTHESIS AND BIOLOGICAL EVALUATION OF N- AND O-ALKYLATED BICYCLIC FURANOPYRIMIDINES AS NON-NUCLEOSIDIC INHIBITORS OF HUMAN CYTOMEGALOVIRUS

E. De Clercq, J. Balzarini, C. Mcguigan, 2005, Nucleosides, nucleotides & nucleic acids.

Bicyclic Nucleoside Inhibitors of Varicella-Zoster Virus Modified on the Sugar Moiety: 3′ and 5′ Derivatives

E. De Clercq, J. Balzarini, C. Mcguigan, 2004, Antiviral chemistry & chemotherapy.

Synthesis and Antiviral Activity Assay of Novel (E)-3′,5′-Diamino-5-(2-bromovinyl)-2′,3′,5′-trideoxyuridine

E. De Clercq, I. Lavandera, S. Fernández, 2003, Nucleosides, nucleotides & nucleic acids.

Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact.

E. De Clercq, E. Clercq, 1993, Advances in virus research.

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

F. Baas, E. De Clercq, J. Wijnholds, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Differential effects of E-5-(2-bromovinyl)-2'-deoxyuridine on infections with herpes simplex virus type 1 and type 2 in hairless mice.

E. De Clercq, Zhen-Xi Zhang, 1982, The Journal of infectious diseases.

The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors

E. De Clercq, F. Ceccherini‐Silberstein, A. Chedad, 2005, Molecular Pharmacology.

Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184.

E. De Clercq, E. Clercq, J. Anné, 2000, European journal of biochemistry.

Chemical crosslinking of the subunits of HIV‐1 reverse transcriptase

E. De Clercq, Z. Debyser, 1996, Protein science : a publication of the Protein Society.

E. De Clercq, R. Borchardt, J. Balzarini, 1992, Journal of medicinal chemistry.

Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.

E. De Clercq, R. Pauwels, M. Baba, 1992, Molecular pharmacology.

Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781.

E. De Clercq, L. Naesens, J. Balzarini, 2002, International journal of pharmaceutics.

Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).

E. De Clercq, J. Balzarini, A. Karlsson, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.

E. De Clercq, J. Balzarini, A. Karlsson, 1995, Antiviral research.

Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.

C. Crumpacker, E. De Clercq, T. Seno, 1986, Anticancer research.

Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.

E. De Clercq, T. Seno, D. Ayusawa, 1985, Molecular pharmacology.

SYNTHESIS OF 1-(2-DEOXY-β-D- RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENE THYMIDINE MIMICS,* SOME RELATED α-ANOMERS, AND THEIR EVALUATION AS ANTIVIRAL AND ANTICANCER AGENTS

E. De Clercq, J. Balzarini, L. Wiebe, 2001, Nucleosides, nucleotides & nucleic acids.

3'-(N-hydroxyimino)-2',3-dideoxynucleosides and their derivatives: synthesis, broad spectrum antiviral properties and synthetical application for the preparation of other nucleoside analogues.

E. De Clercq, J. Balzarini, J. Imbach, 1999, Nucleosides & nucleotides.

Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.

E. De Clercq, K. Nishikata, Z. Veres, 1990, Biochemical pharmacology.

Antiviral Activity of 3-(3,5-Dimethylbenzyl)Uracil Derivatives Against Hiv-1 and HCMV

E. De Clercq, C. Pannecouque, J. Balzarini, 2007, Nucleosides, nucleotides & nucleic acids.

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

E. De Clercq, E De Clercq, 1998, Antiviral research.

Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin.

E. De Clercq, A. Vandamme, S. Van Dooren, 1998, Journal of virological methods.

Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.

E. De Clercq, J. Balzarini, H. Egberink, 1996, Molecular pharmacology.

Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity.

E. De Clercq, J. Balzarini, C. Mcguigan, 2004, Bioorganic & medicinal chemistry letters.

Bicyclic Nucleoside Inhibitors of Varicella-Zoster Virus: Effect of Terminal Aryl Substitution in the Side-Chain

E. De Clercq, J. Balzarini, C. Mcguigan, 2002, Antiviral chemistry & chemotherapy.

Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity.

P. Savy, E. De Clercq, A. Brancale, 2001, Bioorganic & medicinal chemistry letters.

Side-chain derivatives of biologically active nucleosides. 1. Side-chain analogs of 3'-azido-3'-deoxythymidine (AZT).

E. De Clercq, J. Balzarini, E. Zbiral, 1992, Journal of medicinal chemistry.

Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).

E. De Clercq, C. Pannecouque, Xinyong Liu, 2008, Bioorganic & medicinal chemistry.

Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides.

E. De Clercq, J. Balzarini, R. Snoeck, 1999, Journal of medicinal chemistry.

Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?

E. De Clercq, C. Pannecouque, J. Kraus, 2003, Bioorganic & medicinal chemistry letters.

Mechanism of antiviral and cytotoxic action of (+/-)-6' beta-fluoroaristeromycin, a potent inhibitor of S-adenosylhomocysteine hydrolase.

E. De Clercq, J. Balzarini, M. Cools, 1991, Molecular pharmacology.

NOVEL ARYL SUBSTITUTED BICYCLIC FURO NUCLEOSIDES AS EXTREMELY POTENT AND SELECTIVE ANTI-VZV AGENTS

E. De Clercq, J. Balzarini, C. Mcguigan, 2001, Nucleosides, nucleotides & nucleic acids.

Incorporation of the carbocyclic analogue of (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate into a synthetic DNA.

E. De Clercq, J. Sagi, L. Otvös, 1987, Biochemical and biophysical research communications.

Organic Chemist Whose Inventions Reshaped the Antiviral Drug World

E. De Clercq, 2013 .

New inhibitors of human cytomegalovirus (HCMV) on the horizon.

E. De Clercq, 2003, The Journal of antimicrobial chemotherapy.

Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.

H. W. Scheeren, E. De Clercq, J. Balzarini, 1992, Journal of medicinal chemistry.

Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention

E. De Clercq, J. Neyts, 2007, Trends in Pharmacological Sciences.

Anti-HIV I/II activity and molecular cloning of a novel mannose/sialic acid-binding lectin from rhizome of Polygonatum cyrtonema Hua.

E. De Clercq, J. Bao, Lei Dai, 2006, Acta biochimica et biophysica Sinica.

Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase

E. De Clercq, J. Neyts, G. Gáspár, 2002, Journal of Virology.

In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion

E. De Clercq, S. Ikeda, J. Neyts, 1994, Antimicrobial Agents and Chemotherapy.

Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice

E. De Clercq, J. Neyts, C. Drosten, 2004, Journal of Virology.

Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.

E. De Clercq, C. Pannecouque, M. Preobrazhenskaya, 2003, Journal of medicinal chemistry.

Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis.

E. De Clercq, J. Neyts, C. Drosten, 2002, The Journal of general virology.

Cytotoxicity of Natural Compounds Isolated from the Seeds of Garcinia afzelii

E. De Clercq, C. Pannecouque, L. Naesens, 2009, Planta medica.

Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives.

E. De Clercq, C. Pérez, J. Balzarini, 2000, Journal of medicinal chemistry.

TSG101: a novel anti-HIV-1 drug target.

E. De Clercq, P. Zhan, Xinyong Liu, 2010, Current medicinal chemistry.

Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins.

E. De Clercq, R. Pauwels, G. Molema, 1991, Molecular pharmacology.

Chapter 1. Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets

Guangdi Li, E. De Clercq, 2021, Drug Discovery.

Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.

R. Esnouf, E. De Clercq, J. Neyts, 1999, Molecular pharmacology.

LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells*

E. De Clercq, P. Cherepanov, Z. Debyser, 2003, Journal of Biological Chemistry.

Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR.

E. De Clercq, A. Vandamme, S. Van Dooren, 1995, Journal of virological methods.

Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.

E. De Clercq, L. Epstein, P. Gray, 1999, AIDS research and human retroviruses.

CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages

E. De Clercq, G. Simmons, J. Reeves, 1998, Journal of Virology.

Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA.

E. De Clercq, C. Pannecouque, L. Naesens, 1999, International journal of pharmaceutics.

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360

E. De Clercq, C. Pannecouque, M. de Maeyer, 2004, AIDS.

Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations

E. De Clercq, C. Pannecouque, M. de Maeyer, 2003, Journal of Virology.

The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis

J. Barretina, E. De Clercq, B. Clotet, 2000, Antimicrobial Agents and Chemotherapy.

Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

E. De Clercq, R. Pauwels, A. Vandamme, 1992, The Journal of biological chemistry.

An active interferon inducer obtained from Hemophilus influenzae type B.

T. Merigan, E. De Clercq, E. Clercq, 1969, Journal of immunology.

Coreceptor Phenotype of Natural Human Immunodeficiency Virus with Nef Deleted Evolves In Vivo, Leading to Increased Virulence

E. De Clercq, M. Goldsmith, J. Mills, 2002, Journal of Virology.

Impact of the Central Polypurine Tract on the Kinetics of Human Immunodeficiency Virus Type 1 Vector Transduction

E. De Clercq, Z. Debyser, B. Van Maele, 2003, Journal of Virology.

Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro.

E. De Clercq, A. Vandamme, M. Witvrouw, 1997, AIDS research and human retroviruses.

Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells.

E. De Clercq, A. Vandamme, J. Tu, 1995, AIDS research and human retroviruses.

Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector.

P. Lemey, E. De Clercq, A. Vandamme, 2002, Virology.

Human Immunodeficiency Virus Gene Regulation as a Target for Antiviral Chemotherapy

E. De Clercq, A. Vandamme, D. Daelemans, 1999, Antiviral chemistry & chemotherapy.

Interferon clearance rate decreased after repeated injections.

T. Merigan, M. Nuwer, E. De Clercq, 1971, The Journal of general virology.

The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.

E. De Clercq, 2011, Biochemical pharmacology.

Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vector.

P. Lemey, C. Pleij, E. De Clercq, 2002, Journal of General Virology.

Inhibitory effect of a broad-spectrum antiviral agent, (S)-9-(2,3-dihydroxypropyl)adenine, on spermatogenesis in mice.

E. De Clercq, J. Matoušek, P. De Somer, 1981, Toxicology and applied pharmacology.

Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.

E. De Clercq, P. Chiang, J. G. Cory, 1984, Journal of medicinal chemistry.

HIV-1 integration as a target for antiretroviral therapy: a review.

E. De Clercq, Z. Debyser, W. Pluymers, 2001, Current drug targets. Infectious disorders.

Isothiazole Derivatives as Antiviral Agents

E. De Clercq, C. Pannecouque, A. Garozzo, 2007, Antiviral chemistry & chemotherapy.

Isothiazole Derivatives as Novel HIV Replication Inhibitors

E. De Clercq, C. Pannecouque, A. Garozzo, 2004, Antiviral chemistry & chemotherapy.

Synthesis of 5′‐N‐(α‐Amino‐β‐mercaptoacyl)amino‐5′‐deoxynucleosides as potential antiviral compounds

E. De Clercq, M. García-López, J. Balzarini, 1991 .

Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.

Peng Zhan, Christophe Pannecouque, E. De Clercq, 2014, European journal of medicinal chemistry.

4-(beta-Arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidinols and related compounds: a novel class of cytotoxic and anticancer agents.

E. De Clercq, J. Quail, J. Dimmock, 1998, Journal of medicinal chemistry.

Procedures for the measurement of interferon mRNA distribution in induced mouse cells.

E. De Clercq, J. Content, M. I. Johnston, 1981, Methods in enzymology.

Diverging binding capacities of natural LD78β isoforms of macrophage inflammatory protein‐1α to the CC chemokine receptors 1, 3 and 5 affect their anti‐HIV‐1 activity and chemotactic potencies for neutrophils and eosinophils

Dominique Schols, Paul Proost, E. De Clercq, 2001, European journal of immunology.

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

E. De Clercq, D. Schols, G. Bridger, 2002, FEBS letters.

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

E. De Clercq, C. Pannecouque, P. Zhan, 2022, Molecules.

Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, European journal of medicinal chemistry.

New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle.

E. De Clercq, Xinyong Liu, Yan Jiang, 2011, Current Medicinal Chemistry.

In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells

E. De Clercq, M. Goldsmith, D. Schols, 2003, Journal of Virology.

Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors

Guangdi Li, E. De Clercq, Ji-yang Liu, 2022, Journal of medical virology.

From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Chinese Chemical Letters.

Highlights in the development of new antiviral agents.

E. De Clercq, 2002, Mini reviews in medicinal chemistry.

Replication of not-known-vector flaviviruses in mosquito cells is restricted by intracellular host factors rather than by the viral envelope proteins.

E. De Clercq, J. Neyts, A. Davidson, 2010, The Journal of general virology.

A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses.

E. De Clercq, A. Vandamme, J. Neyts, 2003, Journal of virological methods.

Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Bioorganic chemistry.

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.

E. De Clercq, Dongwei Kang, Boshi Huang, 2021, Journal of medicinal chemistry.

Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, European journal of medicinal chemistry.

Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.

E. De Clercq, C. Pannecouque, Li Ding, 2021, Journal of medicinal chemistry.

Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.

E. De Clercq, C. Pannecouque, Fen‐er Chen, 2020, Bioorganic chemistry.

Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.

E. De Clercq, C. Pannecouque, Fener Chen, 2019, European journal of medicinal chemistry.

Discovery of potent HIV‐1 non‐nucleoside reverse transcriptase inhibitors by exploring the structure–activity relationship of solvent‐exposed regions I

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, Chemical biology & drug design.

Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.

Peng Zhan, F. J. Luque, Ye Tian, 2019, Journal of medicinal chemistry.

Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Peng Zhan, Jian Zhang, F. J. Luque, 2019, Journal of medicinal chemistry.

Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.

E. De Clercq, Dongwei Kang, Boshi Huang, 2017, European journal of medicinal chemistry.

Productive Infection of Primary Macrophages with Human Herpesvirus 7

E. De Clercq, D. Schols, S. Aquaro, 2001, Journal of Virology.

Drug targets in cytomegalovirus infection.

E. De Clercq, R. Snoeck, G. Andrei, 2009, Infectious disorders drug targets.

In the face of the persistent threat of human influenza A (H3N2, H1N1) and B infections, the outbreaks of avian influenza (H5N1) in Southeast Asia, and the potential of a new human or avian influenza A variant to unleash

E. De Clercq, 2017 .

Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19

Nuno R. Faria, T. Lam, Guangdi Li, 2022, Immunity & Ageing.

Bone marrow transplantation in a child with Wiskott‐Aldrich syndrome latently infected with acyclovir‐resistant (ACVr) herpes simplex virus type 1: Emergence of foscarnet‐resistant virus originating from the ACVr virus

E. De Clercq, M. Saijo, I. Kurane, 2002 .

Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo.

E. De Clercq, M. Hosoya, S. Shigeta, 1993, The Journal of infectious diseases.

S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.

E. De Clercq, C. Pannecouque, A. Vandamme, 1997, Molecular pharmacology.

Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives.

E. De Clercq, C. Pannecouque, P. Herdewijn, 2007, Virology.

Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A

L. Stamatatos, E. De Clercq, C. Pannecouque, 2005, Journal of Virology.

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Pharmaceuticals.

Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.

E. De Clercq, R. Pauwels, A. Vandamme, 1992, Virology.

3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.

Stephen G. Dimmock, E. De Clercq, J. Dimmock, 2016, Journal of medicinal chemistry.

Cytotoxic 1,3-diarylidene-2-tetralones and related compounds.

E. De Clercq, J. Quail, J. Dimmock, 2002, European journal of medicinal chemistry.

Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.

E. De Clercq, J. Dimmock, Rajendra K. Sharma, 2007, European journal of medicinal chemistry.

Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins

Marco Rusnati, Antonella Bugatti, E. De Clercq, 2007, Antimicrobial Agents and Chemotherapy.

A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells.

E. De Clercq, R. Pauwels, J. Balzarini, 1988, Journal of immunological methods.

Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs.

J Desmyter, E. De Clercq, C. Pannecouque, 2000, Methods in molecular medicine.

Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins of Hippeastrum Hybrid and Galanthus nivalis

E. De Clercq, M. Froeyen, K. Van Laethem, 2005, Molecular Pharmacology.

Isolation and characterization of a human fibroblast interferon gene and its expression in Escherichia coli.

G. Volckaert, R. Derynck, J. Tavernier, 1981, Reviews of infectious diseases.

Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.

E. De Clercq, B. Clotet, L. Ruiz, 2000, AIDS research and human retroviruses.

Sepharose-bound poly (I)-poly (C): interaction with cells and interferon production.

E. De Clercq, L. Bachner, M. Thang, 1975, Biochemical and biophysical research communications.

CXCR4 chemokine receptor antagonists: nickel(II) complexes of configurationally restricted macrocycles.

E. De Clercq, C. Pannecouque, D. Schols, 2012, Dalton transactions.

NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors.

E. De Clercq, Xinyong Liu, Mingyan Yu, 2009, Mini reviews in medicinal chemistry.

Role of CXCR4 in Cell-Cell Fusion and Infection of Monocyte-Derived Macrophages by Primary Human Immunodeficiency Virus Type 1 (HIV-1) Strains: Two Distinct Mechanisms of HIV-1 Dual Tropism

E. De Clercq, D. Kolson, I. Frank, 1999, Journal of Virology.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

R. Esnouf, E. De Clercq, C. Pannecouque, 2001, AIDS.

Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.

E. De Clercq, M. Witvrouw, J. Anné, 1998, AIDS research and human retroviruses.

Current race in the development of DAAs (direct-acting antivirals) against HCV.

E. De Clercq, 2014, Biochemical pharmacology.

Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives

E. De Clercq, C. Pannecouque, N. Al-Masoudi, 2007, Acta pharmaceutica.

Biological, biochemical and physicochemical evidence for the existence of the polyadenylate - polyuridylate - poly 2'-fluoro-2'-deoxyuridylate triple-stranded complex.

E. De Clercq, B. Janik, R. Sommer, 1976, Chemico-biological interactions.

Human cytomegalovirus modulates the Ca2+ response to vasopressin and ATP in fibroblast cultures.

E. De Clercq, H. de Smedt, J. Neyts, 1995, Cell calcium.

Amides of antibiotic streptonigrin and amino dicarboxylic acids or aminosugars. Synthesis and biological evaluation.

N. V. Kozlova, E. De Clercq, V. Tolstikov, 1992, The Journal of antibiotics.

Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides.

E. De Clercq, S. Ikeda, J. Neyts, 1996, Journal of medicinal chemistry.

Synthesis of Imidazo[1,2-a]pyridine Derivatives as Antiviral Agents

E. De Clercq, J. Balzarini, G. Andrei, 2001, Arzneimittelforschung.

AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1

Dominique Schols, E. De Clercq, A. Billiau, 2001, The Journal of Immunology.

Differential inhibition of retroviral reverse transcriptase by poly(2-fluoroadenylic acid), a template analogue.

E. De Clercq, J. Balzarini, K. Kohda, 1991, AIDS.

Synthesis of 3‐Nitrosoimidazo[1,2‐a]pyridine Derivatives as Potential Antiretroviral Agents

E. De Clercq, C. Pannecouque, A. Kherbeche, 2001, Archiv der Pharmazie.

In Vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses

E. De Clercq, J. Neyts, P. Selvam, 2008, Indian journal of pharmaceutical sciences.

Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.

Peng Zhan, Christophe Pannecouque, E. De Clercq, 2014, European journal of medicinal chemistry.

Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.

E. De Clercq, L. Naesens, Grigoris Zoidis, 2010, European journal of medicinal chemistry.

Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.

Peng Zhan, Jan Balzarini, Ye Tian, 2014, European journal of medicinal chemistry.

E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties.

E. De Clercq, J. Dimmock, J. Balzarini, 2008, Bioorganic & medicinal chemistry.

Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2001, Journal of medicinal chemistry.

Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2000, Bioorganic & medicinal chemistry.

Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency.

E. De Clercq, C. Pannecouque, D. Schols, 1999, Journal of medicinal chemistry.

Polyanion inhibitors of HIV and other viruses. 7. Polyanionic compounds and polyzwitterionic compounds derived from cyclodextrins as inhibitors of HIV transmission.

E. De Clercq, C. Pannecouque, J. Neyts, 1998, Journal of medicinal chemistry.

Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Micelle-like anti-HIV polyanionic compounds based on a carbohydrate core.

E. De Clercq, M. Witvrouw, J. Esté, 1997, Journal of medicinal chemistry.

Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids.

E. De Clercq, J. Montero, M. Witvrouw, 1997, Journal of medicinal chemistry.

Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase.

Y. Pommier, E. De Clercq, W. Rice, 1995, Journal of medicinal chemistry.

Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2000, Bioorganic & medicinal chemistry letters.

Inhibition of Human Immunodeficiency Virus Type (HIV‐1) Replication by some Diversely Functionalized Spirocyclopropyl Derivatives

E. De Clercq, C. Pannecouque, M. Witvrouw, 1999, Archiv der Pharmazie.

Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle.

E. De Clercq, C. Pannecouque, B. Rosenwirth, 2010, Antiviral research.

Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay.

E. De Clercq, E. Fenyö, D. Schols, 2001, Virology.

Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, K. Uberla, J. Balzarini, 1995, Biochemical and biophysical research communications.

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.

Peng Zhan, Xiao Ding, Dongwei Kang, 2016, Journal of medicinal chemistry.

Charge modification of plasma and milk proteins results in antiviral active compounds

E. De Clercq, R. Pauwels, M. Harmsen, 1999, Journal of peptide science : an official publication of the European Peptide Society.

5-Nitro-2'-deoxyuridine 5'-monophosphate is a potent irreversible inhibitor of Lactobacillus caesi thymidylate synthetase.

E. De Clercq, P. Torrence, C. Chang, 1978, Biochemical and biophysical research communications.

Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

E. De Clercq, E. Clercq, D. Schols, 2001, Antiviral chemistry & chemotherapy.

Selective Inhibition of Porcine Endogenous Retrovirus Replication in Human Cells by Acyclic Nucleoside Phosphonates

E. De Clercq, S. Takao, M. Baba, 2007, Antimicrobial Agents and Chemotherapy.

Poor glycemic control in type‐2 diabetic patients infected with hepatitis B: A retrospective propensity‐matched study

Min Zhang, Guangdi Li, E. De Clercq, 2023, Journal of medical virology.

HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.

E. De Clercq, Erik De Clercq, 2004, The international journal of biochemistry & cell biology.

T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use

E. De Clercq, D. Schols, J. Esté, 1998, Journal of Virology.

Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo.

E. De Clercq, A. Billiau, E. Schonne, 1968, Journal of virology.

Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.

E. De Clercq, Hong-tao Lu, Shibo Jiang, 2003, AIDS research and human retroviruses.

Suramin in the treatment of AIDS: mechanism of action.

E. De Clercq, 1987, Antiviral research.

ADA, a potential anti-HIV drug.

E. De Clercq, M. Witvrouw, J. Schmit, 1996, AIDS research and human retroviruses.

Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy

E. De Clercq, B. Clotet, J. Martinez-Picado, 1998 .

Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.

E. De Clercq, J. Balzarini, C. Mcguigan, 1998, Bioorganic & medicinal chemistry letters.

Effects of topical and subconjunctival cidofovir (HPMPC) in an animal model.

W. Freeman, E. De Clercq, A. Banker, 1998, Current eye research.

Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes.

W. Freeman, E. De Clercq, A. Banker, 1998, Investigative ophthalmology & visual science.

Chicoric acid analogues as HIV-1 integrase inhibitors.

K. Kohn, Y. Pommier, E. De Clercq, 1999, Journal of medicinal chemistry.

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication

E. De Clercq, J. Anné, G. Werner, 1996, Journal of virology.

An in situ pig liver esterase assay as a useful predictive tool for the likely in vitro anti viral activity of phosphoramidate pro-drugs.

E. De Clercq, J. Balzarini, C. Mcguigan, 1999, Nucleosides & nucleotides.

Establishment of an in vitro assay system mimicking human immunodeficiency virus type 1-induced neural cell death and evaluation of inhibitors thereof.

E. De Clercq, M. Baba, Z. Debyser, 2003, Journal of virological methods.

Prevalence of Genotypic Resistance among Antiretroviral Drug-Naive HIV-1-Infected Patients in Belgium

E. De Clercq, M. Van Ranst, C. Declercq, 2001, Antiviral therapy.

E. De Clercq, B. Clotet, J. Leonard, 1996, AIDS.

Systemic cidofovir in papillomatosis.

E. De Clercq, E. Clercq, K. De Boeck, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cidofovir in the treatment of HPV-associated lesions.

E. De Clercq, R. Snoeck, G. Andrei, 2001, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents

E. De Clercq, J. Balzarini, Kiran Gangarapu, 2013, Medicinal Chemistry Research.

DNA-Dependent Protein Kinase Is Not Required for Efficient Lentivirus Integration

B. de Strooper, E. De Clercq, B. Nuttin, 2000, Journal of Virology.

Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential.

E. De Clercq, 2015, Current medicinal chemistry.

Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT.

E. De Clercq, D. Meijer, M. Witvrouw, 1999, Journal of drug targeting.

Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.

E. De Clercq, R. Pauwels, D. Meijer, 1993, Molecular pharmacology.

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.

Dominique Schols, E. De Clercq, T. Schwartz, 2005, Biochemical pharmacology.

Mutations at the CXCR4 interaction sites for AMD3100 influence anti‐CXCR4 antibody binding and HIV‐1 entry

Dominique Schols, E. De Clercq, T. Schwartz, 2003, FEBS letters.

Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.

E. De Clercq, C. Pannecouque, P. Zhan, 2013, Bioorganic & medicinal chemistry.

Chemotherapy of respiratory syncytial virus infections: the final breakthrough.

E. De Clercq, 2015, International journal of antimicrobial agents.

Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, Journal of medicinal chemistry.

Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.

E. De Clercq, J. Neyts, A. Hay, 2008, Bioorganic & medicinal chemistry letters.

Synthesis, and cytotoxic activity of N(ind)-alkoxy derivatives of antibiotic arcyriarubin and dechloro-rebeccamycin aglycon.

E. De Clercq, M. Preobrazhenskaya, J. Balzarini, 2002, The Journal of antibiotics.

Chemical modification of antibiotic streptonigrin; synthesis and properties of 2'-decarboxy-2'-aminostreptonigrin (streptonigrone-2'-imine).

E. De Clercq, V. Tolstikov, M. Preobrazhenskaya, 1992, The Journal of antibiotics.

HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation.

R. Doms, E. De Clercq, B. Freedman, 2000, Proceedings of the National Academy of Sciences of the United States of America.

ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds.

Rafael Bello, Isis Bonet, Lourdes Santana, 2007, European journal of medicinal chemistry.

Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.

E. De Clercq, B. Schmidt, H. Walter, 2002, AIDS research and human retroviruses.

Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.

Y. Pommier, E. De Clercq, C. Pannecouque, 2000, Molecular pharmacology.

Cytotoxic 1,4-bis(2-oxo-1-cycloalkylmethylene)benzenes and related compounds.

E. De Clercq, J. Quail, J. Dimmock, 2002, European journal of medicinal chemistry.

6-Benzylidene-2-[4-(pyridin-3-ylcarboxy)benzylidene]cyclohexanones: A novel cluster of tumour-selective cytotoxins.

Stephen G. Dimmock, E. De Clercq, J. Dimmock, 2017, Bioorganic & medicinal chemistry letters.

Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: further optimization of anti-hepatitis C virus activity.

E. De Clercq, J. Neyts, J. Paeshuyse, 2007, Bioorganic & medicinal chemistry letters.

Therapeutic strategies for COVID-19: progress and lessons learned

Guangdi Li, E. De Clercq, R. Hilgenfeld, 2023, Nature Reviews Drug Discovery.

Differential signalling of the chemokine receptor CXCR4 by stromal cell‐derived factor 1 and the HIV glycoprotein in rat neurons and astrocytes

E. De Clercq, F. Baleux, P. Casanova, 2000, The European journal of neuroscience.

Antivirals: past, present and future.

E. De Clercq, 2013, Biochemical pharmacology.

Interactions of the dimeric triad of HIV-1 aspartyl protease with inhibitors.

E. De Clercq, M. Froeyen, P. Mager, 2003, Drug design and discovery.

Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, International Journal of Molecular Sciences.

Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.

E. De Clercq, 2004, Biochemical pharmacology.

Discovery of novel 1,2,4‐triazole phenylalanine derivatives targeting an unexplored region within the interprotomer pocket of the HIV capsid protein

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Journal of medical virology.

Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.

E. De Clercq, R. Pauwels, Z. Debyser, 1992, The Journal of general virology.

Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses.

E. De Clercq, D. Michel, J. Neyts, 1997, Antiviral research.

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.

Peng Zhan, Xiao Ding, Ye Tian, 2017, Journal of medicinal chemistry.

3,5‐Bis(benzylidene)‐4‐oxo‐1‐phosphonopiperidines and Related Diethyl Esters: Potent Cytotoxins with Multi‐Drug‐Resistance Reverting Properties

E. De Clercq, J. Molnár, J. Dimmock, 2009, ChemMedChem.

Recent advances in the research of HIV-1 RNase H inhibitors.

E. De Clercq, P. Zhan, Xinyong Liu, 2008, Mini reviews in medicinal chemistry.

Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV

Dominique Schols, Paul Proost, E. De Clercq, 1998, The Journal of Biological Chemistry.

Trends in the disease burden of HBV and HCV infection in China from 1990 to 2019.

Guangdi Li, E. De Clercq, Ting Cai, 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

The history of antiretrovirals: key discoveries over the past 25 years

E. De Clercq, 2009, Reviews in medical virology.

FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?

E. De Clercq, 2022, Viruses.

Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, Acta pharmaceutica Sinica. B.

The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.

E. De Clercq, J. Quail, J. Dimmock, 2009, European journal of medicinal chemistry.

Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, European journal of medicinal chemistry.

Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides.

J. Liu, Y. Pommier, E. De Clercq, 2001, DNA and cell biology.

1984—Discovery of the First Anti-HIV Drug, Suramin

E. De Clercq, 2021, Viruses.

Tumor induction by Moloney sarcoma virus in athymic nude mice.

E. De Clercq, 1975, Journal of the National Cancer Institute.

Antihistaminic and antiviral activities of steroids of Turbinaria conoides

E. De Clercq, J. Anbu, Y. Kumar, 2011, Natural product research.

Antimicrobial and Cytotoxic Activities of Turbinariaconoides (J.Agardh) Kuetz

E. De Clercq, Vivek Gupta, Y. Kumar, 2010, Iranian journal of pharmaceutical research : IJPR.

Species-dependent and site-specific intestinal metabolism of ester prodrugs.

E. De Clercq, P. Augustijns, F. Penninckx, 2000, International journal of pharmaceutics.

Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).

E. De Clercq, G. Andrei, R. Snoeck, 2007, Bioorganic & Medicinal Chemistry.

Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).

E. De Clercq, 1986, Journal of medicinal chemistry.

Cytotoxic and Topographical Properties of 6-Arylidene-2-dimethylaminomethylcyclohexanone Hydrochlorides and Related Compounds

E. De Clercq, R. Sharma, J. Quail, 2004, Journal of enzyme inhibition and medicinal chemistry.

Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.

E. De Clercq, D. Schols, G. Andrei, 2001, Oncology research.

Phenotypic Resistance of Herpes Simplex Virus Type 1 Strains Selected in Vitro with Antiviral Compounds and Combinations Thereof

E. De Clercq, G. Andrei, R. Snoeck, 1996 .

Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.

E. De Clercq, J. Quail, J. Dimmock, 2000, Journal of medicinal chemistry.

Stability-Activity Relationships of a Family of G-tetrad Forming Oligonucleotides as Potent HIV Inhibitors

E. De Clercq, N. Jing, M. Hogan, 2000, The Journal of Biological Chemistry.

Development of novel S-N3-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity.

F. Chen, E. De Clercq, C. Pannecouque, 2022, European journal of medicinal chemistry.

Phosphonylmethoxyalkyl derivatives of purine as inhibitors of human hepatitis B virus DNA synthesis.

E. De Clercq, T. Yokota, K. Konno, 1990, Nucleic acids symposium series.

Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety

F. Chen, E. De Clercq, C. Pannecouque, 2023, Chinese Chemical Letters.

Design, synthesis, and biological evaluation of novel 5‐Alkyl‐6‐Adamantylmethylpyrimidin‐4(3H)‐ones as HIV‐1 non‐nucleoside reverse‐transcriptase inhibitors

E. De Clercq, Dongwei Kang, Boshi Huang, 2016, Chemical biology & drug design.

Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.

E. De Clercq, L. Naesens, Grigoris Zoidis, 2009, Bioorganic & medicinal chemistry.

Cytotoxic evaluation of some 3,5-diarylidene-4-piperidones and various related quaternary ammonium compounds and analogs.

E. De Clercq, J. Quail, V. Arora, 1994, Journal of pharmaceutical sciences.

Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.

Peng Zhan, Jan Balzarini, Xuwang Chen, 2012, European journal of medicinal chemistry.

Hydrogen Bonding (Base Pairing) in Antiviral Activity

E. De Clercq, 2023, Viruses.

Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle.

E. De Clercq, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Synthesis and Biological Evaluation of a Series of 2‐((1‐substituted‐1H‐1,2,3‐triazol‐4‐yl)methylthio)‐6‐(naphthalen‐1‐ylmethyl)pyrimidin‐4(3H)‐one As Potential HIV‐1 Inhibitors

Peng Zhan, Dongwei Kang, Christophe Pannecouque, 2015, Chemical biology & drug design.

Effect of Separate and Combined Injections of Poly rI: Poly rC and Endotoxin on Reticulo-endothelial Activity, Interferon, and Antibody Production in the Mouse

T. Merigan, E. De Clercq, T. Chester, 1971, Infection and immunity.

Antiviral and tumor cell antiproliferative SAR studies on tetracyclic eudistomins. II.

H. W. Scheeren, E. De Clercq, J. Balzarini, 1997, Bioorganic & medicinal chemistry.

Design, synthesis and biological evaluation of substituted guanidine indole derivatives as potential inhibitors of HIV-1 Tat-TAR interaction.

E. De Clercq, C. Pannecouque, P. Zhan, 2013, Medicinal chemistry.

In vitro and in vivo inhibition of virus multiplicaton by microwave hyperthemia.

E. De Clercq, M. Luczak, S. Szmigielski, 1977, Archives of virology.

Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain.

E. De Clercq, J. Balzarini, C. Mcguigan, 2002, Bioorganic & medicinal chemistry letters.

Inhibition of HIV-1-Induced Cytopathogenicity, Syncytium Formation, and Virus-Cell Binding by Naphthalenedisulphonic Acids through Interaction with the Viral Envelope gp120 Glycoprotein

E. De Clercq, M. Baba, D. Schols, 1993 .

DNA-induced Polymerization of HIV-1 Integrase Analyzed with Fluorescence Fluctuation Spectroscopy*

Jo Vercammen, Zeger Debyser, Yves Engelborghs, 2002, The Journal of Biological Chemistry.

Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.

E. De Clercq, M. Van Ranst, M. Peeters, 2001, Journal of acquired immune deficiency syndromes.

Nucleoside analogues as antiviral agents.

E. De Clercq, 1981, Acta microbiologica Academiae Scientiarum Hungaricae.

The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.

C. Crumpacker, E. De Clercq, G. Bubley, 1987, Virology.

Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication.

E. De Clercq, P. Zhan, Xinyong Liu, 2011, Current medicinal chemistry.

Design, Synthesis, and Anti‐HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket

E. De Clercq, Huiqing Liu, C. Pannecouque, 2015, Chemical biology & drug design.

Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections.

E. De Clercq, 1996, International journal of antimicrobial agents.

In search of specific inhibitors of retrovirus replication.

E. De Clercq, J. Balzarini, 1985, Antiviral research.

Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro.

E. De Clercq, R. Pauwels, D. Meijer, 1989, Journal of Acquired Immune Deficiency Syndromes.

Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication in vitro.

E. De Clercq, R. Pauwels, M. Baba, 1988, Biochemical and biophysical research communications.

Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.

E. De Clercq, J. Balzarini, S. Manfredini, 1997, Journal of medicinal chemistry.

Interferon Production Linked to Toxicity of Polyriboinosinic Acid-Polyribocytidylic Acid

E. De Clercq, W. Stewart, P. De Somer, 1972, Infection and immunity.

Antiviral Metal Complexes

E. De Clercq, 1997, Metal-based drugs.

Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues.

E. De Clercq, A. Jha, J. Balzarini, 2007, Bioorganic & medicinal chemistry letters.

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.

E. De Clercq, T. Harrer, B. Clotet, 2000, AIDS.

In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents

E. De Clercq, J. Neyts, 1998, Antimicrobial Agents and Chemotherapy.

Discovery, development and characterization of agents active against the AIDS virus.

E. De Clercq, R. Pauwels, K. Andries, 1995, Journal of receptor and signal transduction research.

Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity.

E. De Clercq, P. Proost, A. Lambeir, 1998, European Cytokine Network.

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

E. De Clercq, J. Balzarini, A. Karlsson, 1993, Virology.

Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.

E. De Clercq, T. Schwartz, E. Clercq, 2001, Molecular pharmacology.

Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.

E. De Clercq, C. Paoletti, J. Balzarini, 1989, Journal of medicinal chemistry.

Potent and Selective Inhibition of HIV and SIV by Prostratin Interacting with Viral Entry

E. De Clercq, C. Pannecouque, M. Witvrouw, 2003, Antiviral chemistry & chemotherapy.

Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2014, European journal of medicinal chemistry.

Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.

E. De Clercq, 2005, Mini reviews in medicinal chemistry.

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.

Peng Zhan, Ye Tian, Christophe Pannecouque, 2014, European journal of medicinal chemistry.

Metabolism of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase.

E. De Clercq, A. Matsuda, J. Balzarini, 1997, Advances in experimental medicine and biology.

Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.

E. De Clercq, Boshi Huang, P. Zhan, 2014, European journal of medicinal chemistry.

Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.

E. De Clercq, P. Herdewijn, J. Balzarini, 1993, The Journal of biological chemistry.

Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.

E. De Clercq, 2012, Biochemical pharmacology.

Establishment of a bioassay to determine serum levels of dextran sulfate and pentosan polysulfate, two potent inhibitors of human immunodeficiency virus.

E. De Clercq, R. Pauwels, M. Baba, 1990, Journal of acquired immune deficiency syndromes.

In vitro Activity of Polyhydroxycarboxylates against Herpesviruses and Hiv

E. De Clercq, J. Neyts, J. Balzarini, 2001, Antiviral chemistry & chemotherapy.

Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells.

E. De Clercq, R. Pauwels, D. Schols, 1990, Cytometry.

Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities.

Myriam Witvrouw, Christophe Pannecouque, Jean-Louis Kraus, 2002, Journal of medicinal chemistry.

Differential Susceptibility of Several Drug-Resistant Strains of Herpes Simplex Virus Type 2 to Various Antiviral Compounds

E. De Clercq, R. Snoeck, G. Andrei, 1997 .

Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses.

E. De Clercq, L. Naesens, A. Loregian, 2006, Antiviral research.

Inhibition of Intestinal Metabolism of the Antiviral Ester Prodrug bis(POC)-PMPA by Nature-Identical Fruit Extracts as a Strategy to Enhance Its Oral Absorption: An In Vitro Study

E. De Clercq, L. Naesens, P. Annaert, 1999, Pharmaceutical Research.

Renaturation of inactivated interferons: requirement for reduction of a major component; lack of requirement for reduction of a minor component.

E. De Clercq, W. Stewart, P. De Somer, 1974, The Journal of general virology.

Protective effects of anionic detergents on interferons: reversible denaturation.

E. De Clercq, W. Stewart, P. De Somer, 1974, Biochimica et biophysica acta.

Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, RSC medicinal chemistry.

Synthesis and antiviral activity of three pyrazole analogues of distamycin A.

E. De Clercq, U. Ragnarsson, J. Balzarini, 1994, Acta chemica Scandinavica.

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.

E. De Clercq, Boshi Huang, Huiqing Liu, 2015, European journal of medicinal chemistry.

HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase

E. De Clercq, 1993, Medicinal research reviews.

Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy.

F. Chen, E. De Clercq, C. Pannecouque, 2023, Journal of medicinal chemistry.

An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects.

W. Freeman, E. De Clercq, C. Wiley, 1997, Experimental eye research.

Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999.

Anne-Mieke Vandamme, Inge Derdelinckx, Joke Snoeck, 2002, Virus research.

Non‐nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti‐HIV Activity of Novel 2‐[(Arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues

E. De Clercq, C. Pannecouque, J. Balzarini, 2005, Archiv der Pharmazie.

Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, M. Cushman, 2009, European journal of medicinal chemistry.

Non‐nucleoside HIV Reverse Transcriptase Inhibitors. Part 6. Synthesis and Anti‐HIV Activity of Novel 2‐[(Arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues.

E. De Clercq, C. Pannecouque, J. Balzarini, 2006 .

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.

E. De Clercq, B. Clotet, L. Ruiz, 1998, Journal of virological methods.

1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.

E. De Clercq, J. Dimmock, J. Balzarini, 2008, Bioorganic & medicinal chemistry.

Biological, biochemical, and physicochemical evidence for the existence of the polyadenylic-polyuridylic-polyinosinic acid triplex.

E. De Clercq, P. De Somer, B. Witkop, 1975, The Journal of biological chemistry.

Synthesis and QSAR studies on thiazolidinones as anti-HIV agents.

Y. S. Prabhakar, E. De Clercq, V. Solomon, 2005, Combinatorial chemistry & high throughput screening.

Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels.

E. De Clercq, M. Iigo, A. Hoshi, 1988, Biochemical pharmacology.

Potential of bromovinyldeoxyuridine in anticancer chemotherapy.

E. De Clercq, 1986, Anticancer research.

Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture.

E. De Clercq, J. Balzarini, 2001, AIDS research and human retroviruses.

Comparison of the Disposition of Ester Prodrugs of the Antiviral Agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 Monolayers

E. De Clercq, L. Naesens, P. Annaert, 1998, Pharmaceutical Research.

Therapeutic potential of PMEA as an antiviral drug

E. De Clercq, L. Naesens, J. Balzarini, 1994 .

Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.

E. De Clercq, A. Esteban-Gamboa, J. Balzarini, 1999, Nucleosides and Nucleotides.

Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins

E. De Clercq, A. Vandamme, K. Van Laethem, 2004, Journal of Virology.

Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.

E. De Clercq, L. Naesens, J. Neyts, 2007, Journal of medicinal chemistry.

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues.

E. De Clercq, 2003, Medicinal research reviews.

Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.

E. De Clercq, J. Dimmock, J. Balzarini, 2016, Bioorganic & medicinal chemistry.

3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.

Jan Balzarini, Hiroshi Sakagami, E. De Clercq, 2011, Journal of medicinal chemistry.

Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.

E. De Clercq, G. Fytas, T. Mavromoustakos, 1999, Bioorganic & medicinal chemistry letters.

Dihydro-alkoxyl-benzyl-oxopyrimidine derivatives (DABOs) as non-nucleoside reverse transcriptase inhibitors: an update review (2001-2011).

E. De Clercq, Fener Chen, Shi-qiong Yang, 2012, Current medicinal chemistry.

Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.

E. De Clercq, J. Balzarini, A. Karlsson, 1996, Molecular pharmacology.

Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.

E. De Clercq, Dongwei Kang, Boshi Huang, 2016, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Novel 2‐(Pyridin‐3‐yloxy)acetamide Derivatives as Potential Anti‐HIV‐1 Agents

E. De Clercq, Boshi Huang, C. Pannecouque, 2016, Chemical biology & drug design.

Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.

Peng Zhan, Jan Balzarini, Xuwang Chen, 2014, Bioorganic & medicinal chemistry.

1-Arylmethyl-2,3-dioxo-2,3-dihydroindole thiosemicarbazones as leads for developing cytotoxins and anticonvulsants

E. De Clercq, J. Dimmock, J. Balzarini, 2009, Journal of enzyme inhibition and medicinal chemistry.

Synthesis, antifungal, antibacterial and antiviral effects of some adamantaneketoxime ethers.

E. De Clercq, M. Hosoya, J. Balzarini, 1993, Farmaco.

Cidofovir for the Treatment of Molluscum Contagiosum Virus

E. De Clercq, 2022, Viruses.

Antiviral Classification

Guangdi Li, E. De Clercq, Pan Zhang, 2021, Encyclopedia of Virology.

AIDS in the Third World: how to stop the HIV infection?

E. De Clercq, 2007, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

Peng Zhan, Jan Balzarini, Christophe Pannecouque, 2013, Bioorganic & medicinal chemistry.

Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, Huiqing Liu, C. Pannecouque, 2013, Bioorganic & medicinal chemistry letters.

Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.

E. De Clercq, Boshi Huang, C. Pannecouque, 2016, European journal of medicinal chemistry.

Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside.

E. De Clercq, L. Naesens, J. Balzarini, 1990, Journal of acquired immune deficiency syndromes.

Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses

E. De Clercq, 1995 .

Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses

E. De Clercq, E. Clercq, 2007, Advances in Antiviral Drug Design.

Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)

E. De Clercq, 2007, Advances in Antiviral Drug Design.

Antiviral drug discovery: Ten more compounds, and ten more stories (part B)

E. De Clercq, 2009, Medicinal research reviews.

The discovery of antiviral agents: Ten different compounds, ten different stories

E. De Clercq, E. Clercq, 2008, Medicinal research reviews.

Failure of Athymic-Nude Mice Sensitized with Bacillus Calmette-Guérin to Produce Interferon in Response to Purified Protein Derivative

E. De Clercq, K. Huygen, Zhang Zhen-Xi, 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Ebola virus (EBOV) infection: Therapeutic strategies

E. De Clercq, E. Clercq, 2014, Biochemical Pharmacology.

Inhibition of tubulin polymerization by select alkenyldiarylmethanes.

E. De Clercq, C. Pannecouque, M. Cushman, 2008, Bioorganic & medicinal chemistry letters.

A Combination of Poor Adherence and a Low Baseline Susceptibility Score is Highly Predictive for HAART Failure

E. De Clercq, M. Van Ranst, W. Peetermans, 2002, Antiviral chemistry & chemotherapy.

Antiviral agents active against influenza A viruses

Erik De Clercq, E. De Clercq, E. Clercq, 2006, Nature Reviews Drug Discovery.

Anti-HIV activity of a series of cosalane amino acid conjugates.

E. De Clercq, C. Pannecouque, M. Witvrouw, 2000, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity of 5'-deoxypyrazofurin.

E. De Clercq, S. Ikeda, J. Balzarini, 1993, Journal of medicinal chemistry.

The bicyclam AMD3100 story

E. De Clercq, 2003, Nature reviews. Drug discovery.

Synthesis and antiviral activity of imidazo[1,2-a]pyridines

E. De Clercq, J. Chezal, J. Balzarini, 1999 .

Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.

E. De Clercq, M. Muzard, S. Pilard, 2006, Journal of Medicinal Chemistry.

Synthesis, properties, and biological activity of some nucleoside cyclic phosphoramidates

R. T. Walker, E. De Clercq, J. Balzarini, 1984 .

Biological evaluation of proanthocyanidin dimers and related polyphenols.

E. De Clercq, M. Witvrouw, T. De Bruyne, 1999, Journal of natural products.

HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase

Erik De Clercq, E. De Clercq, E. Clercq, 1993, Medicinal research reviews.

Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.

E. De Clercq, R. Pauwels, Z. Debyser, 1992, Molecular Pharmacology.

In search of a selective therapy of viral infections.

E. De Clercq, 2010, Antiviral Research.

What can be Expected from Non‐nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV‐1) Infections?

E. De Clercq, 1996 .

Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation.

E. De Clercq, J. Balzarini, J. Imbach, 1999, Nucleosides & nucleotides.

Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine

E. De Clercq, H. Keizer, E. Clercq, 2005, Journal of Cancer Research and Clinical Oncology.

Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.

E. De Clercq, C. Pannecouque, J. Balzarini, 2010, Bioorganic & Medicinal Chemistry.

Selective virus inhibitors.

E. De Clercq, 1990, Microbiologica.

Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.

Peng Zhan, Xueshun Wang, Christophe Pannecouque, 2017, Bioorganic & medicinal chemistry.

Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.

Peng Zhan, Ye Tian, Dongwei Kang, 2017, European journal of medicinal chemistry.

Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.

Christophe Pannecouque, E. De Clercq, C. Pannecouque, 2014, Bioorganic & medicinal chemistry.

Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, J. Balzarini, 2007, Journal of medicinal chemistry.

Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.

E. De Clercq, M. Saijo, I. Kurane, 2002, Journal of medical virology.

Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.

E. De Clercq, Huiqing Liu, C. Pannecouque, 2014, European journal of medicinal chemistry.

5-Cyano substituted diarylpyridines as potent HIV-1 NNRTIs: Rational design, synthesis, and activity evaluation.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, European journal of medicinal chemistry.

Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.

E. De Clercq, L. Naesens, Grigoris Zoidis, 2010, European journal of medicinal chemistry.

CXCR4 chemokine receptor antagonists: nickel(II) complexes of configurationally restricted macrocycles.

E. De Clercq, C. Pannecouque, D. Schols, 2012, Dalton transactions.

1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, P. Zhan, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents

E. De Clercq, J. Balzarini, Kiran Gangarapu, 2013, Medicinal Chemistry Research.

The race for interferon‐free HCV therapies: a snapshot by the spring of 2012

E. De Clercq, 2012, Reviews in medical virology.

Improving the anti-HIV-1 activity and solubility of poorly water-soluble DAPYs by heteroaromatic replacement strategy: From naphthalene-DAPYs to quinoline-DAPYs.

F. Chen, E. De Clercq, C. Pannecouque, 2023, Bioorganic chemistry.

Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.

E. De Clercq, C. Pannecouque, D. Daelemans, 2015, Bioorganic & medicinal chemistry.

The role of tenofovir in the prevention of HIV infections.

E. De Clercq, 2006, AIDS.

HIV Genome-Wide Protein Associations: a Review of 30 Years of Research

Guangdi Li, E. De Clercq, 2016, Microbiology and Molecular Reviews.

Structure-activity relationships for interferon induction and inhibition of protein synthesis by polynucleotides.

E. De Clercq, P. Torrence, 1981, Texas reports on biology and medicine.

Antiproliferative and Antiviral Activity of Three Libraries of Adamantane Derivatives

E. De Clercq, J. Balzarini, N. Basarić, 2014, Archiv der Pharmazie.

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

E. De Clercq, Dongwei Kang, Boshi Huang, 2023, Communications chemistry.

Design, Synthesis, and Anti‐HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket

E. De Clercq, Huiqing Liu, C. Pannecouque, 2015, Chemical biology & drug design.

New perspectives for the chemotherapy and chemoprophylaxis of AIDS (acquired immune deficiency syndrome).

E. De Clercq, 1992, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

The development of BVDU: An odyssey

E. De Clercq, 2023, Antiviral chemistry & chemotherapy.

Antiviral Drug Development – Success and Failure: A Personal Perspective with a Japanese Connection

E. De Clercq, 2013, Antiviral chemistry & chemotherapy.

Alkyloxyphenyl Furano Pyrimidines as Potent and Selective Anti-VZV Agents with Enhanced Water Solubility

J. T. Erichsen, E. De Clercq, J. Balzarini, 2002, Antiviral chemistry & chemotherapy.

Inhibitory Activity of (E)‐5‐(2‐Bromovinyl)‐2′‐Deoxyuridine on the Salmonid Herpesviruses, Oncorhynchus masou Virus (OMV) and Herpesvirus salmonis

E. De Clercq, T. Nishizawa, M. Yoshimizu, 1988, Microbiology and immunology.

Novel carbocyclic nucleosides containing a cyclobutyl ring. Guanosine and adenosine analogues.

E. De Clercq, J. Balzarini, G. Andrei, 1998, Nucleosides & nucleotides.

Synthesis of 3′-C-branched 1′,5′-anhydromannitol nucleosides as new antiherpes agents

E. De Clercq, P. Herdewijn, E. Clercq, 1998 .

Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.

C. Crumpacker, E. De Clercq, G. Bubley, 1983, Virology.

Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.

E. De Clercq, C. Pannecouque, J. Balzarini, 2008, Bioorganic & medicinal chemistry letters.

Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

E. De Clercq, C. Pannecouque, D. Daelemans, 2015, European journal of medicinal chemistry.

Tanovea® for the treatment of lymphoma in dogs.

E. De Clercq, 2018, Biochemical pharmacology.

Human herpesvirus 6 infection arrests cord blood mononuclear cells in G(2) phase of the cell cycle.

E. De Clercq, L. Naesens, E. Verbeken, 2004, FEBS letters.

Inhibition of oncornavirus functions by 2'-azido polynucleotides.

E. De Clercq, A. Billiau, B. Witkop, 1975, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.

Christophe Pannecouque, E. De Clercq, C. Pannecouque, 2014, Bioorganic & medicinal chemistry.

Nucleoside Inhibitors of Tick-Borne Encephalitis Virus

E. De Clercq, J. Černý, J. Valdés, 2015, Antimicrobial Agents and Chemotherapy.

Stochastic entropy QSAR for the in silico discovery of anticancer compounds: prediction, synthesis, and in vitro assay of new purine carbanucleosides.

Lourdes Santana, Humberto González-Díaz, Eugenio Uriarte, 2006, Bioorganic & medicinal chemistry.

Differential effects of various double-stranded RNAs on protein synthesis in rabbit reticulocyte lysates.

E. De Clercq, B. Lebleu, J. Content, 1978, Biochemistry.

Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents.

Jan Balzarini, Laura De Luca, Maria Zappalà, 2002, Journal of medicinal chemistry.

Pd-catalyzed C-C bond-forming reactions of thymidine mesitylene sulfonate.

E. De Clercq, M. Lakshman, S. B. Kang, 2007, The Journal of organic chemistry.

Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A

L. Stamatatos, E. De Clercq, C. Pannecouque, 2005, Journal of Virology.

Synthesis and biological evaluation of iodinated and fluorinated 9-(2-hydroxypropyl) and 9-(2-hydroxyethoxy)methyl purine nucleoside analogues.

E. De Clercq, G. Folkers, L. Scapozza, 2003, Journal of Medicinal Chemistry.

Increased resistance of trisomic-21 cells to virus replication: role of interferon.

E. De Clercq, 1978, Virology.

Comparative study of the efficacy of different forms of interferon therapy in the treatment of mice challenged intranassaly with vesicular stomatitis virus (VSV).

E. De Clercq, P. De Somer, 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus.

E. De Clercq, P. De Somer, 1968, Life sciences.

3',3'-Difluoro-3'-deoxythymidine: comparison of anti-HIV activity to 3'-fluoro-3'-deoxythymidine.

E. De Clercq, J. Balzarini, D. Bergstrom, 1992, Journal of medicinal chemistry.

Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibito

E. De Clercq, Dongwei Kang, C. Pannecouque, 2023, Journal of medicinal chemistry.

Chemotherapy of respiratory syncytial virus infections: the final breakthrough.

E. De Clercq, 2015, International journal of antimicrobial agents.

1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.

E. De Clercq, J. Dimmock, J. Balzarini, 2008, Bioorganic & medicinal chemistry.

Gammaherpesviruses encode functional dihydrofolate reductase activity.

E. De Clercq, J. Neyts, G. Gáspár, 2002, Biochemical and biophysical research communications.

Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.

E. De Clercq, J. Dimmock, A. Jha, 2010, Bioorganic & medicinal chemistry letters.